← Back to search
6ktm

The ligand-free structure of human PPARgamma ligand-binding domain R288A mutant in the presence of the SRC-1 coactivator peptide

Method: X-RAY DIFFRACTION Dmax: 67.2 Å Quality: GOOD
▼

1. Protein Identity and Related Structures Protein Identity & Related Structures

Peroxisome proliferator-activated receptor gamma

Homo sapiens

UniProt P37231

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Protein heterocomplex Heteromer Protein × 2 PDB declaration: dimeric（2） Consistent with protein copy count Chain A； UniProt 223–505 Mutation：R316A 16-mer peptide from Nuclear receptor coactivator 1 × 1 （Q15788） X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；2.2 M sodium malonate (pH 7.0) Resolution 2.70 Å R-free 0.258

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 6KTM Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
1FM6 THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES. Deposited 2000-08-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain D 204–475（272 aa） Fragment：LIGAND BINDING DOMAIN - RESIDUES 206 - 477
Not recorded 9CR (9cis)-retinoic acid × 1 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；17% PEG 4K, 200mM NaSCN, 8% Ethylene Glycol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.10 Å R-free 0.292
1FM6 THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES. Deposited 2000-08-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain X 204–475（272 aa） Fragment：LIGAND BINDING DOMAIN - RESIDUES 206 - 477
Not recorded 9CR (9cis)-retinoic acid × 1 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；17% PEG 4K, 200mM NaSCN, 8% Ethylene Glycol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.10 Å R-free 0.292
1FM9 THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND GI262570 AND CO-ACTIVATOR PEPTIDES. Deposited 2000-08-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain D 234–505（272 aa） Fragment：LIGAND BINDING DOMAIN - RESIDUES 206 - 477
Not recorded 9CR (9cis)-retinoic acid × 1 570 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；17% PEG 4K, 200mM NaSCN, 8% Ethylene Glycol , pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 22K
Resolution 2.10 Å R-free 0.268
1I7I CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST AZ 242 Deposited 2001-03-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 225–505（281 aa） Fragment：LIGAND BINDING DOMAIN
Not recorded AZ2 (2S)-2-ETHOXY-3-[4-(2-{4-[(METHYLSULFONYL)OXY]PHENYL}ETHOXY)PHENYL]PROPANOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；sodium citrate, hepes, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.35 Å R-free 0.284
1I7I CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST AZ 242 Deposited 2001-03-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 225–505（281 aa） Fragment：LIGAND BINDING DOMAIN
Not recorded AZ2 (2S)-2-ETHOXY-3-[4-(2-{4-[(METHYLSULFONYL)OXY]PHENYL}ETHOXY)PHENYL]PROPANOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；sodium citrate, hepes, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.35 Å R-free 0.284
1K74 The 2.3 Angstrom resolution crystal structure of the heterodimer of the human PPARgamma and RXRalpha ligand binding domains respectively bound with GW409544 and 9-cis retinoic acid and co-activator peptides. Deposited 2001-10-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain D 234–505（272 aa） Fragment：ligand binding domain residues - 206 - 477
Not recorded 9CR (9cis)-retinoic acid × 1 544 2-(1-METHYL-3-OXO-3-PHENYL-PROPYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；PEG4K, NaSCN, Ethylene Glycol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.30 Å R-free 0.279
1KNU LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH A SYNTHETIC AGONIST Deposited 2001-12-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 232–505（274 aa） Fragment：LIGAND BINDING DOMAIN
Chain B 232–505（274 aa） Fragment：LIGAND BINDING DOMAIN
Not recorded YPA (S)-3-(4-(2-CARBAZOL-9-YL-ETHOXY)-PHENYL)-2-ETHOXY-PROPIONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；294 K；CITRIC ACID, TRIS-HCL, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 294.0K
Resolution 2.50 Å R-free 0.264
1NYX Ligand binding domain of the human peroxisome proliferator activated receptor gamma in complex with an agonist Deposited 2003-02-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 230–505（276 aa） Fragment：Ligand binding domain
Chain B 230–505（276 aa） Fragment：Ligand binding domain
Not recorded DRF (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；Citrate, Tris, pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.65 Å R-free 0.306
1PRG LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA Deposited 1998-07-02 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 205–474（270 aa） Fragment：LBD (LIGAND BINDING DOMAIN), RESIDUES 207-476
Chain B 205–474（270 aa） Fragment：LBD (LIGAND BINDING DOMAIN), RESIDUES 207-476
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；VAPOR DIFFUSION METHOD, HANGING DROP TECHNIQUE, 1.4M SODIUM CITRATE, 100MM HEPES, PH 7.5
Resolution 2.20 Å R-free 0.318
1RDT Crystal Structure of a new rexinoid bound to the RXRalpha ligand binding doamin in the RXRalpha/PPARgamma heterodimer Deposited 2003-11-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain D 235–505（271 aa） Fragment：ligand binding doamin
Not recorded L79 (S)-(2E)-3[4-(5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRO-2-NAPHTHALENYL)TETRAHYDRO-1-BENZOFURAN-2-YL]-2-PROPENOIC ACID × 1 570 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；295 K；17% PEG 4K, 200mM NaSCN, 8% ethylene glycol, 8% glycerol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K, pH 7.50
Resolution 2.40 Å R-free 0.259
1ZEO Crystal Structure of Human PPAR-gamma Ligand Binding Domain Complexed with an Alpha-Aryloxyphenylacetic Acid Agonist Deposited 2005-04-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa） Fragment：Ligand Binding Domain (LBD), residues 203-477
Chain B 231–505（275 aa） Fragment：Ligand Binding Domain (LBD), residues 203-477
Not recorded C01 (2S)-(4-ISOPROPYLPHENYL)[(2-METHYL-3-OXO-5,7-DIPROPYL-2,3-DIHYDRO-1,2-BENZISOXAZOL-6-YL)OXY]ACETATE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；0.95 M Trisodium Citrate, 0.1 M Tris/HCl, 1 mM TCEP, pH 8.5, temperature 298K, VAPOR DIFFUSION, SITTING DROP
Resolution 2.50 Å R-free 0.280
1ZGY Structural and Biochemical Basis for Selective Repression of the Orphan Nuclear Receptor LRH-1 by SHP Deposited 2005-04-22 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa） Fragment：PPARgamma Ligand Binding Domain
Not recorded BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；PEG 3350, tri-sodium citrate, ethylene glycol, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.80 Å R-free 0.258
2ATH Crystal structure of the ligand binding domain of human PPAR-gamma im complex with an agonist Deposited 2005-08-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：ligand binding domain
Chain B 235–505（271 aa） Fragment：ligand binding domain
Not recorded 3EA 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；20% PEG3350, 0.2 Sodium Citrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP
Resolution 2.28 Å R-free 0.288
2F4B Crystal structure of the ligand binding domain of human PPAR-gamma in complex with an agonist Deposited 2005-11-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN
Not recorded EHA (5-{3-[(6-BENZOYL-1-PROPYL-2-NAPHTHYL)OXY]PROPOXY}-1H-INDOL-1-YL)ACETIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；20% PEG3350, 0.2 Sodium Citrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.07 Å R-free 0.288
2F4B Crystal structure of the ligand binding domain of human PPAR-gamma in complex with an agonist Deposited 2005-11-23 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；20% PEG3350, 0.2 Sodium Citrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.07 Å R-free 0.288
2FVJ A novel anti-adipogenic partial agonist of peroxisome proliferator-activated receptor-gamma (PPARG) recruits pparg-coactivator-1 alpha (PGC1A) but potentiates insulin signaling in vitro Deposited 2006-01-31 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 207-477
Not recorded RO0 1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXY-4-{[4-(2-METHOXYPHENYL)PIPERIDIN-1-YL]METHYL}ISOQUINOLINE × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；20% PEG3350, 0.2M magnesium chloride, 0.1M Tris, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.99 Å R-free 0.246
2G0G Structure-based drug design of a novel family of PPAR partial agonists: virtual screening, x-ray crystallography and in vitro/in vivo biological activities Deposited 2006-02-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：Ligand binding domain(residues 207-477)
Chain B 235–505（271 aa） Fragment：Ligand binding domain(residues 207-477)
Not recorded SP0 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；20% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.54 Å R-free 0.264
2GTK Structure-based Design of Indole Propionic Acids as Novel PPARag CO-Agonists Deposited 2006-04-28 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Not recorded 208 (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.1M TRIS, PEG 3350, 0.2M MGSO4, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.10 Å R-free 0.261
2HWQ Structural basis for the structure-activity relationships of Peroxisome Proliferator-Activated Receptor agonists Deposited 2006-08-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 235–505（271 aa） Fragment：Ligand binding domain
Chain B 235–505（271 aa） Fragment：Ligand binding domain
Not recorded DRY [(1-{3-[(6-BENZOYL-1-PROPYL-2-NAPHTHYL)OXY]PROPYL}-1H-INDOL-5-YL)OXY]ACETIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；28.25% PEG3350, 0.016M sodium citrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.97 Å R-free 0.265
2HWR Structural basis for the structure-activity relationships of Peroxisome Proliferator-Activated Receptor agonists Deposited 2006-08-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 235–505（271 aa） Fragment：Ligand binding domain
Chain B 235–505（271 aa） Fragment：Ligand binding domain
Not recorded DRD 2-[(1-{3-[(6-BENZOYL-1-PROPYL-2-NAPHTHYL)OXY]PROPYL}-1H-INDOL-4-YL)OXY]-2-METHYLPROPANOIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；28% PEG3350, 0.016M sodium citrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.34 Å R-free 0.316
2I4J Crystal structure of the complex between PPARgamma and the agonist LT160 (ureidofibrate derivative) Deposited 2006-08-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain (LBD), residues 223-504
Chain B 223–504（282 aa） Fragment：ligand binding domain (LBD), residues 223-504
Not recorded DRJ (2R)-2-(4-{2-[1,3-BENZOXAZOL-2-YL(HEPTYL)AMINO]ETHYL}PHENOXY)-2-METHYLBUTANOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M NaCitrate, 0.15 M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.10 Å R-free 0.278
2I4P Crystal structure of the complex between PPARgamma and the partial agonist LT127 (ureidofibrate derivative). Structure obtained from crystals of the apo-form soaked for 30 days. Deposited 2006-08-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain (LBD)
Chain B 223–504（282 aa） Fragment：ligand binding domain (LBD)
Not recorded DRH (2S)-2-(4-{2-[1,3-BENZOXAZOL-2-YL(HEPTYL)AMINO]ETHYL}PHENOXY)-2-METHYLBUTANOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M NaCitrate, 0.15 M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.10 Å R-free 0.295
2I4Z Crystal structure of the complex between PPARgamma and the partial agonist LT127 (ureidofibrate derivative). This structure has been obtained from crystals soaked for 6 hours. Deposited 2006-08-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain (LBD), residues 223-504
Chain B 223–504（282 aa） Fragment：ligand binding domain (LBD), residues 223-504
Not recorded DRH (2S)-2-(4-{2-[1,3-BENZOXAZOL-2-YL(HEPTYL)AMINO]ETHYL}PHENOXY)-2-METHYLBUTANOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M NaCitrate, 0.15 M Tris. Crystals of the apo-form have been soaked for 6 hours in a solution containing the ligand, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.25 Å R-free 0.290
2OM9 Ajulemic acid, a synthetic cannabinoid bound to PPAR gamma Deposited 2007-01-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 232–505（274 aa） Fragment：Ligand binding domain, residues 232-505
Not recorded AJA (6AR,10AR)-3-(1,1-DIMETHYLHEPTYL)-1-HYDROXY-6,6-DIMETHYL-6A,7,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMENE-9-CARBOXYLIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions 283 K；4M sodium formate, VAPOR DIFFUSION, HANGING DROP, temperature 283K
Resolution 2.80 Å R-free 0.267
2OM9 Ajulemic acid, a synthetic cannabinoid bound to PPAR gamma Deposited 2007-01-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 232–505（274 aa） Fragment：Ligand binding domain, residues 232-505
Not recorded AJA (6AR,10AR)-3-(1,1-DIMETHYLHEPTYL)-1-HYDROXY-6,6-DIMETHYL-6A,7,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMENE-9-CARBOXYLIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions 283 K；4M sodium formate, VAPOR DIFFUSION, HANGING DROP, temperature 283K
Resolution 2.80 Å R-free 0.267
2OM9 Ajulemic acid, a synthetic cannabinoid bound to PPAR gamma Deposited 2007-01-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 232–505（274 aa） Fragment：Ligand binding domain, residues 232-505
Not recorded AJA (6AR,10AR)-3-(1,1-DIMETHYLHEPTYL)-1-HYDROXY-6,6-DIMETHYL-6A,7,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMENE-9-CARBOXYLIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions 283 K；4M sodium formate, VAPOR DIFFUSION, HANGING DROP, temperature 283K
Resolution 2.80 Å R-free 0.267
2OM9 Ajulemic acid, a synthetic cannabinoid bound to PPAR gamma Deposited 2007-01-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 232–505（274 aa） Fragment：Ligand binding domain, residues 232-505
Not recorded AJA (6AR,10AR)-3-(1,1-DIMETHYLHEPTYL)-1-HYDROXY-6,6-DIMETHYL-6A,7,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMENE-9-CARBOXYLIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions 283 K；4M sodium formate, VAPOR DIFFUSION, HANGING DROP, temperature 283K
Resolution 2.80 Å R-free 0.267
2P4Y Crystal structure of human PPAR-gamma-ligand binding domain complexed with an indole-based modulator Deposited 2007-03-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa） Fragment：Ligand-binding Domain (LBD), Residues 231-505
Chain B 231–505（275 aa） Fragment：Ligand-binding Domain (LBD), Residues 231-505
Not recorded C03 (2R)-2-(4-CHLORO-3-{[3-(6-METHOXY-1,2-BENZISOXAZOL-3-YL)-2-METHYL-6-(TRIFLUOROMETHOXY)-1H-INDOL-1-YL]METHYL}PHENOXY)PROPANOIC ACID × 2 TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；0.95M Trisodium citrate, 0.1M Tris-HCl pH 8.5, 1mM TCEP, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 2.25 Å R-free 0.274
2POB PPARgamma Ligand binding domain complexed with a farglitazar analogue gw4709 Deposited 2007-04-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa） Fragment：Ligand binding domain
Chain B 234–505（272 aa） Fragment：Ligand binding domain
Not recorded GW4 N-[(2S)-2-[(2-BENZOYLPHENYL)AMINO]-3-{4-[2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ETHOXY]PHENYL}PROPYL]ACETAMIDE × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM Hepes and 1.4M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.273
2PRG LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA Deposited 1998-08-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 205–475（271 aa） Fragment：LBD (LIGAND BINDING DOMAIN), RESIDUES 207-477
Not recorded BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 2.30 Å R-free 0.264
2PRG LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA Deposited 1998-08-14 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 205–475（271 aa） Fragment：LBD (LIGAND BINDING DOMAIN), RESIDUES 207-477
Not recorded BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 2.30 Å R-free 0.264
2Q59 Crystal Structure of PPARgamma LBD bound to full agonist MRL20 Deposited 2007-05-31 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 233–505（273 aa） Fragment：Ligand binding domain
Chain B 233–505（273 aa） Fragment：Ligand binding domain
Non-standard monomer：Yes (specific site not provided by mmCIF) 240 (2S)-2-(2-{[1-(4-METHOXYBENZOYL)-2-METHYL-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL]METHYL}PHENOXY)PROPANOIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4 M sodium citrate, 0.125 M Tris 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.20 Å R-free 0.230
2Q5P Crystal Structure of PPARgamma bound to partial agonist MRL24 Deposited 2007-06-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 233–505（273 aa） Fragment：Ligand binding domain
Chain B 233–505（273 aa） Fragment：Ligand binding domain
Not recorded 241 (2S)-2-(3-{[1-(4-METHOXYBENZOYL)-2-METHYL-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL]METHYL}PHENOXY)PROPANOIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4M sodium citrate, 0.125M Tris 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.247
2Q5S Crystal Structure of PPARgamma bound to partial agonist nTZDpa Deposited 2007-06-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 233–505（273 aa） Fragment：Ligand binding domain
Chain B 233–505（273 aa） Fragment：Ligand binding domain
Not recorded NZA 5-CHLORO-1-(4-CHLOROBENZYL)-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4M sodium citrate, 0.125M Tris8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.05 Å R-free 0.245
2Q61 Crystal Structure of PPARgamma ligand binding domain bound to partial agonist SR145 Deposited 2007-06-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 233–505（273 aa） Fragment：Ligand binding domain
Chain B 233–505（273 aa） Fragment：Ligand binding domain
Not recorded SF1 1-BENZYL-5-CHLORO-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4M sodium citrate, 0.125M Tris 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.20 Å R-free 0.229
2Q6R Crystal structure of PPAR gamma complexed with partial agonist SF147 Deposited 2007-06-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 233–505（273 aa） Fragment：Ligand binding domain
Chain B 233–505（273 aa） Fragment：Ligand binding domain
Not recorded SF2 5-CHLORO-1-(3-METHOXYBENZYL)-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4M sodium citrate, 0.125M Tris 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.41 Å R-free 0.284
2Q6S 2.4 angstrom crystal structure of PPAR gamma complexed to BVT.13 without co-activator peptides Deposited 2007-06-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 233–505（273 aa） Fragment：Ligand binding domain
Chain B 233–505（273 aa） Fragment：Ligand binding domain
Not recorded PLB 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4M sodium citrate, 0.125 M Tris 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.40 Å R-free 0.264
2Q8S X-ray Crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a PPAR gamma/alpha dual agonist Deposited 2007-06-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：Ligand binding domain (residue 235-505)
Chain B 235–505（271 aa） Fragment：Ligand binding domain (residue 235-505)
Not recorded L92 (2S)-3-{4-[3-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)PROPYL]PHENYL}-2-(1H-PYRROL-1-YL)PROPANOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；100 mM Immidizole, 860 mM Sodium Citrate, Glycerol 5 % (v/v) , pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.30 Å R-free 0.282
2QMV High Resolution Structure of Peroxisone Proliferation-Activated Receptor gamma and Characterisation of its Interaction with the Co-activator Transcriptional Intermediary Factor 2 Deposited 2007-07-17 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 235–504（270 aa） Fragment：Ligand Binding Domain, residues 235-504
Not recorded No recorded non-water small molecule SOLUTION NMR mmCIF provides none of the parsed conditions Resolution not provided
2VSR hPPARgamma Ligand binding domain in complex with 9-(S)-HODE Deposited 2008-04-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 202–475（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
Not recorded 9HO (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；pH 8
Resolution 2.05 Å R-free 0.266
2VSR hPPARgamma Ligand binding domain in complex with 9-(S)-HODE Deposited 2008-04-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 202–475（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
Not recorded 9HO (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；pH 8
Resolution 2.05 Å R-free 0.266
2VST hPPARgamma Ligand binding domain in complex with 13-(S)-HODE Deposited 2008-04-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 202–475（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
Not recorded 243 (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；pH 8
Resolution 2.35 Å R-free 0.274
2VST hPPARgamma Ligand binding domain in complex with 13-(S)-HODE Deposited 2008-04-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 202–475（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
Not recorded 243 (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；pH 8
Resolution 2.35 Å R-free 0.274
2VV0 hPPARgamma Ligand binding domain in complex with DHA Deposited 2008-06-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 202–475（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
Not recorded HXA DOCOSA-4,7,10,13,16,19-HEXAENOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NACITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
Resolution 2.55 Å R-free 0.261
2VV0 hPPARgamma Ligand binding domain in complex with DHA Deposited 2008-06-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 202–475（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
Not recorded HXA DOCOSA-4,7,10,13,16,19-HEXAENOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NACITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
Resolution 2.55 Å R-free 0.261
2VV1 hPPARgamma Ligand binding domain in complex with 4-HDHA Deposited 2008-06-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 202–475（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
Not recorded 4HD (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NACITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
Resolution 2.20 Å R-free 0.277
2VV1 hPPARgamma Ligand binding domain in complex with 4-HDHA Deposited 2008-06-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 202–475（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
Not recorded 4HD (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NACITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
Resolution 2.20 Å R-free 0.277
2VV2 hPPARgamma Ligand binding domain in complex with 5-HEPA Deposited 2008-06-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 202–475（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
Not recorded 5HE (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NA CITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELCIUS
Resolution 2.75 Å R-free 0.263
2VV2 hPPARgamma Ligand binding domain in complex with 5-HEPA Deposited 2008-06-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 202–475（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
Not recorded 5HE (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NA CITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELCIUS
Resolution 2.75 Å R-free 0.263
2VV3 hPPARgamma Ligand binding domain in complex with 4-oxoDHA Deposited 2008-06-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 202–475（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
Not recorded 4R8 (6E,10Z,13Z,16Z,19Z)-4-oxodocosa-6,10,13,16,19-pentaenoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；295 K；TRIS 100MM PH 8, 0.7M NA-CITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
Resolution 2.85 Å R-free 0.252
2VV3 hPPARgamma Ligand binding domain in complex with 4-oxoDHA Deposited 2008-06-02 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 202–475（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；295 K；TRIS 100MM PH 8, 0.7M NA-CITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
Resolution 2.85 Å R-free 0.252
2VV4 hPPARgamma Ligand binding domain in complex with 6-oxoOTE Deposited 2008-06-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 202–475（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
Not recorded 6OC (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NACITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
Resolution 2.35 Å R-free 0.252
2VV4 hPPARgamma Ligand binding domain in complex with 6-oxoOTE Deposited 2008-06-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 202–475（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
Not recorded 6OB (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NACITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
Resolution 2.35 Å R-free 0.252
2XKW LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST PIOGLITAZONE Deposited 2010-07-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 204–477（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 204-477
Not recorded P1B (5R)-5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione × 1 PE4 2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.5；292 K；PROTEIN CONC. 17MG/ML, 50 MM TRIS PH 8.0,0.1M NACL, 0.5 MM DTT, 2 MM EDTA. RESERVOIR: 20% PEG4000,10% ISOPROPANOL, 0.1M HEPES PH 7.5 , VAPOR DIFFUSION,TEMPERATURE 292K
Resolution 2.02 Å R-free 0.202
2XKW LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST PIOGLITAZONE Deposited 2010-07-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 204–477（274 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 204-477
Not recorded P1B (5R)-5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.5；292 K；PROTEIN CONC. 17MG/ML, 50 MM TRIS PH 8.0,0.1M NACL, 0.5 MM DTT, 2 MM EDTA. RESERVOIR: 20% PEG4000,10% ISOPROPANOL, 0.1M HEPES PH 7.5 , VAPOR DIFFUSION,TEMPERATURE 292K
Resolution 2.02 Å R-free 0.202
2YFE Ligand binding domain of human PPAR gamma in complex with amorfrutin 1 Deposited 2011-04-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 195–477（283 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 195-477
Not recorded YFE Amorfrutin 1 × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；0.8M TRI-SODIUM CITRATE, 0.1M IMIDAZOLE, PH 8.0
Resolution 2.00 Å R-free 0.254
2YFE Ligand binding domain of human PPAR gamma in complex with amorfrutin 1 Deposited 2011-04-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 195–477（283 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 195-477
Not recorded YFE Amorfrutin 1 × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；0.8M TRI-SODIUM CITRATE, 0.1M IMIDAZOLE, PH 8.0
Resolution 2.00 Å R-free 0.254
2ZK0 Human peroxisome proliferator-activated receptor gamma ligand binding domain Deposited 2008-03-12 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain
Chain B 223–504（282 aa） Fragment：ligand binding domain
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.36 Å R-free 0.313
2ZK0 Human peroxisome proliferator-activated receptor gamma ligand binding domain Deposited 2008-03-12 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain
Chain B 223–504（282 aa） Fragment：ligand binding domain
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.36 Å R-free 0.313
2ZK1 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 15-deoxy-delta12,14-prostaglandin J2 Deposited 2008-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain
Chain B 223–504（282 aa） Fragment：ligand binding domain
Not recorded PTG (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.61 Å R-free 0.307
2ZK1 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 15-deoxy-delta12,14-prostaglandin J2 Deposited 2008-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain
Chain B 223–504（282 aa） Fragment：ligand binding domain
Not recorded PTG (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.61 Å R-free 0.307
2ZK2 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with glutathion conjugated 15-deoxy-delta12,14-prostaglandin J2 Deposited 2008-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain
Chain B 223–504（282 aa） Fragment：ligand binding domain
Not recorded GSH Glutathione × 1 PTG (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.26 Å R-free 0.299
2ZK2 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with glutathion conjugated 15-deoxy-delta12,14-prostaglandin J2 Deposited 2008-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain
Chain B 223–504（282 aa） Fragment：ligand binding domain
Not recorded GSH Glutathione × 1 PTG (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.26 Å R-free 0.299
2ZK3 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 8-oxo-eicosatetraenoic acid Deposited 2008-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain
Chain B 223–504（282 aa） Fragment：ligand binding domain
Not recorded OCX (5E,11E,14E)-8-oxoicosa-5,9,11,14-tetraenoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.58 Å R-free 0.299
2ZK3 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 8-oxo-eicosatetraenoic acid Deposited 2008-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain
Chain B 223–504（282 aa） Fragment：ligand binding domain
Not recorded OCX (5E,11E,14E)-8-oxoicosa-5,9,11,14-tetraenoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.58 Å R-free 0.299
2ZK4 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 15-oxo-eicosatetraenoic acid Deposited 2008-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain
Chain B 223–504（282 aa） Fragment：ligand binding domain
Not recorded OCR (5E,8E,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.57 Å R-free 0.306
2ZK4 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 15-oxo-eicosatetraenoic acid Deposited 2008-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain
Chain B 223–504（282 aa） Fragment：ligand binding domain
Not recorded OCR (5E,8E,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.57 Å R-free 0.306
2ZK5 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with nitro-233 Deposited 2008-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain
Chain B 223–504（282 aa） Fragment：ligand binding domain
Not recorded NRO 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.45 Å R-free 0.306
2ZK5 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with nitro-233 Deposited 2008-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain
Chain B 223–504（282 aa） Fragment：ligand binding domain
Not recorded NRO 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.45 Å R-free 0.306
2ZK6 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with C8-BODIPY Deposited 2008-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain
Chain B 223–504（282 aa） Fragment：ligand binding domain
Not recorded C08 difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.41 Å R-free 0.299
2ZK6 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with C8-BODIPY Deposited 2008-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain
Chain B 223–504（282 aa） Fragment：ligand binding domain
Not recorded C08 difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.41 Å R-free 0.299
2ZNO Human PPAR gamma ligand binding domain in complex with a synthetic agonist TIPP703 Deposited 2008-04-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：Ligand binding domain
Chain B 223–504（282 aa） Fragment：Ligand binding domain
Not recorded S44 (2S)-2-(4-propoxy-3-{[({4-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]phenyl}carbonyl)amino]methyl}benzyl)butanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M Sodium citrate, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.40 Å R-free 0.286
2ZNO Human PPAR gamma ligand binding domain in complex with a synthetic agonist TIPP703 Deposited 2008-04-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：Ligand binding domain
Chain B 223–504（282 aa） Fragment：Ligand binding domain
Not recorded S44 (2S)-2-(4-propoxy-3-{[({4-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]phenyl}carbonyl)amino]methyl}benzyl)butanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M Sodium citrate, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.40 Å R-free 0.286
2ZVT Cys285Ser mutant PPARgamma ligand-binding domain complexed with 15-deoxy-delta12,14-prostaglandin J2 Deposited 2008-11-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：Ligand-binding domain
Chain B 223–504（282 aa） Fragment：Ligand-binding domain
Mutation：C285S Mutation：C285S PTG (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M Hepes, 0.8M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.90 Å R-free 0.275
2ZVT Cys285Ser mutant PPARgamma ligand-binding domain complexed with 15-deoxy-delta12,14-prostaglandin J2 Deposited 2008-11-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：Ligand-binding domain
Chain B 223–504（282 aa） Fragment：Ligand-binding domain
Mutation：C285S Mutation：C285S PTG (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M Hepes, 0.8M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.90 Å R-free 0.275
3ADS Human PPARgamma ligand-binding domain in complex with indomethacin Deposited 2010-01-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Chain B 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Not recorded IMN INDOMETHACIN × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.25 Å R-free 0.277
3ADS Human PPARgamma ligand-binding domain in complex with indomethacin Deposited 2010-01-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Chain B 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Not recorded IMN INDOMETHACIN × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.25 Å R-free 0.277
3ADT Human PPARgamma ligand-binding domain in complex with 5-hydroxy-indole acetate Deposited 2010-01-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Chain B 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Not recorded HID (5-hydroxy-1H-indol-3-yl)acetic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.70 Å R-free 0.283
3ADT Human PPARgamma ligand-binding domain in complex with 5-hydroxy-indole acetate Deposited 2010-01-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Chain B 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Not recorded HID (5-hydroxy-1H-indol-3-yl)acetic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.70 Å R-free 0.283
3ADU Human PPARgamma ligand-binding domain in complex with 5-methoxy-indole acetate Deposited 2010-01-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Chain B 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Not recorded MYI (5-methoxy-1H-indol-3-yl)acetic acid × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.77 Å R-free 0.276
3ADU Human PPARgamma ligand-binding domain in complex with 5-methoxy-indole acetate Deposited 2010-01-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Chain B 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Not recorded MYI (5-methoxy-1H-indol-3-yl)acetic acid × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.77 Å R-free 0.276
3ADV Human PPARgamma ligand-binding domain in complex with serotonin Deposited 2010-01-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Chain B 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Not recorded SRO SEROTONIN × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.27 Å R-free 0.267
3ADV Human PPARgamma ligand-binding domain in complex with serotonin Deposited 2010-01-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Chain B 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Not recorded SRO SEROTONIN × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.27 Å R-free 0.267
3ADW Human PPARgamma ligand-binding domain in complex with 5-methoxy-indole acetate and 15-oxo-eicosatetraenoic acid Deposited 2010-01-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Chain B 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Not recorded MYI (5-methoxy-1H-indol-3-yl)acetic acid × 1 OCR (5E,8E,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.07 Å R-free 0.265
3ADW Human PPARgamma ligand-binding domain in complex with 5-methoxy-indole acetate and 15-oxo-eicosatetraenoic acid Deposited 2010-01-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Chain B 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Not recorded MYI (5-methoxy-1H-indol-3-yl)acetic acid × 1 OCR (5E,8E,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.07 Å R-free 0.265
3ADX Human PPARgamma ligand-binding domain in complex with indomethacin and nitro-233 Deposited 2010-01-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Chain B 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Not recorded NRO 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid × 1 IMN INDOMETHACIN × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.95 Å R-free 0.275
3ADX Human PPARgamma ligand-binding domain in complex with indomethacin and nitro-233 Deposited 2010-01-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Chain B 223–505（283 aa） Fragment：ligand-binding domain, residues in UNP 223-505
Not recorded NRO 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid × 1 IMN INDOMETHACIN × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.95 Å R-free 0.275
3AN3 Human PPAR gamma ligand binding domain in complex with a gamma selective agonist MO3S Deposited 2010-08-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：Ligand binding domain
Chain B 223–504（282 aa） Fragment：Ligand binding domain
Not recorded M7S (2S)-2-benzyl-3-(4-propoxy-3-{[({4-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]phenyl}carbonyl)amino]methyl}phenyl)propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.30 Å R-free 0.278
3AN3 Human PPAR gamma ligand binding domain in complex with a gamma selective agonist MO3S Deposited 2010-08-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：Ligand binding domain
Chain B 223–504（282 aa） Fragment：Ligand binding domain
Not recorded M7S (2S)-2-benzyl-3-(4-propoxy-3-{[({4-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]phenyl}carbonyl)amino]methyl}phenyl)propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.30 Å R-free 0.278
3AN4 Human PPAR gamma ligand binding domain in complex with a gamma selective agonist MO4R Deposited 2010-08-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：Ligand binding domain
Chain B 223–504（282 aa） Fragment：Ligand binding domain
Not recorded M7R (2R)-2-benzyl-3-(4-propoxy-3-{[({4-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]phenyl}carbonyl)amino]methyl}phenyl)propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.30 Å R-free 0.288
3AN4 Human PPAR gamma ligand binding domain in complex with a gamma selective agonist MO4R Deposited 2010-08-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：Ligand binding domain
Chain B 223–504（282 aa） Fragment：Ligand binding domain
Not recorded M7R (2R)-2-benzyl-3-(4-propoxy-3-{[({4-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]phenyl}carbonyl)amino]methyl}phenyl)propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.30 Å R-free 0.288
3B0Q Human PPAR gamma ligand binding domain in complex with MCC555 Deposited 2011-06-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–504（274 aa） Fragment：UNP RESIDUES 231-504
Chain B 231–504（274 aa） Fragment：UNP RESIDUES 231-504
Not recorded MC5 (5S)-5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M Sodium Citrate, 0.1M Hepes (pH7.5), VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.10 Å R-free 0.229
3B0R Human PPAR gamma ligand binding dmain complexed with GW9662 in a covalent bonded form Deposited 2011-06-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–504（274 aa） Fragment：UNP RESIDUES 231-504
Chain B 231–504（274 aa） Fragment：UNP RESIDUES 231-504
Not recorded GW9 2-chloro-5-nitro-N-phenylbenzamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M sodium citrate, 0.1M Hepes (pH7.5), VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.15 Å R-free 0.249
3B1M Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Cerco-A Deposited 2011-07-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa） Fragment：ligand binding domain, UNP residues 234-505
Not recorded KRC (9aS)-8-acetyl-N-[(2-ethylnaphthalen-1-yl)methyl]-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, sodium thiocyanate, Tris-hydrochloride, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 1.60 Å R-free 0.244
3B3K Crystal structure of the complex between PPARgamma and the full agonist LT175 Deposited 2007-10-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：UNP residues 223-504
Chain B 223–504（282 aa） Fragment：UNP residues 223-504
Not recorded LRG (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.60 Å R-free 0.316
3B3K Crystal structure of the complex between PPARgamma and the full agonist LT175 Deposited 2007-10-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：UNP residues 223-504
Chain B 223–504（282 aa） Fragment：UNP residues 223-504
Not recorded LRG (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.60 Å R-free 0.316
3BC5 X-ray crystal structure of human ppar gamma with 2-(5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-2-phenyl-2h-1,2,3-triazol-4-yl)acetic acid Deposited 2007-11-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa） Fragment：ligand binding domain
Not recorded ZAA (5-{3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzyl}-2-phenyl-2H-1,2,3-triazol-4-yl)acetic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294 K；2.4M Na-Formate, 0.3M ammonium acetate, pH 7.5, vapor diffusion, hanging drop, temperature 294K
Resolution 2.27 Å R-free 0.249
3CDP Crystal structure of PPAR-gamma LBD complexed with a partial agonist, analogue of clofibric acid Deposited 2008-02-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Chain B 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Not recorded YRG (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15mM Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.80 Å R-free 0.298
3CDP Crystal structure of PPAR-gamma LBD complexed with a partial agonist, analogue of clofibric acid Deposited 2008-02-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Not recorded YRG (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15mM Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.80 Å R-free 0.298
3CDP Crystal structure of PPAR-gamma LBD complexed with a partial agonist, analogue of clofibric acid Deposited 2008-02-27 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15mM Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.80 Å R-free 0.298
3CDS Crystal structure of the complex between PPAR-gamma and the agonist LT248 (clofibric acid analogue) Deposited 2008-02-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Chain B 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Not recorded GRR (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15mM Tris, pH 8.000, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.65 Å R-free 0.319
3CDS Crystal structure of the complex between PPAR-gamma and the agonist LT248 (clofibric acid analogue) Deposited 2008-02-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Not recorded GRR (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15mM Tris, pH 8.000, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.65 Å R-free 0.319
3CDS Crystal structure of the complex between PPAR-gamma and the agonist LT248 (clofibric acid analogue) Deposited 2008-02-27 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15mM Tris, pH 8.000, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.65 Å R-free 0.319
3CS8 Structural and Biochemical Basis for the Binding Selectivity of PPARg to PGC-1a Deposited 2008-04-09 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–504（271 aa） Fragment：LBD domain (UNP residues 234-504)
Not recorded SO4 SULFATE ION × 4 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.2；298 K；20% PEG3350, 0.2M Ammonium Iodide, pH 6.2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.282
3CWD Molecular recognition of nitro-fatty acids by PPAR gamma Deposited 2008-04-21 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 236–505（270 aa） Fragment：PPAR gamma LBD domain
Not recorded LNA (9E,12Z)-10-nitrooctadeca-9,12-dienoic acid × 1 LNB (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.40 Å R-free 0.290
3CWD Molecular recognition of nitro-fatty acids by PPAR gamma Deposited 2008-04-21 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 236–505（270 aa） Fragment：PPAR gamma LBD domain
Not recorded LNA (9E,12Z)-10-nitrooctadeca-9,12-dienoic acid × 1 LNB (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.40 Å R-free 0.290
3D6D Crystal Structure of the complex between PPARgamma LBD and the LT175(R-enantiomer) Deposited 2008-05-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Chain B 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Not recorded LRG (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.40 Å R-free 0.305
3D6D Crystal Structure of the complex between PPARgamma LBD and the LT175(R-enantiomer) Deposited 2008-05-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Chain B 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Not recorded LRG (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.40 Å R-free 0.305
3DZU Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with BVT.13, 9-cis Retinoic Acid and NCOA2 Peptide Deposited 2008-07-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: hexameric
Chain D 102–505（404 aa） Fragment：UNP residues 102-505
Not recorded ZN ZINC ION × 4 9CR (9cis)-retinoic acid × 1 PLB 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；15-18% PEG 3350, 25mM MgCl2, 100mM NH4Cl, 5mM DTT and 0.1M MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 3.20 Å R-free 0.272
3DZY Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with Rosiglitazone, 9-cis Retinoic Acid and NCOA2 Peptide Deposited 2008-07-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: hexameric
Chain D 102–505（404 aa） Fragment：UNP residues 102-505
Not recorded 9CR (9cis)-retinoic acid × 1 ZN ZINC ION × 4 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；15-18% PEG 3350, 25mM MgCl2, 100mM NH4Cl, 5mM DTT and 0.1M MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 3.10 Å R-free 0.268
3E00 Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with GW9662, 9-cis Retinoic Acid and NCOA2 Peptide Deposited 2008-07-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: hexameric
Chain D 102–505（404 aa） Fragment：UNP residues 102-505
Not recorded ZN ZINC ION × 4 9CR (9cis)-retinoic acid × 1 GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；15-18% PEG 3350, 25mM MgCl2, 100mM NH4Cl, 5mM DTT and 0.1M MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 3.10 Å R-free 0.276
3ET0 Structure of PPARgamma with 3-(5-Methoxy-1H-indol-3-yl)-propionic acid Deposited 2008-10-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN
Non-standard monomer：Yes (specific site not provided by mmCIF) ET0 3-(5-methoxy-1H-indol-3-yl)propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；The purified PPARg ligand binding domain (LBD) protein was diluated to 12 mg/ml and 1mM of compound 1 was added to the protein prior to crystallization by mixing equal volumes of protein/compound sample with reservoir solution containing 0.9 M sodium citrate and 0.1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) at pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 2.40 Å R-free 0.255
3ET0 Structure of PPARgamma with 3-(5-Methoxy-1H-indol-3-yl)-propionic acid Deposited 2008-10-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN
Non-standard monomer：Yes (specific site not provided by mmCIF) GLC alpha-D-glucopyranose × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；The purified PPARg ligand binding domain (LBD) protein was diluated to 12 mg/ml and 1mM of compound 1 was added to the protein prior to crystallization by mixing equal volumes of protein/compound sample with reservoir solution containing 0.9 M sodium citrate and 0.1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) at pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 2.40 Å R-free 0.255
3ET3 Structure of PPARgamma with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid Deposited 2008-10-06 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN
Not recorded ET1 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5；277 K；The purified PPARg LBD protein was diluted to 12 mg/ml and 1mM of indeglitazar and 2x molar excess of SRC-1 peptide were added prior to crystallization by mixing equal volumes of protein/compound sample with reservoir solution containing 27% polyethylene glycol (PEG) 4000, 0.1 M 2-(bis-(2-hydroxy-ethyl)-amino)-2-hydroxymethyl- propane-1,3-diol (BisTris) buffer at pH 6.5, 0.2 M ammonium acetate, and 5% glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.95 Å R-free 0.236
3FEJ Design and biological evaluation of novel, balanced dual PPARa/g agonists Deposited 2008-11-30 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：PPAR gamma ligand binding domain
Not recorded CTM (2S)-3-(4-{[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methoxy}-2-methylphenyl)-2-ethoxypropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.1M Tris, 15-20% PEG3350, 10% Glycerol, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.01 Å R-free 0.250
3FUR Crystal Structure of PPARg in complex with INT131 Deposited 2009-01-14 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa） Fragment：LBD (ligand binding domain), UNP residues 234-505
Not recorded Z12 2,4-dichloro-N-[3,5-dichloro-4-(quinolin-3-yloxy)phenyl]benzenesulfonamide × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；30% PEG 4000, 0.2M MgCl2, Tris-HCl 8.5, vapor diffusion, hanging drop, temperature 298K
Resolution 2.30 Å R-free 0.242
3G9E Aleglitaar. a new. potent, and balanced dual ppara/g agonist for the treatment of type II diabetes Deposited 2009-02-13 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN
Not recorded RO7 (2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.2M NaK TARTRATE, 25% PEG 3350, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.30 Å R-free 0.262
3GBK Crystal Structure of Human PPAR-gamma Ligand Binding Domain Complexed with a Potent and Selective Agonist Deposited 2009-02-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：ligand binding domian, UNP residues 235-505
Chain B 235–505（271 aa） Fragment：ligand binding domian, UNP residues 235-505
Not recorded 2PQ 2-[(1-{3-[4-(biphenyl-4-ylcarbonyl)-2-propylphenoxy]propyl}-1,2,3,4-tetrahydroquinolin-5-yl)oxy]-2-methylpropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；28.25% PEG 3350. 0.016M sodium citrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.30 Å R-free 0.298
3H0A Crystal Structure of Peroxisome Proliferator-Activated Receptor Gamma (PPARg) and Retinoic Acid Receptor Alpha (RXRa) in Complex with 9-cis Retinoic Acid, Co-activator Peptide, and a Partial Agonist Deposited 2009-04-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain D 234–505（272 aa） Fragment：UNP RESIDUES 234-505
Not recorded 9RA 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid × 1 D30 [(4-{[2-(pent-2-yn-1-yloxy)-4-{[4-(trifluoromethyl)phenoxy]methyl}phenyl]sulfanyl}-5,6,7,8-tetrahydronaphthalen-1-yl)oxy]acetic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.5；289 K；25% PEG 2000 monomethyl ether, 0.3 M sodium acetate, 0.1 M Hepes 7.5, vapor diffusion, temperature 289K
Resolution 2.10 Å R-free 0.342
3HO0 Crystal structure of the PPARgamma-LBD complexed with a new aryloxy-3phenylpropanoic acid Deposited 2009-06-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Chain B 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Not recorded DKD (2S)-2-(4-phenethylphenoxy)-3-phenyl-propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.60 Å R-free 0.328
3HOD Crystal structure of the PPARgamma-LBD complexed with a new aryloxy-3phenylpropanoic acid Deposited 2009-06-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Chain B 223–504（282 aa） Fragment：ligand binding domain (LBD), UNP residues 223-504
Not recorded ZZH (2S)-2-(4-benzylphenoxy)-3-phenylpropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.10 Å R-free 0.290
3IA6 X-ray Crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a PPAR gamma/alpha dual agonist Deposited 2009-07-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：UNP residue 235-505
Chain B 235–505（271 aa） Fragment：UNP residue 235-505
Not recorded UNT (2S)-3-{4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propyl]phenyl}-2-(2H-1,2,3-triazol-2-yl)propanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；288 K；well solution consisting of 0.6 - 0.8 M tri-sodium citrate, 0.1 M imidazole pH 8 and 1 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 288K
Resolution 2.31 Å R-free 0.297
3IA6 X-ray Crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a PPAR gamma/alpha dual agonist Deposited 2009-07-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：UNP residue 235-505
Chain B 235–505（271 aa） Fragment：UNP residue 235-505
Not recorded UNT (2S)-3-{4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propyl]phenyl}-2-(2H-1,2,3-triazol-2-yl)propanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；288 K；well solution consisting of 0.6 - 0.8 M tri-sodium citrate, 0.1 M imidazole pH 8 and 1 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 288K
Resolution 2.31 Å R-free 0.297
3K8S Crystal Structure of PPARg in complex with T2384 Deposited 2009-10-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa） Fragment：UNP residues 234-505, Ligand binding domain
Chain B 234–505（272 aa） Fragment：UNP residues 234-505, Ligand binding domain
Not recorded Z27 2-chloro-N-{3-chloro-4-[(5-chloro-1,3-benzothiazol-2-yl)sulfanyl]phenyl}-4-(trifluoromethyl)benzenesulfonamide × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.55 Å R-free 0.273
3K8S Crystal Structure of PPARg in complex with T2384 Deposited 2009-10-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 234–505（272 aa） Fragment：UNP residues 234-505, Ligand binding domain
Not recorded Z27 2-chloro-N-{3-chloro-4-[(5-chloro-1,3-benzothiazol-2-yl)sulfanyl]phenyl}-4-(trifluoromethyl)benzenesulfonamide × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.55 Å R-free 0.273
3K8S Crystal Structure of PPARg in complex with T2384 Deposited 2009-10-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 234–505（272 aa） Fragment：UNP residues 234-505, Ligand binding domain
Not recorded Z27 2-chloro-N-{3-chloro-4-[(5-chloro-1,3-benzothiazol-2-yl)sulfanyl]phenyl}-4-(trifluoromethyl)benzenesulfonamide × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.55 Å R-free 0.273
3KMG The X-ray Crystal Structure of PPAR-gamma in Complex with an Indole Derivative Modulator, GSK538, and an SRC-1 Peptide Deposited 2009-11-10 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa） Fragment：UNP residues 234-505
Not recorded 538 4'-[(2,3-dimethyl-5-{[(1S)-1-phenylpropyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；Diffraction grade crystals grew in 7-14 days at 22C using 2uL vapor diffused hanging drops made with 1uL of the complex and 1uL of the well solution comprised of 14% PEG4K, 0.2M NaSCN and 0.1M Bis-tris pH 6.5., VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.10 Å R-free 0.230
3KMG The X-ray Crystal Structure of PPAR-gamma in Complex with an Indole Derivative Modulator, GSK538, and an SRC-1 Peptide Deposited 2009-11-10 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 234–505（272 aa） Fragment：UNP residues 234-505
Not recorded 538 4'-[(2,3-dimethyl-5-{[(1S)-1-phenylpropyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；Diffraction grade crystals grew in 7-14 days at 22C using 2uL vapor diffused hanging drops made with 1uL of the complex and 1uL of the well solution comprised of 14% PEG4K, 0.2M NaSCN and 0.1M Bis-tris pH 6.5., VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.10 Å R-free 0.230
3LMP Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Deposited 2010-01-31 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa） Fragment：UNP residues 234-505
Not recorded CEK (9aS)-8-acetyl-1,7-dihydroxy-3-methoxy-9a-methyl-N-(1-naphthylmethyl)-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, NaSCN, vapor diffusion, temperature 295K, VAPOR DIFFUSION, HANGING DROP, pH 8.5
Resolution 1.90 Å R-free 0.242
3NOA Crystal structure of human PPAR-gamma ligand binding domain complex with a potency improved agonist Deposited 2010-06-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：lignad binding domain
Chain B 235–505（271 aa） Fragment：lignad binding domain
Not recorded 5BC (5-{3-[4-(biphenyl-4-ylcarbonyl)-2-propylphenoxy]propoxy}-1H-indol-1-yl)acetic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；27.5% PEG 3350, 16mM sodium citrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.98 Å R-free 0.275
3OSI Crystal structure of PPARgamma ligand binding domain in complex with tetrachloro-bisphenol A (TCBPA) Deposited 2010-09-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 224–504（281 aa） Fragment：ligand binding domain
Not recorded XDH 4,4'-propane-2,2-diylbis(2,6-dichlorophenol) × 1 PGO S-1,2-PROPANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1M tri-sodium citrate, 100 mM Hepes, 3% 1,2-propanediol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.70 Å R-free 0.253
3OSI Crystal structure of PPARgamma ligand binding domain in complex with tetrachloro-bisphenol A (TCBPA) Deposited 2010-09-09 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 224–504（281 aa） Fragment：ligand binding domain
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1M tri-sodium citrate, 100 mM Hepes, 3% 1,2-propanediol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.70 Å R-free 0.253
3OSW Crystal structure of PPARgamma ligand binding domain in complex with tetrabromo-bisphenol A (TBBPA) Deposited 2010-09-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 224–504（281 aa） Fragment：ligand binding domain
Not recorded XDI 4,4'-propane-2,2-diylbis(2,6-dibromophenol) × 1 PGO S-1,2-PROPANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1M tri-sodium citrate, 100 mM Hepes, 3.5% 1,2-propanediol, 0.2 mM TBBPA, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.55 Å R-free 0.251
3OSW Crystal structure of PPARgamma ligand binding domain in complex with tetrabromo-bisphenol A (TBBPA) Deposited 2010-09-10 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 224–504（281 aa） Fragment：ligand binding domain
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1M tri-sodium citrate, 100 mM Hepes, 3.5% 1,2-propanediol, 0.2 mM TBBPA, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.55 Å R-free 0.251
3PBA Crystal structure of PPARgamma ligand binding domain in complex with monosulfate tetrabromo-bisphenol A (MonoTBBPA) Deposited 2010-10-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 224–505（282 aa） Fragment：ligand binding domain
Not recorded ZXG 2,6-dibromo-4-[2-(3,5-dibromo-4-hydroxyphenyl)propan-2-yl]phenyl hydrogen sulfate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；tri-sodium citrate, Hepes, 1,2-propanediol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.30 Å R-free 0.255
3PBA Crystal structure of PPARgamma ligand binding domain in complex with monosulfate tetrabromo-bisphenol A (MonoTBBPA) Deposited 2010-10-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 224–505（282 aa） Fragment：ligand binding domain
Not recorded PGO S-1,2-PROPANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；tri-sodium citrate, Hepes, 1,2-propanediol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.30 Å R-free 0.255
3PO9 Crystal structure of PPARgamma ligand binding domain in complex with tripropyltin Deposited 2010-11-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 224–505（282 aa） Fragment：ligand binding domain
Not recorded XPT 1-[chloro(dipropyl)-lambda~4~-sulfanyl]propane × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；1.2M tri-sodium citrate, 100mM Hepes, 3.5% 1,2-propanediol, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.35 Å R-free 0.269
3PO9 Crystal structure of PPARgamma ligand binding domain in complex with tripropyltin Deposited 2010-11-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 224–505（282 aa） Fragment：ligand binding domain
Not recorded XPT 1-[chloro(dipropyl)-lambda~4~-sulfanyl]propane × 1 PGO S-1,2-PROPANEDIOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；1.2M tri-sodium citrate, 100mM Hepes, 3.5% 1,2-propanediol, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.35 Å R-free 0.269
3PRG LIGAND BINDING DOMAIN OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR Deposited 1998-08-24 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 202–475（274 aa） Fragment：LIGAND BINDING DOMAIN
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 9.5；pH 9.50
Resolution 2.90 Å R-free 0.271
3QT0 Revealing a steroid receptor ligand as a unique PPARgamma agonist Deposited 2011-02-22 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：UNP residues 235-505
Not recorded 486 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；PEG, Tris-HCl, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.50 Å R-free 0.277
3R5N Crystal structure of PPARgammaLBD complexed with the agonist magnolol Deposited 2011-03-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 232–505（274 aa） Fragment：ligand binding domain (UNP residues 232-505)
Not recorded MLO 5,5'-di(prop-2-en-1-yl)biphenyl-2,2'-diol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；4 M sodium formate, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.00 Å R-free 0.293
3R8A X-ray crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a compound with dual PPAR gamma agonism and Angiotensin II Type I receptor antagonism activity Deposited 2011-03-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 235–505（271 aa）
Not recorded HIG 2-ethyl-5,7-dimethyl-3-{(1S)-5-[2-(1H-tetrazol-5-yl)phenyl]-2,3-dihydro-1H-inden-1-yl}-3H-imidazo[4,5-b]pyridine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；Apo crystals grown from Citrate/Imidazole, then soaked with 0.5 mM compound 2a, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.41 Å R-free 0.281
3R8A X-ray crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a compound with dual PPAR gamma agonism and Angiotensin II Type I receptor antagonism activity Deposited 2011-03-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 235–505（271 aa）
Not recorded HIG 2-ethyl-5,7-dimethyl-3-{(1S)-5-[2-(1H-tetrazol-5-yl)phenyl]-2,3-dihydro-1H-inden-1-yl}-3H-imidazo[4,5-b]pyridine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；Apo crystals grown from Citrate/Imidazole, then soaked with 0.5 mM compound 2a, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.41 Å R-free 0.281
3R8I Crystal Structure of PPARgamma with an achiral ureidofibrate derivative (RT86) Deposited 2011-03-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：unp residues 223-505
Chain B 223–505（283 aa） Fragment：unp residues 223-505
Not recorded XCX 2-(4-{2-[1,3-benzoxazol-2-yl(heptyl)amino]ethyl}phenoxy)-2-methylpropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；293 K；0.8 M NA Citrate, 0.15 M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.30 Å R-free 0.285
3R8I Crystal Structure of PPARgamma with an achiral ureidofibrate derivative (RT86) Deposited 2011-03-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 223–505（283 aa） Fragment：unp residues 223-505
Not recorded XCX 2-(4-{2-[1,3-benzoxazol-2-yl(heptyl)amino]ethyl}phenoxy)-2-methylpropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；293 K；0.8 M NA Citrate, 0.15 M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.30 Å R-free 0.285
3R8I Crystal Structure of PPARgamma with an achiral ureidofibrate derivative (RT86) Deposited 2011-03-24 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 223–505（283 aa） Fragment：unp residues 223-505
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；293 K；0.8 M NA Citrate, 0.15 M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.30 Å R-free 0.285
3S9S Ligand binding domain of PPARgamma complexed with a benzimidazole partial agonist Deposited 2011-06-02 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa） Fragment：LIGAND BINDING DOMAIN (RESIDUES 234-505)
Not recorded M0T 1-(3,4-dichlorobenzyl)-2-methyl-N-[(1R)-1-phenylpropyl]-1H-benzimidazole-5-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100MM HEPES, 1.4M SODIUM CITRATE, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.55 Å R-free 0.284
3SZ1 Human PPAR gamma ligand binding domain in complex with luteolin and myristic acid Deposited 2011-07-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 232–505（274 aa） Fragment：Ligand binding domain
Not recorded KNA nonanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；Sodium Citrate 0.90 M, HEPES 0.1 M, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.30 Å R-free 0.240
3SZ1 Human PPAR gamma ligand binding domain in complex with luteolin and myristic acid Deposited 2011-07-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 232–505（274 aa） Fragment：Ligand binding domain
Not recorded LU2 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；Sodium Citrate 0.90 M, HEPES 0.1 M, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.30 Å R-free 0.240
3T03 Crystal structure of PPAR gamma ligand binding domain in complex with a novel partial agonist GQ-16 Deposited 2011-07-19 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: monomeric
Chain A 234–505（272 aa） Fragment：UNP residues 234-505
Not recorded 3T0 (5Z)-5-(5-bromo-2-methoxybenzylidene)-3-(4-methylbenzyl)-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.2 M Ammonium acetate, 0.1 M Sodium citrate, pH 5.6, 30%(w/v) PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.10 Å R-free 0.247
3T03 Crystal structure of PPAR gamma ligand binding domain in complex with a novel partial agonist GQ-16 Deposited 2011-07-19 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: monomeric
Chain B 234–505（272 aa） Fragment：UNP residues 234-505
Not recorded 3T0 (5Z)-5-(5-bromo-2-methoxybenzylidene)-3-(4-methylbenzyl)-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.2 M Ammonium acetate, 0.1 M Sodium citrate, pH 5.6, 30%(w/v) PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.10 Å R-free 0.247
3TY0 Structure of PPARgamma ligand binding domain in complex with (R)-5-(3-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenyl)-5-methyloxazolidine-2,4-dione Deposited 2011-09-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Chain B 231–505（275 aa）
Not recorded 082 (5R)-5-(3-{[3-(6-methoxy-1,2-benzoxazol-3-yl)-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl]methyl}phenyl)-5-methyl-1,3-oxazolidine-2,4-dione × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.00 Å R-free 0.273
3U9Q Ligand binding domain of PPARgamma complexed with Decanoic Acid and PGC-1a peptide Deposited 2011-10-19 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 236–504（269 aa） Fragment：Ligand Binding Domain, UNP residues 236-504
Not recorded DKA DECANOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.2；298 K；0.2 M sodium acetate (pH 6.2), 20% PEG 3350, 15% glycerol and 1 mM concentration of the ligand., VAPOR DIFFUSION, temperature 298K
Resolution 1.52 Å R-free 0.222
3V9T Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Deposited 2011-12-28 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa） Fragment：ligand binding domain, UNP residues 234-505
Not recorded 17L (9aS)-8-acetyl-N-[(3-ethoxynaphthalen-1-yl)methyl]-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, sodium thiocyanate, Tris-hydrochloride, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 1.65 Å R-free 0.219
3V9V Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Deposited 2011-12-28 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa） Fragment：ligand binding domain, UNP residues 234-505
Not recorded 21L methyl 3-{4-[({[(9aS)-8-acetyl-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-yl]carbonyl}amino)methyl]naphthalen-2-yl}propanoate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, sodium thiocyanate, Tris-hydrochloride, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 1.60 Å R-free 0.244
3V9Y Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Deposited 2011-12-28 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa） Fragment：ligand binding domain, UNP residues 234-505
Not recorded 24L 4-{4-[({[(9aS)-8-acetyl-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-yl]carbonyl}amino)methyl]naphthalen-2-yl}butanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, sodium thiocyanate, Tris-hydrochloride, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.10 Å R-free 0.252
3VJH Human PPAR GAMMA ligand binding domain in complex with JKPL35 Deposited 2011-10-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：UNP RESIDUES 223-504
Chain B 223–504（282 aa） Fragment：UNP RESIDUES 223-504
Not recorded J35 (2S)-2-[4-methoxy-3-({[4-(trifluoromethyl)benzoyl]amino}methyl)benzyl]pentanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M Sodium citrate, 0.1M HEPES (pH7.5), VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.22 Å R-free 0.247
3VJI Human PPAR gamma ligand binding domain in complex with JKPL53 Deposited 2011-10-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：UNP RESIDUES 223-504
Chain B 223–504（282 aa） Fragment：UNP RESIDUES 223-504
Not recorded J53 (2S)-2-{4-butoxy-3-[({4-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]benzoyl}amino)methyl]benzyl}butanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.8M Sodium Citrate, 0.1M HEPES (pH7.5), VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.61 Å R-free 0.280
3VN2 Crystal Structure of PPARgamma complexed with Telmisartan Deposited 2011-12-21 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 225–505（281 aa） Fragment：Ligand biding domain, UNP residues 225-505
Not recorded TLS 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M TRIS-HCL, 0.8M SODIUM CITRATE TRIBASIC DIHYDRATE, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293.0K
Resolution 2.18 Å R-free 0.309
3VSO Human PPAR gamma ligand binding domain in complex with a gamma selective agonist mekt21 Deposited 2012-04-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：Ligand binding domain
Chain B 223–504（282 aa） Fragment：Ligand binding domain
Not recorded EK1 (2R)-2-benzyl-3-[4-propoxy-3-({[4-(pyrimidin-2-yl)benzoyl]amino}methyl)phenyl]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.00 Å R-free 0.257
3VSO Human PPAR gamma ligand binding domain in complex with a gamma selective agonist mekt21 Deposited 2012-04-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：Ligand binding domain
Chain B 223–504（282 aa） Fragment：Ligand binding domain
Not recorded EK1 (2R)-2-benzyl-3-[4-propoxy-3-({[4-(pyrimidin-2-yl)benzoyl]amino}methyl)phenyl]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.00 Å R-free 0.257
3VSP Human PPAR gamma ligand binding domain in complex with a gamma selective agonist mekt28 Deposited 2012-04-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：Ligand binding domain
Chain B 223–504（282 aa） Fragment：Ligand binding domain
Not recorded EK8 (2R)-2-benzyl-3-[3-({[4-(piperidin-1-yl)benzoyl]amino}methyl)-4-propoxyphenyl]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.40 Å R-free 0.274
3VSP Human PPAR gamma ligand binding domain in complex with a gamma selective agonist mekt28 Deposited 2012-04-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：Ligand binding domain
Chain B 223–504（282 aa） Fragment：Ligand binding domain
Not recorded EK8 (2R)-2-benzyl-3-[3-({[4-(piperidin-1-yl)benzoyl]amino}methyl)-4-propoxyphenyl]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.40 Å R-free 0.274
3WJ4 Crystal structure of PPARgamma ligand binding domain in complex with tributyltin Deposited 2013-10-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：UNP residues 235-505
Chain B 235–505（271 aa） Fragment：UNP residues 235-505
Not recorded TBY tributylstannanyl × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；100mM Tris-HCl pH 8.5, 160mM CH3COONH4, 19-23% PEG 4000, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.95 Å R-free 0.241
3WJ5 Crystal structure of PPARgamma ligand binding domain in complex with triphenyltin Deposited 2013-10-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：UNP residues 235-505
Chain B 235–505（271 aa） Fragment：UNP residues 235-505
Not recorded T9T triphenylstannanyl × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；100mM Tris-HCl pH 8.5, 160mM CH3COONH4, 19-23% PEG 4000, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.89 Å R-free 0.247
3WMH Human PPAR gamma ligand binding domain in complex with a gammma selective synthetic partial agonist MEKT75 Deposited 2013-11-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：Ligand binding domain, UNP residues 223-504
Chain B 223–504（282 aa） Fragment：Ligand binding domain, UNP residues 223-504
Not recorded JJA N-(phenylsulfonyl)-4-propoxy-3-({[4-(pyrimidin-2-yl)benzoyl]amino}methyl)benzamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.10 Å R-free 0.258
3X1H hPPARgamma Ligand binding domain in complex with 5-oxo-tricosahexaenoic acid Deposited 2014-11-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 232–505（274 aa） Fragment：ligand binding domain, UNP residues 232-505
Not recorded 5OX (7E,11Z,14Z,17Z,20Z)-5-oxotricosa-7,11,14,17,20-pentaenoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；0.1M Tris-HCl PH 8, 0.7M sodium citrate, 1MM TCEP, 0.5MM EDTA, UNDER NITROGEN, temperature 293K, VAPOR DIFFUSION, HANGING DROP
Resolution 2.30 Å R-free 0.266
3X1H hPPARgamma Ligand binding domain in complex with 5-oxo-tricosahexaenoic acid Deposited 2014-11-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 232–505（274 aa） Fragment：ligand binding domain, UNP residues 232-505
Not recorded 5OX (7E,11Z,14Z,17Z,20Z)-5-oxotricosa-7,11,14,17,20-pentaenoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；0.1M Tris-HCl PH 8, 0.7M sodium citrate, 1MM TCEP, 0.5MM EDTA, UNDER NITROGEN, temperature 293K, VAPOR DIFFUSION, HANGING DROP
Resolution 2.30 Å R-free 0.266
3X1I hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid Deposited 2014-11-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 232–505（274 aa） Fragment：ligand binding domain, UNP residues 232-505
Not recorded 66B (8E,12Z,15Z,18Z,21Z)-6-oxotetracosa-8,12,15,18,21-pentaenoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1M Tris-HCl PH 7.4, 0.7M sodium citrate, 1MM TCEP, 0.5MM EDTA, UNDER NITROGEN, temperature 293K, VAPOR DIFFUSION, HANGING DROP
Resolution 2.40 Å R-free 0.279
3X1I hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid Deposited 2014-11-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 232–505（274 aa） Fragment：ligand binding domain, UNP residues 232-505
Not recorded 66B (8E,12Z,15Z,18Z,21Z)-6-oxotetracosa-8,12,15,18,21-pentaenoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1M Tris-HCl PH 7.4, 0.7M sodium citrate, 1MM TCEP, 0.5MM EDTA, UNDER NITROGEN, temperature 293K, VAPOR DIFFUSION, HANGING DROP
Resolution 2.40 Å R-free 0.279
4A4V Ligand binding domain of human PPAR gamma in complex with amorfrutin 2 Deposited 2011-10-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 195–477（283 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 195-477
Not recorded YFD AMORFRUTIN 2 × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；0.8 M TRI-SODIUM CITRATE, 0.1 M IMIDAZOLE, PH 8.0
Resolution 2.00 Å R-free 0.259
4A4V Ligand binding domain of human PPAR gamma in complex with amorfrutin 2 Deposited 2011-10-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 195–477（283 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 195-477
Not recorded YFD AMORFRUTIN 2 × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；0.8 M TRI-SODIUM CITRATE, 0.1 M IMIDAZOLE, PH 8.0
Resolution 2.00 Å R-free 0.259
4A4W Ligand binding domain of human PPAR gamma in complex with amorfrutin B Deposited 2011-10-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 195–477（283 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 195-477
Not recorded YFB AMORFRUTIN B × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；0.8 M TRI-SODIUM CITRATE 0.1 M IMIDAZOLE, PH 8.0
Resolution 2.00 Å R-free 0.234
4A4W Ligand binding domain of human PPAR gamma in complex with amorfrutin B Deposited 2011-10-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 195–477（283 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 195-477
Not recorded YFB AMORFRUTIN B × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；0.8 M TRI-SODIUM CITRATE 0.1 M IMIDAZOLE, PH 8.0
Resolution 2.00 Å R-free 0.234
4CI5 Structural basis for GL479 a dual Peroxisome Proliferator-Activated Receptor gamma agonist Deposited 2013-12-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 206–477（272 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 206-477
Not recorded Y1N 2-methyl-2-[4-[2-[4-[(E)-phenyldiazenyl]phenoxy]ethyl]phenoxy]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 0.8 M SODIUM CITRATE TRIBASIC DIHYDRATE, 0.1 M HEPES PH 8.0
Resolution 1.77 Å R-free 0.212
4CI5 Structural basis for GL479 a dual Peroxisome Proliferator-Activated Receptor gamma agonist Deposited 2013-12-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 206–477（272 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 206-477
Not recorded Y1N 2-methyl-2-[4-[2-[4-[(E)-phenyldiazenyl]phenoxy]ethyl]phenoxy]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 0.8 M SODIUM CITRATE TRIBASIC DIHYDRATE, 0.1 M HEPES PH 8.0
Resolution 1.77 Å R-free 0.212
4E4K Crystal Structure of PPARgamma with the ligand JO21 Deposited 2012-03-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：Ligand binding domain (UNP residues 223-505)
Chain B 223–505（283 aa） Fragment：Ligand binding domain (UNP residues 223-505)
Not recorded RRG (2S)-3-phenyl-2-{[2'-(propan-2-yl)biphenyl-4-yl]oxy}propanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；293 K；0.8M NACITRATE, 0.15M TRIS, PH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293 KK
Resolution 2.50 Å R-free 0.335
4E4K Crystal Structure of PPARgamma with the ligand JO21 Deposited 2012-03-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：Ligand binding domain (UNP residues 223-505)
Chain B 223–505（283 aa） Fragment：Ligand binding domain (UNP residues 223-505)
Not recorded RRG (2S)-3-phenyl-2-{[2'-(propan-2-yl)biphenyl-4-yl]oxy}propanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；293 K；0.8M NACITRATE, 0.15M TRIS, PH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293 KK
Resolution 2.50 Å R-free 0.335
4E4Q Crystal structure of PPARgamma with the ligand FS214 Deposited 2012-03-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：Ligand binding domain (UNP residues 223-505)
Chain B 223–505（283 aa） Fragment：Ligand binding domain (UNP residues 223-505)
Not recorded RRH (2R)-3-phenyl-2-{[2'-(propan-2-yl)biphenyl-4-yl]oxy}propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293 KK
Resolution 2.50 Å R-free 0.298
4E4Q Crystal structure of PPARgamma with the ligand FS214 Deposited 2012-03-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：Ligand binding domain (UNP residues 223-505)
Chain B 223–505（283 aa） Fragment：Ligand binding domain (UNP residues 223-505)
Not recorded RRH (2R)-3-phenyl-2-{[2'-(propan-2-yl)biphenyl-4-yl]oxy}propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293 KK
Resolution 2.50 Å R-free 0.298
4EM9 Human PPAR gamma in complex with nonanoic acids Deposited 2012-04-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
Not recorded KNA nonanoic acid × 3 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1M tris-HCl, 0.9M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.10 Å R-free 0.235
4EM9 Human PPAR gamma in complex with nonanoic acids Deposited 2012-04-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
Not recorded KNA nonanoic acid × 1 GOL GLYCEROL × 2 TCE 3,3',3''-phosphanetriyltripropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1M tris-HCl, 0.9M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.10 Å R-free 0.235
4EM9 Human PPAR gamma in complex with nonanoic acids Deposited 2012-04-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
Chain B 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
Not recorded KNA nonanoic acid × 8 GOL GLYCEROL × 6 TCE 3,3',3''-phosphanetriyltripropanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1M tris-HCl, 0.9M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.10 Å R-free 0.235
4EMA Human peroxisome proliferator-activated receptor gamma in complex with rosiglitazone Deposited 2012-04-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
Not recorded BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1M tris-HCl, 0.9M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.54 Å R-free 0.225
4EMA Human peroxisome proliferator-activated receptor gamma in complex with rosiglitazone Deposited 2012-04-11 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1M tris-HCl, 0.9M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.54 Å R-free 0.225
4EMA Human peroxisome proliferator-activated receptor gamma in complex with rosiglitazone Deposited 2012-04-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
Chain B 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
Not recorded BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1M tris-HCl, 0.9M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.54 Å R-free 0.225
4F9M Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Deposited 2012-05-19 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa） Fragment：Ligand binding domain, UNP residues 234-505
Not recorded FCM (9aS)-8-acetyl-N-[(2-ethyl-4-fluoronaphthalen-1-yl)methyl]-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, Sodium thiocyanate, Tris-HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 1.90 Å R-free 0.254
4FGY Identification of a unique PPAR ligand with an unexpected binding mode and antibetic activity Deposited 2012-06-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 235–504（270 aa） Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-504
Not recorded 0W3 (4R,6S,8S,12R,14R,16Z,18R,19R,20S,21S)-19,21-dihydroxy-22-{(2S,2'R,5S,5'S)-5'-[(1R)-1-hydroxyethyl]-2,5'-dimethyloctahydro-2,2'-bifuran-5-yl}-4,6,8,12,14,18,20-heptamethyl-9,11-dioxodocos-16-enoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；0.2 M sodium acetate, 5% ethylene glycol, 20% PEG 3350, pH 7.0, VAPOR DIFFUSION, HANGING DROP
Resolution 2.84 Å R-free 0.285
4HEE Crystal structure of PPARgamma in complex with compound 13 Deposited 2012-10-03 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain X 235–505（271 aa） Fragment：peroxisome proliferator-activated receptor-gamma (UNP Residues 235-505)
Not recorded 14R 5-benzyl-2-ethyl-3-{(1S)-5-[2-(1H-tetrazol-5-yl)phenyl]-2,3-dihydro-1H-inden-1-yl}-3,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；100mM PIPES, 200mM Sodium Thiocyanate, 16% PEG4000, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.50 Å R-free 0.258
4JAZ Crystal structure of the complex between PPARgamma LBD and trans-resveratrol Deposited 2013-02-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：UNP residues 223-505
Chain B 223–505（283 aa） Fragment：UNP residues 223-505
Not recorded STL RESVERATROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NA CITRATE, 0.15M TRIS, PH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.85 Å R-free 0.264
4JL4 Crystal structure of the complex between PPARgamma LBD and the ligand LJ570 [(2S)-3-(biphenyl-4-yl)-2-(biphenyl-4-yloxy)propanoic acid] Deposited 2013-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：UNP residues 223-505
Chain B 223–505（283 aa） Fragment：UNP residues 223-505
Not recorded AXY (2S)-3-(biphenyl-4-yl)-2-(biphenyl-4-yloxy)propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M Na Citrate, 0.15 M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.50 Å R-free 0.287
4JL4 Crystal structure of the complex between PPARgamma LBD and the ligand LJ570 [(2S)-3-(biphenyl-4-yl)-2-(biphenyl-4-yloxy)propanoic acid] Deposited 2013-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：UNP residues 223-505
Chain B 223–505（283 aa） Fragment：UNP residues 223-505
Not recorded AXY (2S)-3-(biphenyl-4-yl)-2-(biphenyl-4-yloxy)propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M Na Citrate, 0.15 M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.50 Å R-free 0.287
4L96 Structure of the complex between the F360L PPARgamma mutant and the ligand LT175 (space group I222) Deposited 2013-06-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN (UNP RESIDUES 235-505)
Mutation：F360L LRG (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.9；293 K；0.35M Na-phosphate, 0.65 M K-phosphate., pH 6.9, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.38 Å R-free 0.226
4L98 Crystal structure of the complex of F360L PPARgamma mutant with the ligand LT175 Deposited 2013-06-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN (UNP RESIDUES 235-505)
Chain B 235–505（271 aa） Fragment：LIGAND BINDING DOMAIN (UNP RESIDUES 235-505)
Mutation：F360L Mutation：F360L LRG (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；3.3 M Sodium Formate, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.28 Å R-free 0.258
4O8F Crystal Structure of the complex between PPARgamma mutant R357A and rosiglitazone Deposited 2013-12-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：Ligand Binding Domain
Chain B 223–505（283 aa） Fragment：Ligand Binding Domain
Mutation：R357A Mutation：R357A BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；MORPHEUS A5: 10% w/v PEG 20 000, 20% v/v PEG MME 550, 0.1 M MOPS/HEPES-Na, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.60 Å R-free 0.297
4O8F Crystal Structure of the complex between PPARgamma mutant R357A and rosiglitazone Deposited 2013-12-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 223–505（283 aa） Fragment：Ligand Binding Domain
Mutation：R357A BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；MORPHEUS A5: 10% w/v PEG 20 000, 20% v/v PEG MME 550, 0.1 M MOPS/HEPES-Na, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.60 Å R-free 0.297
4O8F Crystal Structure of the complex between PPARgamma mutant R357A and rosiglitazone Deposited 2013-12-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 223–505（283 aa） Fragment：Ligand Binding Domain
Mutation：R357A BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；MORPHEUS A5: 10% w/v PEG 20 000, 20% v/v PEG MME 550, 0.1 M MOPS/HEPES-Na, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.60 Å R-free 0.297
4OJ4 Crystal structure of V290M PPARgamma mutant in complex with diclofenac Deposited 2014-01-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 232–505（274 aa） Fragment：Ligand binding domain (UNP residues 232-505)
Mutation：V290M DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 2 CA CALCIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；PEG 4000 30%, CaCl2 200 mM, HEPES 100 mM, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K
Resolution 2.30 Å R-free 0.284
4PRG 0072 PARTIAL AGONIST PPAR GAMMA COCRYSTAL Deposited 1999-05-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 205–474（270 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 207-476
Chain B 205–474（270 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 207-476
Chain C 205–474（270 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 207-476
Chain D 205–474（270 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 207-476
Not recorded 072 (+/-)(2S,5S)-3-(4-(4-CARBOXYPHENYL)BUTYL)-2-HEPTYL-4-OXO-5-THIAZOLIDINE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 2.90 Å R-free 0.283
4PVU Crystal structure of the complex between PPARgamma-LBD and the R enantiomer of Mbx-102 (Metaglidasen) Deposited 2014-03-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：Ligand Binding Domain, UNP RESIDUES 223-505
Chain B 223–505（283 aa） Fragment：Ligand Binding Domain, UNP RESIDUES 223-505
Not recorded MGZ (2R)-(4-chlorophenyl)[3-(trifluoromethyl)phenoxy]ethanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M Sodium Citrate, pH 8, 0.15M Tris, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.60 Å R-free 0.251
4PWL Crystal structure of the complex between PPARgamma-LBD and the S enantiomer of Mbx-102 (Metaglidasen) Deposited 2014-03-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：Ligand Binding Domain, UNP RESIDUES 223-505
Chain B 223–505（283 aa） Fragment：Ligand Binding Domain, UNP RESIDUES 223-505
Not recorded MSZ (2S)-(4-chlorophenyl)[3-(trifluoromethyl)phenoxy]ethanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M Sodium Citrate, pH 8, 0.15M Tris, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.60 Å R-free 0.308
4R06 Crystal Structure of SR2067 bound to PPARgamma Deposited 2014-07-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 233–505（273 aa） Fragment：UNP residues 233-505
Chain B 233–505（273 aa） Fragment：UNP residues 233-505
Not recorded 3E7 1-(naphthalen-1-ylsulfonyl)-N-[(1S)-1-phenylpropyl]-1H-indole-5-carboxamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；289 K；Protein ligand complex at 10mg/mL in 20mM Tris 8.0, 10mM NaCl, 1mM TCEP mixed with equal volume of well solution of 2M ammonium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 289K
Resolution 2.22 Å R-free 0.240
4R2U Crystal Structure of PPARgamma in complex with SR1664 Deposited 2014-08-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa） Fragment：UNP residues 231-505
Chain D 231–505（275 aa） Fragment：UNP residues 231-505
Not recorded 3JX 4'-[(2,3-dimethyl-5-{[(1S)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；295 K；1uL protein-ligand complex solution (10mg/mL) was mixed with 1uL well solution (2M ammonium sulfate and 0.1M Tris 8.0), VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.30 Å R-free 0.248
4R2U Crystal Structure of PPARgamma in complex with SR1664 Deposited 2014-08-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa） Fragment：UNP residues 231-505
Chain D 231–505（275 aa） Fragment：UNP residues 231-505
Not recorded 3JX 4'-[(2,3-dimethyl-5-{[(1S)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；295 K；1uL protein-ligand complex solution (10mg/mL) was mixed with 1uL well solution (2M ammonium sulfate and 0.1M Tris 8.0), VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.30 Å R-free 0.248
4R6S Crystal structure of PPARgammma in complex with SR1663 Deposited 2014-08-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa） Fragment：UNP residues 231-505
Chain B 231–505（275 aa） Fragment：UNP residues 231-505
Mutation：T447F Mutation：T447F 3K2 4'-[(2,3-dimethyl-5-{[(1R)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4M sodium citrate, 0.125M Tris 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.233
4R6S Crystal structure of PPARgammma in complex with SR1663 Deposited 2014-08-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa） Fragment：UNP residues 231-505
Chain B 231–505（275 aa） Fragment：UNP residues 231-505
Mutation：T447F Mutation：T447F 3K2 4'-[(2,3-dimethyl-5-{[(1R)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4M sodium citrate, 0.125M Tris 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.233
4XLD Crystal structure of the human PPARg-LBD/rosiglitazone complex obtained by dry co-crystallization and in situ diffraction Deposited 2015-01-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 203–477（275 aa） Fragment：UNP residues 203-477
Not recorded FMT FORMIC ACID × 1 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；291 K；3-4 M Sodium Formate
Resolution 2.45 Å R-free 0.222
4XTA MECHANISMS OF PPARgamma ACTIVATION BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS Deposited 2015-01-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 232–505（274 aa） Fragment：UNP residues 232-505
Not recorded DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；1 M sodium citrate, 0.1 M HEPES pH 7.5, and 10 mM MgCl2
Resolution 2.50 Å R-free 0.274
4XTA MECHANISMS OF PPARgamma ACTIVATION BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS Deposited 2015-01-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 232–505（274 aa） Fragment：UNP residues 232-505
Not recorded DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；1 M sodium citrate, 0.1 M HEPES pH 7.5, and 10 mM MgCl2
Resolution 2.50 Å R-free 0.274
4XTA MECHANISMS OF PPARgamma ACTIVATION BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS Deposited 2015-01-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 232–505（274 aa） Fragment：UNP residues 232-505
Chain B 232–505（274 aa） Fragment：UNP residues 232-505
Not recorded DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；1 M sodium citrate, 0.1 M HEPES pH 7.5, and 10 mM MgCl2
Resolution 2.50 Å R-free 0.274
4XUH PPARgamma ligand binding domain in complex with sulindac sulfide Deposited 2015-01-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 232–505（274 aa） Fragment：UNP residues 232-505
Not recorded SFI 2-[(3Z)-6-fluoranyl-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]ethanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；291 K；25% (w/v) PEG 6000 and 0.1 M Tris-HCl pH 8.5.
Resolution 2.22 Å R-free 0.230
4XUH PPARgamma ligand binding domain in complex with sulindac sulfide Deposited 2015-01-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 232–505（274 aa） Fragment：UNP residues 232-505
Not recorded SFI 2-[(3Z)-6-fluoranyl-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]ethanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；291 K；25% (w/v) PEG 6000 and 0.1 M Tris-HCl pH 8.5.
Resolution 2.22 Å R-free 0.230
4XUM PPARgamma ligand binding domain in complex with indomethacin Deposited 2015-01-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 232–505（274 aa）
Not recorded IMN INDOMETHACIN × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；0.95 M sodium citrate and 0.1 M HEPES pH 8.0
Resolution 2.40 Å R-free 0.240
4XUM PPARgamma ligand binding domain in complex with indomethacin Deposited 2015-01-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 232–505（274 aa）
Not recorded IMN INDOMETHACIN × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；0.95 M sodium citrate and 0.1 M HEPES pH 8.0
Resolution 2.40 Å R-free 0.240
4Y29 Identification of a novel PPARg ligand that regulates metabolism Deposited 2015-02-09 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 236–504（269 aa） Fragment：UNP residues 236-504
Not recorded CTI 1,2-dimethoxy-12-methyl[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293.15 K；0.2 M Sodium thiocyanate, 20% w/v PEG 3350
Resolution 1.98 Å R-free 0.219
4YT1 Human PPAR Gamma Ligand Binding Domain in complex with a Gammma Selective Synthetic Partial Agonist MEKT76 Deposited 2015-03-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa） Fragment：ligand binding domain, UNP residues 223-504
Chain B 223–504（282 aa） Fragment：ligand binding domain, UNP residues 223-504
Not recorded JJB N-(benzylsulfonyl)-4-propoxy-3-({[4-(pyrimidin-2-yl)benzoyl]amino}methyl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES
Resolution 2.20 Å R-free 0.256
5AZV Crystal structure of hPPARgamma ligand binding domain complexed with 17-oxoDHA Deposited 2015-10-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 232–505（274 aa） Fragment：UNP residues 203-505
Not recorded 4M5 (4~{Z},7~{Z},10~{Z},13~{Z},19~{Z})-17-oxidanylidenedocosa-4,7,10,13,19-pentaenoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1 M Tris-HCl, 0.825 M sodium citrate
Resolution 2.70 Å R-free 0.307
5AZV Crystal structure of hPPARgamma ligand binding domain complexed with 17-oxoDHA Deposited 2015-10-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 232–505（274 aa） Fragment：UNP residues 203-505
Not recorded 4M5 (4~{Z},7~{Z},10~{Z},13~{Z},19~{Z})-17-oxidanylidenedocosa-4,7,10,13,19-pentaenoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1 M Tris-HCl, 0.825 M sodium citrate
Resolution 2.70 Å R-free 0.307
5DSH Human PPARgamma ligand binding dmain complexed with SB1406 in a covalent bonded form Deposited 2015-09-17 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：UNP RESIDUES 223-505
Not recorded 6BH N-[3-(benzyloxy)phenyl]-3-nitrobenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；2.2M sodium malonate pH 7.0
Resolution 2.95 Å R-free 0.257
5DV3 Human PPARgamma ligand binding dmain complexed with SB1405 in a covalent bonded form Deposited 2015-09-21 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：UNP RESIDUES 223-505
Not recorded B05 N-[2-(benzyloxy)phenyl]-3-nitrobenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；2.2M sodium malonate pH 7.0
Resolution 2.75 Å R-free 0.230
5DV6 Human PPARgamma ligand binding dmain complexed with SB1404 in a covalent bonded form Deposited 2015-09-21 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：UNP RESIDUES 223-505
Not recorded B4H N-methylidene-3-nitrobenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；2.2M sodium malonate pH 7.0
Resolution 2.80 Å R-free 0.244
5DV8 Human PPARgamma ligand binding dmain complexed with SB1451 in a covalent bonded form Deposited 2015-09-21 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：UNP RESIDUES 223-505
Not recorded T51 N-[2-({2-[({4-[(4-methylpiperazin-1-yl)methyl]benzoyl}amino)methyl]benzyl}oxy)phenyl]-3-nitrobenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；297 K；0.19M sodium acetate trihydrate, 0.1M sodium cacodylate pH 6.5, 26% PEG 8000
Resolution 2.75 Å R-free 0.243
5DVC Human PPARgamma ligand binding dmain complexed with SB1453 in a covalent bonded form Deposited 2015-09-21 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：UNP RESIDUES 223-505
Not recorded T53 N-[2-({3-[({4-[(4-methylpiperazin-1-yl)methyl]benzoyl}amino)methyl]benzyl}oxy)phenyl]-3-nitrobenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；2.2 M sodium malonate pH 7.0
Resolution 2.30 Å R-free 0.241
5DWL Human PPARgamma ligand binding dmain in complex with SR1664 Deposited 2015-09-22 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：UNP RESIDUES 223-505
Not recorded 3JX 4'-[(2,3-dimethyl-5-{[(1S)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；2.2 M sodium malonate pH7.0
Resolution 2.20 Å R-free 0.238
5F9B X-ray crystal structure of PPARgamma in the complex with caulophyllogenin Deposited 2015-12-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 195–477（283 aa） Fragment：UNP residues 195-477
Chain B 195–477（283 aa） Fragment：UNP residues 195-477
Not recorded 5VN Caulophyllogenin × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NA CITRATE, 0.15M TRIS, PH8.0
Resolution 2.25 Å R-free 0.281
5GTN Human PPARgamma ligand binding dmain complexed with R35 Deposited 2016-08-22 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：UNP RESIDUES 223-505
Not recorded Q35 2-[4-[5-[(1~{R})-1-[(3,5-dimethoxyphenyl)carbamoyl-(phenylmethyl)carbamoyl]oxypropyl]-1,2-oxazol-3-yl]phenoxy]-2-methyl-propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；57.5% (v/v) Tacsimate pH7.0
Resolution 1.85 Å R-free 0.232
5GTO Human PPARgamma ligand binding dmain complexed with S35 Deposited 2016-08-22 Different construct Different mutation/modification Different ligand/ion Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：UNP RESIDUES 1-283
Not recorded T35 2-[4-[5-[(1~{S})-1-[(3,5-dimethoxyphenyl)carbamoyl-(phenylmethyl)carbamoyl]oxypropyl]-1,2-oxazol-3-yl]phenoxy]-2-methyl-propanoic acid × 1 MYR MYRISTIC ACID × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.10 Å R-free 0.242
5GTP The agonist-free structure of human PPARgamma ligand binding domain in the presence of the SRC-1 coactivator peptide Deposited 2016-08-23 Different construct Different mutation/modification Different ligand/ion Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：UNP RESIDUES 223-505
Not recorded MYR MYRISTIC ACID × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.35 Å R-free 0.258
5HZC Crystal structure of the complex PPARgamma/AL26-29 Deposited 2016-02-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Chain B 223–505（283 aa）
Not recorded 65W 2-methyl-2-[4-(naphthalen-1-yl)phenoxy]propanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；291 K；Sodium citrate 0.8 M, Tris base 0.15 M
Resolution 2.00 Å R-free 0.270
5JI0 PPARgamma-RXRalpha(S427F) heterodimer in complex with SRC-1, rosiglitazone, and 9-cis-retanoic acid Deposited 2016-04-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain D 234–505（272 aa）
Not recorded 9CR (9cis)-retinoic acid × 1 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；296 K；Crystals grew in the dark at room temperature from 0.5 + 0.5 uL sitting drops equilibrated over a reservoir containing 20-24% PEG3350 and 0.02M Na Citrate
Resolution 1.98 Å R-free 0.246
5JI0 PPARgamma-RXRalpha(S427F) heterodimer in complex with SRC-1, rosiglitazone, and 9-cis-retanoic acid Deposited 2016-04-21 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 234–505（272 aa）
Not recorded BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；296 K；Crystals grew in the dark at room temperature from 0.5 + 0.5 uL sitting drops equilibrated over a reservoir containing 20-24% PEG3350 and 0.02M Na Citrate
Resolution 1.98 Å R-free 0.246
5LSG PPARgamma complex with the betulinic acid Deposited 2016-08-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 223–505（283 aa） Fragment：UNP residues 223-505
Not recorded QZQ Betulinic Acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；290 K；reservoir: 0.8M NACITRATE, 0.15M TRIS, PH8.0. The crystals were soaked for one week in a storage solution (1.2 M Na Citrate, 0.15M Tris, pH 8.0) containing the ligand BA (0.5 mM).
Resolution 2.00 Å R-free 0.264
5LSG PPARgamma complex with the betulinic acid Deposited 2016-08-26 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 223–505（283 aa） Fragment：UNP residues 223-505
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；290 K；reservoir: 0.8M NACITRATE, 0.15M TRIS, PH8.0. The crystals were soaked for one week in a storage solution (1.2 M Na Citrate, 0.15M Tris, pH 8.0) containing the ligand BA (0.5 mM).
Resolution 2.00 Å R-free 0.264
5TTO X-ray crystal structure of PPARgamma in complex with SR1643 Deposited 2016-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 233–505（273 aa） Fragment：residues 233-505
Chain B 233–505（273 aa） Fragment：residues 233-505
Not recorded 7KK 4-bromo-N-{3,5-dichloro-4-[(quinolin-3-yl)oxy]phenyl}-2,5-difluorobenzene-1-sulfonamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；289 K；2M ammonium sulfate
Resolution 2.25 Å R-free 0.256
5TWO Peroxisome proliferator-activated receptor gamma ligand binding domain in complex with a novel selectively PPAR gamma-modulating ligand VSP-51 Deposited 2016-11-14 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa） Fragment：lignad binding domain (UNP residues 234-505)
Not recorded 7MV N-benzyl-1-[(4-chloro-3-fluorophenyl)methyl]-1H-indole-5-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 5.5；293 K；0.1 M of tri-sodium citrate (pH 5.5), 20% w/v PEG 3350
Resolution 1.93 Å R-free 0.236
5U5L X-ray Crystal Structure of the PPARgamma Ligand Binding Domain in Complex with Rivoglitazone Deposited 2016-12-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 233–505（273 aa） Fragment：residues 233-505
Chain B 233–505（273 aa） Fragment：residues 233-505
Not recorded 7VA (5S)-5-({4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；289 K；1M Na Citrate
Resolution 2.55 Å R-free 0.238
5UGM Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Edaglitazone Deposited 2017-01-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 235–505（271 aa） Fragment：UNP residues 235-505
Not recorded 8A7 (5R)-5-({4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}methyl)-1,3-thiazolidine-2,4-dione × 2 KNA nonanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, PH 7.6
Resolution 2.10 Å R-free 0.216
5UGM Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Edaglitazone Deposited 2017-01-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 235–505（271 aa） Fragment：UNP residues 235-505
Not recorded 8A7 (5R)-5-({4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}methyl)-1,3-thiazolidine-2,4-dione × 2 KNA nonanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, PH 7.6
Resolution 2.10 Å R-free 0.216
5WQX Covalent bond formation of synthetic ligand with hPPARg-LBD Deposited 2016-11-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 232–505（274 aa） Fragment：ligand binding domain, UNP residues 232-505
Chain B 232–505（274 aa） Fragment：ligand binding domain, UNP residues 232-505
Not recorded T65 2-[E-(E-2-oxidanylidenehexadec-5-enylidene)amino]ethanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1M Tris-HCl PH 7.4, 0.8M sodium citrate
Resolution 2.29 Å R-free 0.277
5WR0 Huisgen cycloaddition for PPARg-LBD labeling by soaking method Deposited 2016-11-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 232–505（274 aa） Fragment：ligand binding domain, UNP residues 232-505
Chain B 232–505（274 aa） Fragment：ligand binding domain, UNP residues 232-505
Not recorded 8Y0 (E)-N-[(3E)-2-oxo-16-(8-{6-[(trifluoroacetyl)amino]hexanoyl}-8,9-dihydro-1H-dibenzo[b,f][1,2,3]triazolo[4,5-d]azocin-1-yl)hexadec-3-en-1-ylidene]glycine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1M Tris-HCl PH 7.4, 0.8M sodium citrate
Resolution 2.85 Å R-free 0.300
5WR1 Covalent bond formation of bifunctional ligand with hPPARg-LBD Deposited 2016-11-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 232–505（274 aa） Fragment：ligand binding domain, UNP residues 232-505
Chain B 232–505（274 aa） Fragment：ligand binding domain, UNP residues 232-505
Not recorded 8XO 2-[E-(E-16-azido-2-oxidanylidene-hexadec-3-enylidene)amino]ethanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1M Tris-HCl PH 7.4, 0.8M sodium citrate
Resolution 2.34 Å R-free 0.259
5Y2O Structure of PPARgamma ligand binding domain-pioglitazone complex Deposited 2017-07-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：UNP residues 235-505
Chain B 235–505（271 aa） Fragment：UNP residues 235-505
Not recorded 8N6 (5S)-5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；297 K；0.1M HEPES NaOH pH 7.5, 17.5% PEG 8000, 10% EG
Resolution 1.80 Å R-free 0.232
5Y2T Structure of PPARgamma ligand binding domain - lobeglitazone complex Deposited 2017-07-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa） Fragment：UNP residues 235-505
Chain B 235–505（271 aa） Fragment：UNP residues 235-505
Not recorded 8LX (5S)-5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methyl-amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；297 K；0.1M HEPES NaOH pH7.5, 17.5% PEG 8000, 10% DMSO
Resolution 1.70 Å R-free 0.224
5YCN Human PPARgamma ligand binding domain complexed with Lobeglitazone Deposited 2017-09-07 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：UNP RESIDUES 223-505
Not recorded 8LX (5S)-5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methyl-amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；296 K；1.6 M sodium citrate tribasic dihydrate (pH 6.5)
Resolution 2.15 Å R-free 0.228
5YCP Human PPARgamma ligand binding domain complexed with Rosiglitazone Deposited 2017-09-07 Different construct Different mutation/modification Different ligand/ion Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：UNP RESIDUES 223-505
Not recorded BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.00 Å R-free 0.233
5Z5S Crystal structure of the PPARgamma-LBD complexed with compound 13ab Deposited 2018-01-19 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Not recorded RTE 3-{[6-(4-chloro-3-fluorophenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy}benzoic acid × 1 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, NaSCN, Tris-HCl
Resolution 1.80 Å R-free 0.229
5Z6S Crystal structure of the PPARgamma-LBD complexed with compound DS-6930 Deposited 2018-01-25 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Not recorded RTF 3-[[6-(3,5-dimethylpyridin-2-yl)oxy-1-methyl-benzimidazol-2-yl]methoxy]benzoic acid × 1 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, sodium thiocyanate, Tris-hydrochloride
Resolution 1.80 Å R-free 0.226
6AD9 Crystal Structure of PPARgamma Ligand Binding Domain in complex with dibenzooxepine derivative compound-9 Deposited 2018-07-31 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa） Fragment：ligand binding domain
Not recorded KK4 3-[(1E)-1-{8-[(4-methyl-2-propyl-1H-benzimidazol-1-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}ethyl]-1,2,4-oxadiazol-5(4H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8.5；293 K；0.5M LiCl, 0.1M Tris-HCl pH 8.5, 28% PEG 6000
Resolution 2.20 Å R-free 0.240
6AN1 Crystal structure of the complex between PPARgamma LBD and the ligand AM-879 Deposited 2017-08-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 196–477（282 aa）
Chain B 196–477（282 aa）
Not recorded BKY 4-({2-[(1,3-dioxo-1,3-dihydro-2H-inden-2-ylidene)methyl]phenoxy}methyl)benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.9M tri-sodium citrate, 100mM Hepes, 3.5% 1,2-propanediol, pH 7.0
Resolution 2.69 Å R-free 0.275
6AUG Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with SR16832 Deposited 2017-08-31 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa） Fragment：UNP residues 231-505
Not recorded BXG 2-chloro-N-(6-methoxyquinolin-4-yl)-5-nitrobenzamide × 1 KNA nonanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 2.73 Å R-free 0.281
6AUG Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with SR16832 Deposited 2017-08-31 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa） Fragment：UNP residues 231-505
Not recorded BXG 2-chloro-N-(6-methoxyquinolin-4-yl)-5-nitrobenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 2.73 Å R-free 0.281
6AUG Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with SR16832 Deposited 2017-08-31 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa） Fragment：UNP residues 231-505
Chain B 231–505（275 aa） Fragment：UNP residues 231-505
Not recorded BXG 2-chloro-N-(6-methoxyquinolin-4-yl)-5-nitrobenzamide × 2 KNA nonanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 2.73 Å R-free 0.281
6AVI Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Nonanoic acid Deposited 2017-09-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa） Fragment：UNP residues 231-505
Not recorded GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 KNA nonanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM TRIS, pH 7.6
Resolution 2.29 Å R-free 0.314
6AVI Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Nonanoic acid Deposited 2017-09-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa） Fragment：UNP residues 231-505
Not recorded GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 KNA nonanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM TRIS, pH 7.6
Resolution 2.29 Å R-free 0.314
6C1I Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with T0070907 Deposited 2018-01-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–504（274 aa）
Chain B 231–504（274 aa）
Not recorded EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 2 KNA nonanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；298 K；0.1 M MOPS, pH 6.5, 0.8 M sodium citrate
Resolution 2.26 Å R-free 0.283
6C5Q PPARg LBD bound to SR10171 Deposited 2018-01-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 235–505（271 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) EKS 2-{3-[(5-{[(1S)-1-(4-tert-butylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]phenoxy}-2-methylpropanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；4M ammonium acetate, O.1M bis-tris propane 7.0
Resolution 2.40 Å R-free 0.277
6C5T PPARg LBD bound to SR11023 Deposited 2018-01-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 235–505（271 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) EKP 2-{4-[(5-{[(1R)-1-(3-cyclopropylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]phenyl}-2-methylpropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；289 K；20% PEG 3350 + 0.2M ammonium citrate 7.0
Resolution 2.75 Å R-free 0.286
6D3E PPARg LBD in Complex with SR1988 Deposited 2018-04-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–504（270 aa） Fragment：Ligand Binding Domain
Chain B 235–504（270 aa） Fragment：Ligand Binding Domain
Not recorded FT7 1-[(2,4-difluorophenyl)methyl]-2,3-dimethyl-N-[(1R)-1-phenylpropyl]-1H-indole-5-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；289 K；1.2M sodium citrate
Resolution 2.40 Å R-free 0.264
6D8X PPAR gamma LBD complexed with the agonist GW1929 Deposited 2018-04-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 FLC CITRATE ANION × 1 NA SODIUM ION × 3 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；200mM tri-Lithium Citrate 20% (w/v) PEG 3350
Resolution 1.90 Å R-free 0.245
6D94 Crystal structure of PPAR gamma in complex with Mediator of RNA polymerase II transcription subunit 1 Deposited 2018-04-27 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；100mM HEPES 25% (w/v) PEG 2000 MME
Resolution 1.90 Å R-free 0.258
6DBH Crystal structure of PPAR gamma in complex with NMP422 Deposited 2018-05-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded G3S 4-{2-[(2,3-dioxo-1-pentyl-2,3-dihydro-1H-indol-5-yl)sulfanyl]ethyl}benzoic acid × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；1.0M Sodium citrate
Resolution 2.60 Å R-free 0.262
6DBH Crystal structure of PPAR gamma in complex with NMP422 Deposited 2018-05-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Not recorded G3S 4-{2-[(2,3-dioxo-1-pentyl-2,3-dihydro-1H-indol-5-yl)sulfanyl]ethyl}benzoic acid × 1 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；1.0M Sodium citrate
Resolution 2.60 Å R-free 0.262
6DCU Crystal structure of PPAR gamma co-crystallized with nTZDpa Deposited 2018-05-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 203–477（275 aa）
Not recorded NZA 5-CHLORO-1-(4-CHLOROBENZYL)-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.2 M Potassium thiocyanate 20%(w/v) PEG 3350
Resolution 2.95 Å R-free 0.303
6DCU Crystal structure of PPAR gamma co-crystallized with nTZDpa Deposited 2018-05-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 203–477（275 aa）
Not recorded NZA 5-CHLORO-1-(4-CHLOROBENZYL)-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.2 M Potassium thiocyanate 20%(w/v) PEG 3350
Resolution 2.95 Å R-free 0.303
6DGL Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Darglitazone Deposited 2018-05-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded GEV (5Z)-5-({4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl}methylidene)-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 1.95 Å R-free 0.269
6DGL Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Darglitazone Deposited 2018-05-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Not recorded GEV (5Z)-5-({4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl}methylidene)-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 1.95 Å R-free 0.269
6DGO Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Troglitazone Deposited 2018-05-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Chain B 231–505（275 aa）
Not recorded GD4 (5S)-5-[(4-{[(2R)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-yl]methoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 3.10 Å R-free 0.276
6DGP Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with TRAP220 Coactivator Peptide Deposited 2018-05-17 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.1M Magnesium acetate, 0.1M Sodium cacodylate, pH 6.5 15% w/v, PEG 6000
Resolution 3.10 Å R-free 0.294
6DGP Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with TRAP220 Coactivator Peptide Deposited 2018-05-17 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.1M Magnesium acetate, 0.1M Sodium cacodylate, pH 6.5 15% w/v, PEG 6000
Resolution 3.10 Å R-free 0.294
6DGQ Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with CAY10506 Deposited 2018-05-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded GBV N-(2-{4-[(2,4-dioxo-3,4-dihydro-2H-1lambda~4~,3-thiazol-5-yl)methyl]phenoxy}ethyl)-5-[(3R)-1,2-dithiolan-3-yl]pentanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM Tris, pH 7.6
Resolution 2.45 Å R-free 0.247
6DGQ Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with CAY10506 Deposited 2018-05-17 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM Tris, pH 7.6
Resolution 2.45 Å R-free 0.247
6DGR Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with CAY10638 Deposited 2018-05-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Chain B 231–505（275 aa）
Not recorded GDY (5Z)-5-({4-[2-(thiophen-2-yl)ethoxy]phenyl}methylidene)-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM TRIS, pH 7.6
Resolution 2.15 Å R-free 0.264
6DH9 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with MSDC-0602 Deposited 2018-05-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 235–505（271 aa）
Not recorded GH1 (5S)-5-({4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione × 1 KNA nonanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 2.70 Å R-free 0.250
6DH9 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with MSDC-0602 Deposited 2018-05-18 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 235–505（271 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 2.70 Å R-free 0.250
6DHA Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Hydroxy Pioglitazone (M-IV) Deposited 2018-05-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 235–505（271 aa）
Not recorded GFV Hydroxy Pioglitazone (M-IV) × 1 KNA nonanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM TRIS, pH 7.6
Resolution 1.88 Å R-free 0.255
6DHA Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Hydroxy Pioglitazone (M-IV) Deposited 2018-05-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 235–505（271 aa）
Not recorded GFV Hydroxy Pioglitazone (M-IV) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM TRIS, pH 7.6
Resolution 1.88 Å R-free 0.255
6E5A PPARg in complex with compound 4b Deposited 2018-07-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 233–505（273 aa）
Chain B 233–505（273 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) HV4 (5Z)-5-({4-[(prop-2-yn-1-yl)oxy]phenyl}methylidene)-2-sulfanylidene-1,3-thiazolidin-4-one × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；289 K；1 M Na Citrate
Resolution 2.40 Å R-free 0.268
6ENQ Structure of human PPAR gamma LBD in complex with Lanifibranor (IVA337) Deposited 2017-10-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 224–505（282 aa）
Chain B 224–505（282 aa）
Not recorded BJB 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl]butanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；Na Citrate 0,9 M 1,2 - propanediol 3,5 % Hepes 0,1 M
Resolution 2.20 Å R-free 0.271
6F2L Crystal structure of the complex between PPARgamma LBD and the ligand LJ570: structure obtained from crystals of the apo-form soaked for 15 days. Deposited 2017-11-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Chain B 223–505（283 aa）
Not recorded AXY (2S)-3-(biphenyl-4-yl)-2-(biphenyl-4-yloxy)propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M NA CITRATE, 0.15 M TRIS, PH 8.0
Resolution 2.10 Å R-free 0.302
6FZF PPAR mutant complex Deposited 2018-03-14 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Mutation：T475M EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；290 K；25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Bis-Tris pH 6.5
Resolution 1.95 Å R-free 0.194
6FZF PPAR mutant complex Deposited 2018-03-14 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Mutation：T475M EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；290 K；25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Bis-Tris pH 6.5
Resolution 1.95 Å R-free 0.194
6FZG PPAR gamma mutant complex Deposited 2018-03-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 203–477（275 aa）
Mutation：I290M EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；290 K；25% PEG 3350, 0.2 M NaCl, 0.1 M Hepes pH 7.5
Resolution 2.10 Å R-free 0.208
6FZJ PPAR gamma mutant complex Deposited 2018-03-14 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Mutation：M280I EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 IOD IODIDE ION × 1 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；290 K；20% PEG 550 MME, 10% PEG 20 000, 30 mM sodium fluoride, 30 mM sodium bromide, 30 mM sodium iodide, 0.1 M sodium Hepes / MOPS pH 7.5
Resolution 2.01 Å R-free 0.226
6FZJ PPAR gamma mutant complex Deposited 2018-03-14 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Mutation：M280I EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 IOD IODIDE ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；290 K；20% PEG 550 MME, 10% PEG 20 000, 30 mM sodium fluoride, 30 mM sodium bromide, 30 mM sodium iodide, 0.1 M sodium Hepes / MOPS pH 7.5
Resolution 2.01 Å R-free 0.226
6FZP PPAR gamma complex. Deposited 2018-03-15 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；290 K；NH4 acetate 0.3M, Hepes 0.1M pH 7.5, di-sodium tartrate 0.8 M
Resolution 2.30 Å R-free 0.252
6FZY PPAR mutant Deposited 2018-03-15 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Chain B 231–505（275 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；290 K；0.5 M ammonium sulfate, 0.1 M PIPES pH7, 0.9 M disodium tartrate
Resolution 3.10 Å R-free 0.235
6ICJ Crystal structure of PPARgamma with compound BR102375K Deposited 2018-09-06 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Not recorded GOL GLYCEROL × 2 A0L 2-butyl-5-[(3-tert-butyl-1,2,4-oxadiazol-5-yl)methyl]-6-methyl-3-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl}pyrimidin-4(3H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；0.2 M NH4 Acetate, 0.1 M HEPES 7.5 pH, 25 %w/v PEG 3350
Resolution 2.48 Å R-free 0.282
6IJR Human PPARgamma ligand binding domain complexed with SB1495 Deposited 2018-10-11 Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Not recorded A9C N-{[3-({[(1S,2R)-2-{[(2E)-2-cyano-4,4-dimethylpent-2-enoyl]amino}cyclopentyl]oxy}methyl)phenyl]methyl}-4-[(4-methylpiperazin-1-yl)methyl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；60% (v/v) Tacsimate
Resolution 2.85 Å R-free 0.266
6IJR Human PPARgamma ligand binding domain complexed with SB1495 Deposited 2018-10-11 Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 223–505（283 aa）
Not recorded A9C N-{[3-({[(1S,2R)-2-{[(2E)-2-cyano-4,4-dimethylpent-2-enoyl]amino}cyclopentyl]oxy}methyl)phenyl]methyl}-4-[(4-methylpiperazin-1-yl)methyl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；60% (v/v) Tacsimate
Resolution 2.85 Å R-free 0.266
6IJS Human PPARgamma ligand binding domain complexed with SB1494 Deposited 2018-10-11 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 232–505（274 aa）
Not recorded A9F N-{[3-({[(1R,2S)-2-{[(2E)-2-cyano-4,4-dimethylpent-2-enoyl]amino}cyclopentyl]oxy}methyl)phenyl]methyl}-4-[(4-methylpiperazin-1-yl)methyl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate
Resolution 2.15 Å R-free 0.241
6ILQ Crystal structure of PPARgamma with compound BR101549 Deposited 2018-10-19 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Not recorded AE0 ethyl [2-butyl-6-oxo-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl}-4-(propan-2-yl)-1,6-dihydropyrimidin-5-yl]acetate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；0.2 M MgCl2, 0.1 M TRIS 8.5 pH, 27 %w/v PEG 3350
Resolution 2.41 Å R-free 0.303
6IZM Crystal structure of the PPARgamma-LBD complexed with compound 1l Deposited 2018-12-20 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Not recorded B0X 3-[[6-(2,6-dimethylpyridin-3-yl)oxy-1-methyl-benzimidazol-2-yl]methoxy]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, NaSCN, Tris-HCl
Resolution 1.80 Å R-free 0.248
6IZN Crystal structure of the PPARgamma-LBD complexed with compound 3g Deposited 2018-12-20 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Not recorded B1O 3-[[6-(2,6-dimethylpyridin-3-yl)oxy-7-fluoranyl-1-methyl-benzimidazol-2-yl]methoxy]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, NaSCN, Tris-HCl
Resolution 1.75 Å R-free 0.265
6JEY Covalent bond formation between ynone moiety of synthetic fatty acid and hPPARg-LBD Deposited 2019-02-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 232–505（274 aa）
Chain B 232–505（274 aa）
Not recorded EJL (9Z,12Z,15Z,18Z,21Z)-5-oxidanylidenetetracosa-9,12,15,18,21-pentaen-6-ynoic acid × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.1 M Tris-HCl pH 7.4, 0.8 M sodium citrate
Resolution 2.20 Å R-free 0.310
6JF0 Covalent labeling of hPPARg-LBD by turn-on fluorescent probe mediated by conjugate addition and cyclization Deposited 2019-02-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 232–505（274 aa）
Chain B 232–505（274 aa）
Not recorded EB6 methyl (2~{S})-3-[4-[3-(4-methoxy-2-oxidanyl-phenyl)prop-2-ynoyloxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoate × 1 EBF 7-methoxychromen-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.1 M Tris-HCl pH 7.4, 0.8 M sodium citrate
Resolution 3.40 Å R-free 0.296
6JQ7 The ligand-free structure of human PPARgamma LBD in the presence of the SRC-1 coactivator peptide Deposited 2019-03-29 Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；60% (v/v) Tacsimate (pH 7.0)
Resolution 2.55 Å R-free 0.257
6K0T Crystal Structure of PPARgamma Ligand Binding Domain in complex with dibenzooxepine derivative compound-17 Deposited 2019-05-07 Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) CTU 3-[(1~{E})-1-[8-[(8-chloranyl-2-cyclopropyl-imidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoranyl-6~{H}-benzo[c][1]benzoxepin-11-ylidene]ethyl]-4~{H}-1,2,4-oxadiazol-5-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.05M Magnesium acetate, 0.1M Sodium acetate, 12% PEG 8,000
Resolution 1.84 Å R-free 0.244
6K0T Crystal Structure of PPARgamma Ligand Binding Domain in complex with dibenzooxepine derivative compound-17 Deposited 2019-05-07 Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 223–505（283 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) CTU 3-[(1~{E})-1-[8-[(8-chloranyl-2-cyclopropyl-imidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoranyl-6~{H}-benzo[c][1]benzoxepin-11-ylidene]ethyl]-4~{H}-1,2,4-oxadiazol-5-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.05M Magnesium acetate, 0.1M Sodium acetate, 12% PEG 8,000
Resolution 1.84 Å R-free 0.244
6KTN Human PPARgamma ligand-binding domain R288A mutant in complex with imatinib Deposited 2019-08-28 Different ligand/ion Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Mutation：R316A STI 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.75 Å R-free 0.256
6L89 Human PPARgamma ligand binding domain complexed with Butyrolactone 1 Deposited 2019-11-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Chain B 223–505（283 aa）
Not recorded E7C methyl (2R)-3-(4-hydroxyphenyl)-2-[[3-(3-methylbut-2-enyl)-4-oxidanyl-phenyl]methyl]-4-oxidanyl-5-oxidanylidene-furan-2-carboxylate × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；1.2 M sodium citrate tribasic dihydrate, 0.1 M HEPES pH 7.5
Resolution 2.10 Å R-free 0.269
6L8B The ligand-free structure of human PPARgamma LBD Deposited 2019-11-05 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Chain B 223–505（283 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；1.2 M Sodium citrate tribasic dihydrate, 0.1 M HEPES pH 7.5
Resolution 2.10 Å R-free 0.268
6MCZ Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Arachidonic Acid Deposited 2018-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded ACD ARACHIDONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4 0.8M Sodium Citrate
Resolution 2.10 Å R-free 0.259
6MCZ Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Arachidonic Acid Deposited 2018-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Not recorded ACD ARACHIDONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4 0.8M Sodium Citrate
Resolution 2.10 Å R-free 0.259
6MD0 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Oleic Acid Deposited 2018-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded OLA OLEIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4 0.8M Sodium Citrate
Resolution 1.95 Å R-free 0.273
6MD0 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Oleic Acid Deposited 2018-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Not recorded OLA OLEIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4 0.8M Sodium Citrate
Resolution 1.95 Å R-free 0.273
6MD1 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Oleic acid Deposited 2018-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded OLA OLEIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4 0.8M Sodium Citrate
Resolution 2.20 Å R-free 0.266
6MD1 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Oleic acid Deposited 2018-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Not recorded OLA OLEIC ACID × 1 GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4 0.8M Sodium Citrate
Resolution 2.20 Å R-free 0.266
6MD2 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Arachidonic acid Deposited 2018-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 ACD ARACHIDONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4 0.8M SODIUM CITRATE
Resolution 2.20 Å R-free 0.261
6MD2 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Arachidonic acid Deposited 2018-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Not recorded GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 ACD ARACHIDONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4 0.8M SODIUM CITRATE
Resolution 2.20 Å R-free 0.261
6MD4 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Rosiglitazone and Oleic acid Deposited 2018-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 OLA OLEIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4 0.8M SODIUM CITRATE
Resolution 2.24 Å R-free 0.282
6MD4 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Rosiglitazone and Oleic acid Deposited 2018-09-03 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4 0.8M SODIUM CITRATE
Resolution 2.24 Å R-free 0.282
6MS7 Peroxisome proliferator-activated receptor gamma ligand binding domain in complex with a novel selective PPAR-gamma modulator VSP-77 Deposited 2018-10-16 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Not recorded V77 {[(1S)-1-(4-chlorophenyl)octyl]oxy}acetic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；300 K；0.1 M of tri-sodium citrate (pH 5.5), 20% w/v PEG 3350
Resolution 1.43 Å R-free 0.208
6O67 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Mitoglitazone Deposited 2019-03-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded LO7 Mitoglitazone × 1 KNA nonanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 2.52 Å R-free 0.244
6O67 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Mitoglitazone Deposited 2019-03-05 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 2.52 Å R-free 0.244
6O68 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Ciglitazone Deposited 2019-03-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded LO4 Ciglitazone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 2.78 Å R-free 0.298
6O68 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Ciglitazone Deposited 2019-03-05 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 2.78 Å R-free 0.298
6ONI Crystal structure of PPARgamma ligand binding domain in complex with N-CoR peptide and inverse agonist T0070907 Deposited 2019-04-22 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate 0.1M MES, pH 6.5 30% w/v, PEG 8000
Resolution 1.80 Å R-free 0.226
6ONJ Crystal structure of PPARgamma ligand binding domain in complex with TRAP220 peptide and agonist rosiglitazone Deposited 2019-04-22 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；0.2M Sodium acetate trihydrate 0.1M Tris, pH 8.5 30% w/v, PEG 4000
Resolution 2.30 Å R-free 0.273
6PDZ Crystal structure of PPARgamma ligand binding domain in complex with SMRT peptide and inverse agonist T0070907 Deposited 2019-06-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 231–505（275 aa）
Chain B 231–505（275 aa）
Not recorded EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate 0.1M MES, pH 6.5 30% w/v PEG8000
Resolution 2.10 Å R-free 0.241
6QJ5 X-ray structure of PPARgamma LBD with the ligand NV1380 Deposited 2019-01-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Chain B 223–505（283 aa）
Not recorded H8R (2~{S})-3-methyl-2-[(4-octoxyphenyl)carbonylamino]butanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris
Resolution 2.00 Å R-free 0.276
6T1S PPAR mutant Deposited 2019-10-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Mutation：F310S EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 2 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；290 K；25% PEG3350, 0.2 M LiSO4, BisTris 0.1M pH 6.5
Resolution 1.65 Å R-free 0.204
6T1V Structure of PPARg H494Y mutant in complex with GW1929 Deposited 2019-10-06 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Mutation：H494Y EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；290 K；0.2 M ammonium acetate, 0.1 M Hepes pH 7.5, trisodium citrate 1.2M
Resolution 2.21 Å R-free 0.196
6T6B Crystal structure of PPARgamma in complex with compound 16 (MF27) Deposited 2019-10-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded MLQ (2~{R})-2-[[6-[(2,4-dichlorophenyl)sulfonylamino]-1,3-benzothiazol-2-yl]sulfanyl]octanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293.15 K；33% PEG 3350, 0.15 M sodium citrate and 0.1 M tris, pH 8.0
Resolution 2.80 Å R-free 0.271
6T9C Crystal structure of the complex between PPARgamma LBD and the ligand NV1346 (3a) Deposited 2019-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Chain B 223–505（283 aa）
Not recorded MX8 4-hexoxy-~{N}-[(2~{S})-3-methyl-1-(oxidanylamino)-1-oxidanylidene-butan-2-yl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M Sodium Citrate, 0.15 M Tris
Resolution 1.95 Å R-free 0.262
6TDC PPAR gamma ligand binding domain in complex with MRL-871 Deposited 2019-11-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 207–477（271 aa）
Not recorded 4F1 4-{1-[2-chloro-6-(trifluoromethyl)benzoyl]-1H-indazol-3-yl}benzoic acid × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M Ammonium Nitrate, 20% w/v PEG3350
Resolution 2.33 Å R-free 0.239
6TSG Crystal structure of Peroxisome proliferator-activated receptor gamma (PPARG) in complex with TETRAC Deposited 2019-12-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded T4A 3,3',5,5'-TETRAIODOTHYROACETIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293.15 K；33% PEG 3350 and 0.15 M sodium citrate
Resolution 2.98 Å R-free 0.292
6VZL Crystal structure of human PPARgamma ligand binding domain in complex with GW1929 Deposited 2020-02-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
Resolution 2.07 Å R-free 0.289
6VZL Crystal structure of human PPARgamma ligand binding domain in complex with GW1929 Deposited 2020-02-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Not recorded EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
Resolution 2.07 Å R-free 0.289
6VZM Crystal structure of human PPARgamma ligand binding domain Y473E mutant in complex with Darglitazone Deposited 2020-02-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Mutation：Y473E GEV (5Z)-5-({4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl}methylidene)-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
Resolution 2.40 Å R-free 0.278
6VZM Crystal structure of human PPARgamma ligand binding domain Y473E mutant in complex with Darglitazone Deposited 2020-02-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Mutation：Y473E GEV (5Z)-5-({4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl}methylidene)-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
Resolution 2.40 Å R-free 0.278
6VZN Crystal structure of human PPARgamma ligand binding domain Y473E mutant Deposited 2020-02-28 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Mutation：Y473E No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
Resolution 2.30 Å R-free 0.278
6VZN Crystal structure of human PPARgamma ligand binding domain Y473E mutant Deposited 2020-02-28 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Mutation：Y473E No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
Resolution 2.30 Å R-free 0.278
6VZO Crystal structure of human PPARgamma ligand binding domain (Protein delipidated by denature and refold) Deposited 2020-02-28 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M Tris, pH 7.4 0.8M SODIUM CITRATE
Resolution 2.27 Å R-free 0.271
6VZO Crystal structure of human PPARgamma ligand binding domain (Protein delipidated by denature and refold) Deposited 2020-02-28 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M Tris, pH 7.4 0.8M SODIUM CITRATE
Resolution 2.27 Å R-free 0.271
6Y3U Crystal structure of PPARgamma in complex with compound (R)-16 Deposited 2020-02-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded MLQ (2~{R})-2-[[6-[(2,4-dichlorophenyl)sulfonylamino]-1,3-benzothiazol-2-yl]sulfanyl]octanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293.15 K；33% PEG 3350, 0.1 M sodium citrate
Resolution 2.62 Å R-free 0.254
6ZLY Crystal structure of the complex between PPARgamma LBD and the ligand NV1362 (7a) Deposited 2020-07-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Chain B 223–505（283 aa）
Not recorded QMH (2~{S})-2-[(4-hexoxyphenyl)carbonylamino]-3-methyl-butanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M SODIUM CITRATE, 0.15 M TRIS, PH 8.0
Resolution 1.79 Å R-free 0.280
7A7H Crystal structure of PPARgamma in complex with compound TK90 Deposited 2020-08-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded TK9 (2~{R})-2-[[4-[[4-methoxy-2-(trifluoromethyl)phenyl]methylcarbamoyl]phenyl]methyl]butanoic acid × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；27% PEG 3350, 0.2M Sodium citrate tribasic dehydrate
Resolution 2.40 Å R-free 0.255
7AHJ Crystal structure of PPARgamma V290M mutant ligand binding domain in complex with farglitazar Deposited 2020-09-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 232–505（274 aa）
Chain B 232–505（274 aa）
Mutation：V290M Mutation：V290M 570 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.1M TRIS pH8 0.92-1.2M Sodium Citrate 0.1mM TCEP 0.5 micro molar Farglitazar.
Resolution 2.10 Å R-free 0.237
7AWC Crystal structure of Peroxisome proliferator-activated receptor gamma (PPARG)in complex with rosiglitazone Deposited 2020-11-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 GOL GLYCEROL × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293.15 K；1.4 M ammonium sulfate, 0.1 M tris, pH 7.5
Resolution 1.74 Å R-free 0.204
7AWD Crystal structure of Peroxisome proliferator-activated receptor gamma (PPARG)in complex with garcinoic acid Deposited 2020-11-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded NQD (2Z,6E,10E)-13-[(2R)-6-hydroxy-2,8-dimethyl-3,4-dihydro-2H-1-benzopyran-2-yl]-2,6,10-trimethyltrideca-2,6,10-trienoic acid × 2 CIT CITRIC ACID × 1 GOL GLYCEROL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293.15 K；1.2 M ammonium sulfate, 0.1 M tris, pH 8.0
Resolution 1.93 Å R-free 0.230
7CXE The ligand-free structure of human PPARgamma LBD R280C mutant Deposited 2020-09-01 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Chain B 223–505（283 aa）
Mutation：R308C Mutation：R308C No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；1.2 M Sodium citrate tribasic dihydrate, 0.1 M HEPES pH 7.5
Resolution 2.50 Å R-free 0.265
7CXF The ligand-free structure of human PPARgamma LBD C285Y mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Not recorded MLA MALONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.35 Å R-free 0.269
7CXG The ligand-free structure of human PPARgamma LBD Q286E mutant Deposited 2020-09-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Chain B 223–505（283 aa）
Mutation：Q314E Mutation：Q314E GOL GLYCEROL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；1.2 M Sodium citrate tribasic dihydrate, 0.1 M HEPES pH 7.5
Resolution 1.88 Å R-free 0.231
7CXH The ligand-free structure of human PPARgamma LBD Q286E mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Mutation：Q314E No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.30 Å R-free 0.257
7CXI The ligand-free structure of human PPARgamma LBD F287Y mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Not recorded MLI MALONATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.30 Å R-free 0.276
7CXJ The ligand-free structure of human PPARgamma LBD R288C mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Mutation：R316C No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.65 Å R-free 0.275
7CXK The ligand-free structure of human PPARgamma LBD R288H mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Not recorded MLI MALONATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.20 Å R-free 0.264
7CXL The ligand-free structure of human PPARgamma LBD S289C mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Not recorded MLA MALONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.70 Å R-free 0.255
7E2O X-ray Crystal structure of PPARgamma R288H mutant. Deposited 2021-02-06 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 204–477（274 aa）
Mutation：R288H No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；0.1M Tris-HCl, 0.7M sodium citrate
Resolution 3.20 Å R-free 0.313
7E2O X-ray Crystal structure of PPARgamma R288H mutant. Deposited 2021-02-06 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 204–477（274 aa）
Mutation：R288H No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；0.1M Tris-HCl, 0.7M sodium citrate
Resolution 3.20 Å R-free 0.313
7EFQ Crystal structure of hPPARgamma ligand binding domain complexed with rosiglitazone-based fluorescence probe Deposited 2021-03-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 232–505（274 aa）
Chain B 232–505（274 aa）
Not recorded J3F (5S)-5-[[4-[2-[[7-(diethylamino)-2-oxidanylidene-chromen-4-yl]-methyl-amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；One microliter of PPARgamma-LBD solution (6 mg/mL, in 20 mM Tris-HCl pH 8.0, 1 mM TCEP, 0.5 mM EDTA) with 0.5 equiv. ligand with 1 microliter of reservoir solution (0.8 M sodium citrate and 0.1 M Tris-HCl pH 7.3). Drops were equilibrated against 300 microliter of reservoir solution at 293K.
Resolution 2.30 Å R-free 0.264
7JQG Crystal structure of human PPARgamma ligand binding domain Y473E mutant in complex with GW1929 Deposited 2020-08-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Mutation：Y473E EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
Resolution 2.15 Å R-free 0.270
7JQG Crystal structure of human PPARgamma ligand binding domain Y473E mutant in complex with GW1929 Deposited 2020-08-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Mutation：Y473E EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
Resolution 2.15 Å R-free 0.270
7LOT Human PPAR Gamma LBD in Complex with Tetrazole Compound N-{3-[(4-methylbenzyl)oxy]benzyl}-2H-tetrazol-5-amine. Deposited 2021-02-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 232–505（274 aa） Fragment：UNP residues 232-505
Chain B 232–505（274 aa） Fragment：UNP residues 232-505
Not recorded Y9A ~{N}-[[3-[(4-methylphenyl)methoxy]phenyl]methyl]-1~{H}-1,2,3,4-tetrazol-5-amine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；100 mM HEPES, pH 7.0 and 0.85 M Sodium Citrate
Resolution 2.29 Å R-free 0.259
7P4E Crystal structure of PPARgamma in complex with compound FL217 Deposited 2021-07-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded 5IV ~{N}-[[4-(cyclopropylsulfonylamino)-2-(trifluoromethyl)phenyl]methyl]-1-[(3-fluorophenyl)methyl]indole-5-carboxamide × 1 SO4 SULFATE ION × 1 EDO 1,2-ETHANEDIOL × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；1.4M Ammonium sulfate, 0.1M Tris pH7.5
Resolution 2.40 Å R-free 0.268
7QB1 PPARg in complex with inhibitor Deposited 2021-11-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain AAA 223–505（283 aa） Fragment：UNP residues 195-477
Chain BBB 223–505（283 aa） Fragment：UNP residues 195-477
Not recorded 9WQ 3-[(3,4-dichlorophenyl)methyl]-4-oxidanylidene-6-phenoxy-phthalazine-1-carboxylic acid × 2 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；20mM Tris pH 8.0, 5mM DTT, 100mM NaCl , 2mM EDTA
Resolution 2.20 Å R-free 0.249
7RLE Crystal structure of PPAR gamma in complex with CREB-binding protein and agonist GW1929 Deposited 2021-07-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 231–505（275 aa）
Chain C 231–505（275 aa）
Not recorded EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293.15 K；1M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate, pH 6.5
Resolution 2.50 Å R-free 0.275
7SQA PPAR gamma LBD bound to SR10221 and SMRT corepressor motif Deposited 2021-11-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded A8R (2S)-2-{5-[(5-{[(1S)-1-(4-tert-butylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]-2-chlorophenoxy}propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；289 K；28% PEG 8,000, 0.1M Ammonium sulphate, 0.1M MES pH 6.5
Resolution 2.50 Å R-free 0.285
7SQA PPAR gamma LBD bound to SR10221 and SMRT corepressor motif Deposited 2021-11-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded A8R (2S)-2-{5-[(5-{[(1S)-1-(4-tert-butylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]-2-chlorophenoxy}propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；289 K；28% PEG 8,000, 0.1M Ammonium sulphate, 0.1M MES pH 6.5
Resolution 2.50 Å R-free 0.285
7SQB PPAR gamma LBD bound to Inverse Agonist SR10221 Deposited 2021-11-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded A8R (2S)-2-{5-[(5-{[(1S)-1-(4-tert-butylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]-2-chlorophenoxy}propanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；289 K；4.25M Ammonium acetate, 0.1M Bis Tris Propane pH 6.8
Resolution 2.60 Å R-free 0.261
7WOX PPARgamma antagonist (MMT-160)- PPARgamma LBD complex Deposited 2022-01-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 232–505（274 aa）
Not recorded 5YW N-[[5-(3-phenylprop-2-ynoylamino)-2-propoxy-phenyl]methyl]-4-pyrimidin-2-yl-benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.1M Tris-HCl pH 7.4, 0.8M sodium citrate
Resolution 3.20 Å R-free 0.273
7WOX PPARgamma antagonist (MMT-160)- PPARgamma LBD complex Deposited 2022-01-22 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 232–505（274 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.1M Tris-HCl pH 7.4, 0.8M sodium citrate
Resolution 3.20 Å R-free 0.273
8ADF X-ray crystal structure of PPAR gamma ligand binding domain in complex with CZ39 Deposited 2022-07-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa）
Chain B 223–504（282 aa）
Not recorded LRA (2R)-3-(4-bromophenyl)-2-(3-hydroxyphenyl)-4-oxidanyl-2H-furan-5-one × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293.15 K；0.8 M SODIUM CITRATE, 0.15 M TRIS, PH 8.0
Resolution 2.13 Å R-free 0.257
8AQM Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 6a) Deposited 2022-08-12 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded O2O 2-chloranyl-~{N}-[2-(3-methylphenyl)-1,3-benzoxazol-5-yl]-5-nitro-benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.1M MES pH 6, 0.2M NH4Cl, 20% PEG6000
Resolution 2.30 Å R-free 0.251
8AQM Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 6a) Deposited 2022-08-12 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded O2O 2-chloranyl-~{N}-[2-(3-methylphenyl)-1,3-benzoxazol-5-yl]-5-nitro-benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.1M MES pH 6, 0.2M NH4Cl, 20% PEG6000
Resolution 2.30 Å R-free 0.251
8AQN Crystal structure of PPARG and NCOR2 with BAY-4931, an inverse agonist (compound 6c) Deposited 2022-08-12 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded O0U 2-chloranyl-~{N}-[2-(4-ethylphenyl)-1,3-benzoxazol-5-yl]-5-nitro-benzamide × 1 GOL GLYCEROL × 2 CA CALCIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 0.2 M Ca acetate, 20% PEG8000
Resolution 1.90 Å R-free 0.218
8AQN Crystal structure of PPARG and NCOR2 with BAY-4931, an inverse agonist (compound 6c) Deposited 2022-08-12 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded O0U 2-chloranyl-~{N}-[2-(4-ethylphenyl)-1,3-benzoxazol-5-yl]-5-nitro-benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 0.2 M Ca acetate, 20% PEG8000
Resolution 1.90 Å R-free 0.218
8ATY Crystal structure of PPAR gamma (PPARG) in complex with JP85 (compound 1). Deposited 2022-08-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded O7O 2-[4-chloranyl-6-(5,6,7,8-tetrahydronaphthalen-1-ylamino)pyrimidin-2-yl]sulfanylethanoic acid × 2 GOL GLYCEROL × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293.15 K；1.4 M Ammonium sulfate, 0.1 M tris pH 8.0
Resolution 1.90 Å R-free 0.201
8ATZ Crystal structure of PPAR gamma (PPARG) in complex with SA112 (compound 2). Deposited 2022-08-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded GOL GLYCEROL × 1 O86 2-[4-chloranyl-6-[[3-(2-phenylethoxy)phenyl]amino]pyrimidin-2-yl]sulfanylethanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293.15 K；1.6 M ammonium sulfate, 0.1 M tris pH 7.5
Resolution 1.95 Å R-free 0.245
8B8W Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7a) Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded Q2X 4-chloranyl-~{N}3-phenyl-~{N}1-(phenylmethyl)benzene-1,3-dicarboxamide × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 4000 24%, NaCl 0.2 M, Hepes 0.1 M (pH 7.5)
Resolution 1.86 Å R-free 0.275
8B8W Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7a) Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded Q2X 4-chloranyl-~{N}3-phenyl-~{N}1-(phenylmethyl)benzene-1,3-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 4000 24%, NaCl 0.2 M, Hepes 0.1 M (pH 7.5)
Resolution 1.86 Å R-free 0.275
8B8X Crystal structure of PPARG and NCOR2 with SR10221, an inverse agonist Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded A8R (2S)-2-{5-[(5-{[(1S)-1-(4-tert-butylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]-2-chlorophenoxy}propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, K/Na tartrate 0.2 M
Resolution 1.78 Å R-free 0.216
8B8X Crystal structure of PPARG and NCOR2 with SR10221, an inverse agonist Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded A8R (2S)-2-{5-[(5-{[(1S)-1-(4-tert-butylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]-2-chlorophenoxy}propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, K/Na tartrate 0.2 M
Resolution 1.78 Å R-free 0.216
8B8Y Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7e) Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded Q33 4,5-bis(chloranyl)-~{N}3-phenyl-~{N}1-(phenylmethyl)benzene-1,3-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOOMg 0.2 M
Resolution 2.00 Å R-free 0.242
8B8Y Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7e) Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded Q33 4,5-bis(chloranyl)-~{N}3-phenyl-~{N}1-(phenylmethyl)benzene-1,3-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOOMg 0.2 M
Resolution 2.00 Å R-free 0.242
8B8Z Crystal structure of mutant PPARG (C313A) and NCOR2 with an inverse agonist (compound 7e) Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Mutation：C313A Q33 4,5-bis(chloranyl)-~{N}3-phenyl-~{N}1-(phenylmethyl)benzene-1,3-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOONa 0.2 M
Resolution 2.22 Å R-free 0.248
8B8Z Crystal structure of mutant PPARG (C313A) and NCOR2 with an inverse agonist (compound 7e) Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Mutation：C313A Q33 4,5-bis(chloranyl)-~{N}3-phenyl-~{N}1-(phenylmethyl)benzene-1,3-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOONa 0.2 M
Resolution 2.22 Å R-free 0.248
8B90 Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7d) Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded Q1R 5-chloranyl-~{N}3-phenyl-~{N}1-(phenylmethyl)benzene-1,3-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, LiNO3 0.2 M
Resolution 2.10 Å R-free 0.274
8B90 Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7d) Deposited 2022-10-05 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, LiNO3 0.2 M
Resolution 2.10 Å R-free 0.274
8B91 Crystal structure of mutant PPARG (C313A) and NCOR2 with an inverse agonist (compound SI-1) Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Mutation：C313A Q4O ~{N}3-[4-[bis(fluoranyl)methoxy]-3-fluoranyl-phenyl]-4-chloranyl-6-fluoranyl-~{N}1-[(2-methoxyphenyl)methyl]benzene-1,3-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, NaAc 0.2 M
Resolution 2.23 Å R-free 0.228
8B91 Crystal structure of mutant PPARG (C313A) and NCOR2 with an inverse agonist (compound SI-1) Deposited 2022-10-05 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Mutation：C313A No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, NaAc 0.2 M
Resolution 2.23 Å R-free 0.228
8B92 Crystal structure of PPARG and NCOR2 with an inverse agonist (compound SI-2) Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded Q5X 4-chloranyl-6-fluoranyl-~{N}3-[2-fluoranyl-4-(oxetan-3-yl)phenyl]-~{N}1-[(2-methoxyphenyl)methyl]benzene-1,3-dicarboxamide × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 6000 25%, TRIS 0.1 M (pH 8.0), ZnCl 0.01 M
Resolution 1.66 Å R-free 0.227
8B92 Crystal structure of PPARG and NCOR2 with an inverse agonist (compound SI-2) Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded Q5X 4-chloranyl-6-fluoranyl-~{N}3-[2-fluoranyl-4-(oxetan-3-yl)phenyl]-~{N}1-[(2-methoxyphenyl)methyl]benzene-1,3-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 6000 25%, TRIS 0.1 M (pH 8.0), ZnCl 0.01 M
Resolution 1.66 Å R-free 0.227
8B93 Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 15b) Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded Q8F 4-chloranyl-6-fluoranyl-~{N}1-[[4-fluoranyl-2-(2-methoxyethoxymethyl)phenyl]methyl]-~{N}3-[2-methyl-4-(trifluoromethyl)phenyl]benzene-1,3-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOONa 0.2 M
Resolution 2.21 Å R-free 0.386
8B93 Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 15b) Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded Q8F 4-chloranyl-6-fluoranyl-~{N}1-[[4-fluoranyl-2-(2-methoxyethoxymethyl)phenyl]methyl]-~{N}3-[2-methyl-4-(trifluoromethyl)phenyl]benzene-1,3-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOONa 0.2 M
Resolution 2.21 Å R-free 0.386
8B94 Crystal structure of PPARG and NCOR2 with BAY-5516, an inverse agonist Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded Q5O ~{N}3-[4-[bis(fluoranyl)methoxy]-2-methyl-phenyl]-4-chloranyl-6-fluoranyl-~{N}1-[(4-fluorophenyl)methyl]benzene-1,3-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOOK 0.2 M
Resolution 1.55 Å R-free 0.240
8B94 Crystal structure of PPARG and NCOR2 with BAY-5516, an inverse agonist Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded Q5O ~{N}3-[4-[bis(fluoranyl)methoxy]-2-methyl-phenyl]-4-chloranyl-6-fluoranyl-~{N}1-[(4-fluorophenyl)methyl]benzene-1,3-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOOK 0.2 M
Resolution 1.55 Å R-free 0.240
8B95 Crystal structure of PPARG and NCOR2 with BAY-9683, an inverse agonist Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded Q4C ~{N}1-[[3,4-bis(fluoranyl)phenyl]methyl]-4-chloranyl-6-fluoranyl-~{N}3-(3-methyl-5-morpholin-4-yl-pyridin-2-yl)benzene-1,3-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, BT Prop 0.1 M (pH 7.5), NaAc 0.2 M
Resolution 1.72 Å R-free 0.238
8B95 Crystal structure of PPARG and NCOR2 with BAY-9683, an inverse agonist Deposited 2022-10-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded Q4C ~{N}1-[[3,4-bis(fluoranyl)phenyl]methyl]-4-chloranyl-6-fluoranyl-~{N}3-(3-methyl-5-morpholin-4-yl-pyridin-2-yl)benzene-1,3-dicarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, BT Prop 0.1 M (pH 7.5), NaAc 0.2 M
Resolution 1.72 Å R-free 0.238
8BF1 High-resolution structure of unliganded PPAR gamma in complex with the peptide PGC-1 alpha Deposited 2022-10-23 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；292.15 K；0.1 M Bis-Tris pH 6.5 0.2 M ammonium acetate 0.01 M gunidine hydrochloride
Resolution 1.36 Å R-free 0.181
8BF2 Human PPARgamma in complex with MEHP bound to the AF-2 and omega sub-pockets Deposited 2022-10-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 234–505（272 aa）
Not recorded QGL 2-[(2~{S})-2-ethylhexoxy]carbonylbenzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.6；292.15 K；0.1 M Tris pH, 7.6 0.8 M sodium citrate
Resolution 2.18 Å R-free 0.247
8BF2 Human PPARgamma in complex with MEHP bound to the AF-2 and omega sub-pockets Deposited 2022-10-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 234–505（272 aa）
Not recorded QGL 2-[(2~{S})-2-ethylhexoxy]carbonylbenzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.6；292.15 K；0.1 M Tris pH, 7.6 0.8 M sodium citrate
Resolution 2.18 Å R-free 0.247
8BFF Human PPARgamma in complex with MINCH bound to the AF-2 sub-pocket Deposited 2022-10-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 234–505（272 aa）
Not recorded QG6 (1~{S},2~{R})-2-[(4~{R})-4-methylheptoxy]carbonylcyclohexane-1-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；292.15 K；0.1 M Tris-HCl pH 8.5 30% PEG 2000 0.2 M Lithium sulfate 0.01 M guanidine hydrochloride
Resolution 2.60 Å R-free 0.295
8BFF Human PPARgamma in complex with MINCH bound to the AF-2 sub-pocket Deposited 2022-10-25 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 234–505（272 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；292.15 K；0.1 M Tris-HCl pH 8.5 30% PEG 2000 0.2 M Lithium sulfate 0.01 M guanidine hydrochloride
Resolution 2.60 Å R-free 0.295
8BFF Human PPARgamma in complex with MINCH bound to the AF-2 sub-pocket Deposited 2022-10-25 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 234–505（272 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；292.15 K；0.1 M Tris-HCl pH 8.5 30% PEG 2000 0.2 M Lithium sulfate 0.01 M guanidine hydrochloride
Resolution 2.60 Å R-free 0.295
8C0C X-ray crystal structure of PPAR gamma ligand binding domain in complex with CZ46 Deposited 2022-12-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa）
Chain B 223–504（282 aa）
Not recorded T0C (2~{R})-2-[4-(naphthalen-1-ylmethoxy)phenyl]-4-oxidanyl-3-phenyl-2~{H}-furan-5-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293.15 K；0.8 M SODIUM CITRATE, 0.15 M TRIS, PH 8.0
Resolution 2.20 Å R-free 0.272
8CPH Crystal structure of PPAR gamma (PPARG) in complex with WY-14643 (inactive form) Deposited 2023-03-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Chain B 231–505（275 aa）
Not recorded WY1 2-({4-CHLORO-6-[(2,3-DIMETHYLPHENYL)AMINO]PYRIMIDIN-2-YL}SULFANYL)ACETIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293.15 K；30% PEG 3350, 0.15M sodium citrate
Resolution 2.40 Å R-free 0.263
8CPI Crystal structure of PPAR gamma (PPARG) in complex with WY-14643 Deposited 2023-03-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded WY1 2-({4-CHLORO-6-[(2,3-DIMETHYLPHENYL)AMINO]PYRIMIDIN-2-YL}SULFANYL)ACETIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293.15 K；1.6M ammonium sulfate, 0.1M tris 8.0
Resolution 2.10 Å R-free 0.282
8CPJ Crystal structure of PPAR gamma (PPARG) in an inactive form Deposited 2023-03-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293.15 K；27% PEG 3350, 0.15M sodium citrate
Resolution 2.40 Å R-free 0.282
8DK4 Peroxisome proliferator-activated receptor gamma in complex with VSP-51-2 Deposited 2022-07-02 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa） Fragment：ligand binding domain (UNP residues 234-505)
Not recorded SJ9 5-(benzylcarbamoyl)-1-[(4-chloro-3-fluorophenyl)methyl]-1H-indole-2-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M of trisodium citrate, pH 5.5, 20% w/v PEG3350
Resolution 2.60 Å R-free 0.255
8DKN PPARg bound to T0070907 and Co-R peptide Deposited 2022-07-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Not recorded EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 1 CXS 3-CYCLOHEXYL-1-PROPYLSULFONIC ACID × 2 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 9.5；296 K；2+2 uL drops made from a 2:2:1 molar ratio of T007:NCOR peptide:PPARg and well solution containing 1.8-2.2 M (NH3)2SO4, 0.2 M Li2SO4 and 100 mM CAPS pH 9.5. Protein formulated at 20 mg mL-1 in 20 mM Tris, pH 8.0, 100 mM NaCl, and 1mM TCEP
Resolution 1.95 Å R-free 0.297
8DKV PPARg bound to JTP-426467 and Co-R peptide Deposited 2022-07-06 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Not recorded SKL 2-chloro-N-[4-(5-methyl-1,3-benzoxazol-2-yl)phenyl]-5-nitrobenzamide × 1 CXS 3-CYCLOHEXYL-1-PROPYLSULFONIC ACID × 2 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；296 K；2+2 uL drops made from a 2:2:1 molar ratio of JTP-4:NCOR peptide:PPARg and well solution containing 1.8-2.2 M (NH3)2SO4, 0.2 M Li2SO4 and 100 mM CAPS pH 9.5. Protein formulated at 20 mg mL-1 in 20 mM Tris, pH 8.0, 100 mM NaCl, and 1mM TCEP
Resolution 1.59 Å R-free 0.266
8DSY PPARg bound to inverse agonist H3B-343 Deposited 2022-07-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Chain B 234–505（272 aa）
Not recorded TJC {5-[(5-{[(4-tert-butylphenyl)methyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]-2-chlorophenoxy}acetic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；296 K；2+2 uL drops of protein + reservoir consisting of 0.9-1.2 M Na citrate and 100 mM Tris pH 8.0. Protein formulated at 20 mg mL-1 in 20 mM Tris, pH 8.0, 100 mM NaCl, and 1mM TCEP
Resolution 2.95 Å R-free 0.267
8DSZ PPARg bound to partial agonist H3B-487 Deposited 2022-07-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Chain B 234–505（272 aa）
Not recorded TJO (2R)-2-{5-[(5-{[(1R)-1-(4-tert-butylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]-2-chlorophenoxy}propanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；296 K；2 + 2 uL drops containing protein + reservoir solution containing 0.9-1.2 M Na citrate and 100 mM Tris pH 8.0. Protein formulated in 20 mg mL-1 in 20 mM Tris, pH 8.0, 100 mM NaCl, and 1mM TCEP
Resolution 2.50 Å R-free 0.269
8FHE Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and GW9662 Deposited 2022-12-14 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
Resolution 1.80 Å R-free 0.229
8FHF Crystal structure of PPARgamma ligand-binding domain in complex with ZINC5672437 Deposited 2022-12-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded XZK N-(4-carbamoylphenyl)-2-chloro-5-nitrobenzamide × 1 KNA nonanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
Resolution 2.10 Å R-free 0.285
8FHF Crystal structure of PPARgamma ligand-binding domain in complex with ZINC5672437 Deposited 2022-12-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 231–505（275 aa）
Not recorded XZK N-(4-carbamoylphenyl)-2-chloro-5-nitrobenzamide × 1 KNA nonanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
Resolution 2.10 Å R-free 0.285
8FHG Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and ZINC5672437 Deposited 2022-12-14 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded XZK N-(4-carbamoylphenyl)-2-chloro-5-nitrobenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
Resolution 1.80 Å R-free 0.234
8FKC Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and inverse agonist SR33544 Deposited 2022-12-21 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded Y5F 2-chloro-N-(5-cyanopyridin-3-yl)-5-nitrobenzamide × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
Resolution 1.42 Å R-free 0.198
8FKD Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and inverse agonist SR33068 Deposited 2022-12-21 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded Y5O 2-chloro-N-(6-cyanopyridin-3-yl)-5-nitrobenzamide × 1 EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
Resolution 2.22 Å R-free 0.251
8FKE Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and inverse agonist SR32904 Deposited 2022-12-21 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded Y5T 2-chloro-N-(2-methylpyridin-4-yl)-5-nitrobenzamide × 1 EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
Resolution 2.02 Å R-free 0.249
8FKF Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and inverse agonist SR36706 Deposited 2022-12-21 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded Y5X 2-chloro-N-(5-fluoropyridin-3-yl)-5-nitrobenzamide × 1 EDO 1,2-ETHANEDIOL × 4 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
Resolution 1.82 Å R-free 0.216
8FKG Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and inverse agonist SR33486 Deposited 2022-12-21 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded GOL GLYCEROL × 2 Y62 2-chloro-N-(5-cyanopyridin-2-yl)-5-nitrobenzamide × 1 SO4 SULFATE ION × 1 EDO 1,2-ETHANEDIOL × 8 K POTASSIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
Resolution 2.12 Å R-free 0.218
8HHP Crystal structure of PPARg-LBD complexed with three partial agonists, one nTZDpa and two LT175 Deposited 2022-11-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 204–477（274 aa）
Not recorded NZA 5-CHLORO-1-(4-CHLOROBENZYL)-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 1 LRG (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.7；293 K；0.1 M Tris-HCl pH 7.7, 0.75 M sodium citrate
Resolution 2.45 Å R-free 0.286
8HHQ Covalent bond formation between cysteine of PPARg-LBD and iodoacetic acid Deposited 2022-11-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 204–477（274 aa）
Chain B 204–477（274 aa）
Not recorded GOA GLYCOLIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1 M Tris-HCl pH 7.4, 0.8 M sodium citrate
Resolution 2.40 Å R-free 0.266
8PBO Deep interactome learning for generative drug design Deposited 2023-06-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 232–505（274 aa）
Not recorded Y5I 3-[2-fluoranyl-4-[3-[2-fluoranyl-4-(5-methyl-1,3,4-thiadiazol-2-yl)phenoxy]propoxy]phenyl]propanoic acid × 1 GOL GLYCEROL × 3 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；1.6 M Ammoniumsulphate, 0.1 M Tris/HCl pH 7.5
Resolution 1.85 Å R-free 0.213
8PBO Deep interactome learning for generative drug design Deposited 2023-06-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 232–505（274 aa）
Not recorded GOL GLYCEROL × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；1.6 M Ammoniumsulphate, 0.1 M Tris/HCl pH 7.5
Resolution 1.85 Å R-free 0.213
8REJ Crystal structure of PPAR gamma Ligand Binding Domain in complex with the ligand LBB78 Deposited 2023-12-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–505（283 aa）
Chain B 223–505（283 aa）
Not recorded WUE (2~{S})-2-(4-naphthalen-1-ylphenoxy)-3-phenyl-propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.8 M Na citrate, 0.15 M Tris
Resolution 3.16 Å R-free 0.266
8SC9 Structure of PPARG in complex with MTX-531 Deposited 2023-04-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 232–505（274 aa） Fragment：UNP residues 232-505
Not recorded SO4 SULFATE ION × 5 TAM TRIS(HYDROXYETHYL)AMINOMETHANE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 9；293 K；2.2 M Ammonium Sulfate, 0.1 M BIS-TRIS-Propane pH 9.0
Resolution 1.85 Å R-free 0.241
8SC9 Structure of PPARG in complex with MTX-531 Deposited 2023-04-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 232–505（274 aa） Fragment：UNP residues 232-505
Not recorded SO4 SULFATE ION × 5 D0D N-[(5P)-2-chloro-5-(4-{[(1R)-1-phenylethyl]amino}quinazolin-6-yl)pyridin-3-yl]methanesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 9；293 K；2.2 M Ammonium Sulfate, 0.1 M BIS-TRIS-Propane pH 9.0
Resolution 1.85 Å R-free 0.241
8U57 PPARg LBD in complex with perfluorooctanoic acid (PFOA) Deposited 2023-09-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 203–477（275 aa） Fragment：Ligand binding domain
Non-standard monomer：Yes (specific site not provided by mmCIF) 8PF pentadecafluorooctanoic acid × 4 D1D (4S,5S)-1,2-DITHIANE-4,5-DIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；289.15 K；0.6 - 1.2 M sodium citrate tribasic dihydrate, 0.1 M Tris 8.0
Resolution 2.00 Å R-free 0.254
8WFE The Crystal Structure of PPARg from Biortus. Deposited 2023-09-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Chain B 234–505（272 aa）
Not recorded EDO 1,2-ETHANEDIOL × 1 PEG DI(HYDROXYETHYL)ETHER × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.1M MIB pH9.0, 25% PEG 1500
Resolution 2.20 Å R-free 0.248
8ZFN Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and BVT.13 Deposited 2024-05-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Chain B 231–505（275 aa）
Not recorded GW9 2-chloro-5-nitro-N-phenylbenzamide × 2 PLB 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 2.54 Å R-free 0.321
8ZFO Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and nTZDpa Deposited 2024-05-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Chain B 231–505（275 aa）
Not recorded NZA 5-CHLORO-1-(4-CHLOROBENZYL)-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 2 GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 3.15 Å R-free 0.296
8ZFP Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and MRL24 Deposited 2024-05-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Chain B 231–505（275 aa）
Not recorded GW9 2-chloro-5-nitro-N-phenylbenzamide × 2 241 (2S)-2-(3-{[1-(4-METHOXYBENZOYL)-2-METHYL-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL]METHYL}PHENOXY)PROPANOIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 2.48 Å R-free 0.303
8ZFQ Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with T0070907 and BVT.13 Deposited 2024-05-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Chain B 231–505（275 aa）
Not recorded EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 2 PLB 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 2.49 Å R-free 0.304
8ZFR Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with T0070907 and nTZDpa Deposited 2024-05-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Chain B 231–505（275 aa）
Not recorded EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 1 NZA 5-CHLORO-1-(4-CHLOROBENZYL)-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 2.73 Å R-free 0.302
8ZFS Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with T0070907 and MRL24 Deposited 2024-05-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Chain B 231–505（275 aa）
Not recorded EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 2 241 (2S)-2-(3-{[1-(4-METHOXYBENZOYL)-2-METHYL-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL]METHYL}PHENOXY)PROPANOIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 2.56 Å R-free 0.271
8ZFT Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with T0070907 and SR1664 Deposited 2024-05-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Chain B 231–505（275 aa）
Not recorded EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 2 3JX 4'-[(2,3-dimethyl-5-{[(1S)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
Resolution 3.20 Å R-free 0.280
9CK0 Cocrystal of PPARg LBD and NFKBIB / IKBB peptide with agonist GW1929 Deposited 2024-07-08 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；295.15 K；0.2 M LIthium sulfate, 0.1 M Tris pH 8.5, 16% (w/v) PEG 4000
Resolution 2.60 Å R-free 0.296
9CWN NRIP1_133 / RIP140 SxxLxxLL motif coregulator peptide with agonist GW1929 and PPARg LBD Deposited 2024-07-29 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；293.15 K；1.6 M AmSO4, 100mM Tris pH 8.5
Resolution 2.70 Å R-free 0.242
9F7W Human PPARgamma ligand binding domain in complex with co-activator 1alpha peptide and bisphenol A (BPA) Deposited 2024-05-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Not recorded 2OH 4,4'-PROPANE-2,2-DIYLDIPHENOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；292.15 K；20% w/v PEG 3350, 0.2 M magnesium acetate, 137 mM sodium chloride, 8.1 mM disodium hydrogen phosphate, 1.5 mM potassium dihydrogen phosphate, 2.7 mM potassium chloride, 1 mM peptide, 15 mM BPB, 1.5 % DMSO
Resolution 1.25 Å R-free 0.189
9F7X Human PPARgamma ligand binding domain in complex with co-activator 1alpha peptide and bisphenol B (BPB) Deposited 2024-05-05 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Not recorded H3W bisphenol-B × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；292.15 K；20% w/v PEG 3350, 0.337 M sodium chloride, 8.1 mM disodium hydrogen phosphate, 1.5 mM potassium dihydrogen phosphate, 2.7 mM potassium chloride, 1 mM peptide, 15 mM BPB, 1.5 % DMSO
Resolution 1.63 Å R-free 0.290
9GFU Human PPAR-gamma ligand binding domain in complex with AKGO172 Deposited 2024-08-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IK6 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(3-ethoxycarbonylphenyl)methoxy]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.10 Å R-free 0.250
9GVP Human PPAR-gamma ligand binding domain in complex with WG115 Deposited 2024-09-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–503（269 aa）
Chain B 235–503（269 aa）
Not recorded A1IPP 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.05 Å R-free 0.249
9GVS Human PPAR-gamma ligand binding domain in complex with AK176_C Deposited 2024-09-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IPR 4-[1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-6-(trifluoromethyl)indazol-3-yl]-3-phenylmethoxy-benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.10 Å R-free 0.255
9GVT Human PPAR-gamma ligand binding domain in complex with AK176_D Deposited 2024-09-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IPQ 4-[1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-5-(trifluoromethyloxy)indazol-3-yl]-3-phenylmethoxy-benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.30 Å R-free 0.252
9GW3 Human PPAR-gamma ligand binding domain in complex with LW56 Deposited 2024-09-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IPW 4-[1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-5-methyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.00 Å R-free 0.252
9GW4 Human PPAR-gamma ligand binding domain in complex with LW78 Deposited 2024-09-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IPS 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(2,3-dimethoxyphenyl)methoxy]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.20 Å R-free 0.248
9GW7 Human PPAR-gamma ligand binding domain in complex with LW76 Deposited 2024-09-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IPU 3-(1,3-benzodioxol-5-ylmethoxy)-4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.10 Å R-free 0.248
9GW8 Human PPAR-gamma ligand binding domain in complex with LW75 Deposited 2024-09-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IRG 3-(1,3-benzodioxol-4-ylmethoxy)-4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.20 Å R-free 0.257
9GWB Human PPAR-gamma ligand binding domain in complex with LW69 Deposited 2024-09-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IPZ 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-(oxan-4-ylmethoxy)benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.20 Å R-free 0.245
9GWC Human PPAR-gamma ligand binding domain in complex with LW99 Deposited 2024-09-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IPX 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[(2~{S})-oxan-2-yl]methoxy]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.00 Å R-free 0.247
9GWE Human PPAR-gamma ligand binding domain in complex with LW87 Deposited 2024-09-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IPV 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[3-(trifluoromethyloxy)phenyl]methoxy]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.10 Å R-free 0.259
9GWF Human PPAR-gamma ligand binding domain in complex with LW100 Deposited 2024-09-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IPT 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[3-(methylcarbamoyl)phenyl]methoxy]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.40 Å R-free 0.253
9GWG Human PPAR-gamma ligand binding domain in complex with LW88 Deposited 2024-09-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IP1 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]methoxy]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.30 Å R-free 0.252
9GWH Human PPAR-gamma ligand binding domain in complex with LW77 Deposited 2024-09-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IP0 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-2-phenylmethoxy-benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.10 Å R-free 0.256
9GWI Human PPAR-gamma ligand binding domain in complex with LW23 Deposited 2024-09-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IPY 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-(phenoxymethyl)benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.20 Å R-free 0.253
9GWK Human PPAR-gamma ligand binding domain in complex with AKGO6A Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IP9 4-[7-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.20 Å R-free 0.254
9GWL Human PPAR-gamma ligand binding domain in complex with AKGO157 Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IP7 4-[6-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.20 Å R-free 0.249
9GWM Human PPAR-gamma ligand binding domain in complex with AKGO108 Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IP6 4-[1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-6-cyano-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.20 Å R-free 0.253
9GWN Human PPAR-gamma ligand binding domain in complex with LW30 Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IP4 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-(phenylazanylmethyl)benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.20 Å R-free 0.258
9GWP Human PPAR-gamma ligand binding domain in complex with MRL-871 with two distinct binding modes Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded 4F1 4-{1-[2-chloro-6-(trifluoromethyl)benzoyl]-1H-indazol-3-yl}benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.55 Å R-free 0.269
9GWQ Human PPAR-gamma ligand binding domain in complex with AKGO6D Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQA 4-[1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-5-cyano-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.10 Å R-free 0.255
9GWR Human PPAR-gamma ligand binding domain in complex with AKGO10 Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IP3 4-[5-chloranyl-1-(2-chlorophenyl)carbonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.10 Å R-free 0.255
9GWS Human PPAR-gamma ligand binding domain in complex with AKGO8 Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQB 4-[5-chloranyl-1-[2-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.20 Å R-free 0.237
9GWX Human PPAR-gamma ligand binding domain in complex with AKGO141 Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IP8 4-[1-[2,6-bis(chloranyl)phenyl]carbonyl-5-chloranyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.20 Å R-free 0.248
9GWY Human PPAR-gamma ligand binding domain in complex with AKGO78 Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQD 4-[5-chloranyl-1-[2-(trifluoromethyl)phenyl]sulfonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.09 Å R-free 0.242
9GX0 Human PPAR-gamma ligand binding domain in complex with AKGO79 Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQG 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(4-methylphenyl)methoxy]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.10 Å R-free 0.260
9GX1 Human PPAR-gamma ligand binding domain in complex with AKGO80 Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQI 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(4-methoxyphenyl)methoxy]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.10 Å R-free 0.253
9GX2 Human PPAR-gamma ligand binding domain in complex with AKGO82 Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–503（269 aa）
Chain B 235–503（269 aa）
Not recorded A1IP5 3-[(3-carboxyphenyl)methoxy]-4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.35 Å R-free 0.246
9GX3 Human PPAR-gamma ligand binding domain in complex with AKGO12 Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQE 4-[1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonylindazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 1.90 Å R-free 0.254
9GX4 Human PPAR-gamma ligand binding domain in complex with AKGO156 Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQC 4-[4-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.20 Å R-free 0.270
9GX5 Human PPAR-gamma ligand binding domain in complex with AKGO173 Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQJ 4-[5-chloranyl-1-[[2-chloranyl-6-(trifluoromethyl)phenyl]methyl]indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.45 Å R-free 0.270
9GX6 Human PPAR-gamma ligand binding domain in complex with AKGO166 Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQL 4-[5-chloranyl-1-(2,6-dimethylphenyl)carbonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
Resolution 2.10 Å R-free 0.251
9GX7 Human PPAR-gamma ligand binding domain in complex with WG17 Deposited 2024-09-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQH 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.20 Å R-free 0.271
9GXD Human PPAR-gamma ligand binding domain in complex with AKGO27 Deposited 2024-09-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQF 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-(2-phenylethoxy)benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.20 Å R-free 0.261
9GZ7 Human PPAR-gamma ligand binding domain in complex with AKGO29 Deposited 2024-10-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQ8 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(4-chlorophenyl)methoxy]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 1.80 Å R-free 0.247
9GZ8 Human PPAR-gamma ligand binding domain in complex with AKGO46 Deposited 2024-10-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQ7 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(1~{R})-1-phenylethoxy]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.20 Å R-free 0.254
9GZ9 Human PPAR-gamma ligand binding domain in complex with AKGO48 Deposited 2024-10-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQ6 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(3,4-dichlorophenyl)methoxy]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.10 Å R-free 0.261
9GZA Human PPAR-gamma ligand binding domain in complex with AKGO50 Deposited 2024-10-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQ5 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-(cyclohexylmethoxy)benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 1.90 Å R-free 0.238
9GZB Human PPAR-gamma ligand binding domain in complex with AKGO52 Deposited 2024-10-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQ4 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(3,5-dimethoxyphenyl)methoxy]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.20 Å R-free 0.274
9GZC Human PPAR-gamma ligand binding domain in complex with AKGO142 Deposited 2024-10-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQ3 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(3-methoxyphenyl)methoxy]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.30 Å R-free 0.255
9GZE Human PPAR-gamma ligand binding domain in complex with AKGO72 Deposited 2024-10-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–504（270 aa）
Chain B 235–504（270 aa）
Not recorded A1IRD 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-(pyrimidin-2-ylmethoxy)benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.20 Å R-free 0.256
9GZF Human PPAR-gamma ligand binding domain in complex with AKGO88 Deposited 2024-10-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IQ2 4-[5-chloranyl-1-(phenylsulfonyl)indazol-3-yl]-3-phenylmethoxy-benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.65 Å R-free 0.258
9GZI Human PPAR-gamma ligand binding domain in complex with LW98 Deposited 2024-10-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1IRA 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(4-methylsulfonylphenyl)methoxy]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.70 Å R-free 0.264
9HX2 X-ray crystal structure of PPAR gamma Ligand Binding Domain in complex with CZ58 Deposited 2025-01-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 223–504（282 aa）
Chain B 223–504（282 aa）
Not recorded A1IYE 2-[3-[(2~{R})-3-(4-bromophenyl)-4-oxidanyl-5-oxidanylidene-2~{H}-furan-2-yl]phenoxy]ethanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293.15 K；0.8 M SODIUM CITRATE, 0.15 M TRIS, pH 8.0
Resolution 2.85 Å R-free 0.282
9L3T PPARgamma Ligand binding domain in complex with piperine Deposited 2024-12-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 204–477（274 aa）
Chain B 204–477（274 aa）
Not recorded AYR (2E,4E)-5-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)penta-2,4-dien-1-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；0.1 M Tris-HCl, 0.7 M sodium citrate
Resolution 2.36 Å R-free 0.255
9MAH PPARG-Spermine analogs Deposited 2025-03-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 234–505（272 aa）
Chain B 234–505（272 aa）
Not recorded A1ENO N'-methyl-N'-phenyl-propane-1,3-diamine × 2 IMD IMIDAZOLE × 1 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；1.0 M Na3citrate, 0.1 M Imidazole pH 8.0
Resolution 2.10 Å R-free 0.234
9MAH PPARG-Spermine analogs Deposited 2025-03-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 234–505（272 aa）
Chain B 234–505（272 aa）
Not recorded A1ENO N'-methyl-N'-phenyl-propane-1,3-diamine × 4 IMD IMIDAZOLE × 2 GOL GLYCEROL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；1.0 M Na3citrate, 0.1 M Imidazole pH 8.0
Resolution 2.10 Å R-free 0.234
9O9N Crystal structure of PPARgamma ligand binding domain (LBD) in complex with NCoR1 corepressor peptide and inverse agonist FX-909 Deposited 2025-04-18 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded A1CAA (3P)-3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methanesulfonyl)benzonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M MES (pH 6.5), 0.2 M Ammonium Sulfate, 30% PEG 8000
Resolution 2.10 Å R-free 0.297
9OLC Crystal structure of PPARg ligand-binding domain in complex with NCoR1 peptide and FTX-6746 Deposited 2025-05-12 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded A1CCT (3P)-4-chloro-3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；0.1 M MES pH 6.5, 0.1M Ammonium Sulfate, 24% PEG8000
Resolution 2.83 Å R-free 0.298
9OLC Crystal structure of PPARg ligand-binding domain in complex with NCoR1 peptide and FTX-6746 Deposited 2025-05-12 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 231–505（275 aa）
Not recorded A1CCT (3P)-4-chloro-3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；0.1 M MES pH 6.5, 0.1M Ammonium Sulfate, 24% PEG8000
Resolution 2.83 Å R-free 0.298
9OLC Crystal structure of PPARg ligand-binding domain in complex with NCoR1 peptide and FTX-6746 Deposited 2025-05-12 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 231–505（275 aa）
Not recorded A1CCT (3P)-4-chloro-3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；0.1 M MES pH 6.5, 0.1M Ammonium Sulfate, 24% PEG8000
Resolution 2.83 Å R-free 0.298
9OLC Crystal structure of PPARg ligand-binding domain in complex with NCoR1 peptide and FTX-6746 Deposited 2025-05-12 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 231–505（275 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；0.1 M MES pH 6.5, 0.1M Ammonium Sulfate, 24% PEG8000
Resolution 2.83 Å R-free 0.298
9QFZ Human PPAR-gamma ligand binding domain in complex with LW132 Deposited 2025-03-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1I6M 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(phenylmethyl)amino]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.10 Å R-free 0.265
9QG0 Human PPAR-gamma ligand binding domain in complex with LW128 Deposited 2025-03-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1I6U 5-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-6-phenylmethoxy-pyridine-2-carboxylic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.10 Å R-free 0.250
9QG2 Human PPAR-gamma ligand binding domain in complex with LW86 Deposited 2025-03-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1I6S 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-(cyclopentylmethoxy)benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.00 Å R-free 0.242
9QG3 Human PPAR-gamma ligand binding domain in complex with LW129 Deposited 2025-03-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1I6T 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-2-fluoranyl-3-phenylmethoxy-benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.30 Å R-free 0.255
9QG4 Human PPAR-gamma ligand binding domain in complex with LW130 Deposited 2025-03-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1I6O 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[3-(ethylcarbamoyl)phenyl]methoxy]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 1.90 Å R-free 0.234
9QG5 Human PPAR-gamma ligand binding domain in complex with LW112 Deposited 2025-03-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1I6P 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[(3~{S})-piperidin-3-yl]methoxy]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.30 Å R-free 0.244
9QG6 Human PPAR-gamma ligand binding domain in complex with LW109 Deposited 2025-03-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1I6N 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[(3~{R})-piperidin-3-yl]methoxy]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.70 Å R-free 0.270
9QGJ Human PPAR-gamma ligand binding domain in complex with LW90 Deposited 2025-03-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 235–505（271 aa）
Chain B 235–505（271 aa）
Not recorded A1I6R 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[(3~{S})-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]methoxy]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
Resolution 2.20 Å R-free 0.255
9R6I Crystal structure of PPARgamma in complex with the bisphenol derivative BPS4BE Deposited 2025-05-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded A1JDE 4-(4-phenylmethoxyphenyl)sulfonylphenol × 1 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；1.2 M trisodium citrate, 100 mM HEPES, pH 7.5, 4.2% 1,2 propanediol
Resolution 1.70 Å R-free 0.229
9R6K Crystal structure of PPARgamma in complex with the bisphenol derivative BPPH Deposited 2025-05-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 231–505（275 aa）
Not recorded A1JDD 4-[2-(4-oxidanyl-3-phenyl-phenyl)propan-2-yl]-2-phenyl-phenol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.8 M trisodium citrate, 100 mM HEPES, pH 7.5, 4.4% 1,2 propanediol
Resolution 2.30 Å R-free 0.259
9V8D PPARgamma ligand-binding domain in complex with PG08 Deposited 2025-05-29 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded PEG DI(HYDROXYETHYL)ETHER × 1 PGE TRIETHYLENE GLYCOL × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；283 K；0.1 M KCl, 0.1 M MgCl2, 18% PEG Smear Medium, and 10% ethylene glycol
Resolution 1.44 Å R-free 0.201
9V8E PPARgamma ligand-binding domain in complex with PG11 Deposited 2025-05-29 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded PEG DI(HYDROXYETHYL)ETHER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.1 M phosphate/citrate buffer (pH 5.5) and 30% PEG Smear Low
Resolution 1.70 Å R-free 0.215
9V8F PPARgamma ligand-binding domain in complex with PG14 Deposited 2025-05-29 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 233–505（273 aa）
Not recorded PEG DI(HYDROXYETHYL)ETHER × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.1 M Bis-Tris HCl (pH 6.2 to 6.5), 23% PEG 3,350, and 0.2 M MgCl2
Resolution 1.75 Å R-free 0.230
9V8G PPARgamma ligand-binding domain in complex with PG08-NL Deposited 2025-05-29 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded PEG DI(HYDROXYETHYL)ETHER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.2 M sodium malonate (pH 7.0) and 20% PEG 3,350
Resolution 1.39 Å R-free 0.182
9V8H PPARgamma ligand-binding domain in complex with PG08-NL and rosiglitazone Deposited 2025-05-29 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 231–505（275 aa）
Not recorded BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 PGE TRIETHYLENE GLYCOL × 1 PEG DI(HYDROXYETHYL)ETHER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.2 M sodium malonate (pH 7.5 to 8.0) and 15 to 20% PEG 3,350
Resolution 1.39 Å R-free 0.190

369 other PDB entries and 500 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name PPARG_HUMAN
Isoform —
PDB entities 1
Chains and sequence ranges Author chain A； PDBConstruct 1–283； UniProt 223–505

16-mer peptide from Nuclear receptor coactivator 1

OrganismNot specified

UniProt Q15788

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Protein heterocomplex Heteromer Protein × 2 PDB declaration: dimeric（2） Consistent with protein copy count Chain B； UniProt 685–700 Not recorded Peroxisome proliferator-activated receptor gamma × 1 （P37231） X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；2.2 M sodium malonate (pH 7.0) Resolution 2.70 Å R-free 0.258

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 6KTM Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
1TFC CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH A STEROID RECEPTOR COACTIVATOR-1 PEPTIDE Deposited 2004-05-27 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 686–700（15 aa） Fragment：SECOND NR-BOX
Chain D 686–700（15 aa） Fragment：SECOND NR-BOX
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；TRIS.HCL, AMMONIUM SULFATE, GLYCEROL, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.40 Å R-free 0.258
1XIU Crystal structure of the agonist-bound ligand-binding domain of Biomphalaria glabrata RXR Deposited 2004-09-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain E 686–700（15 aa）
Chain F 686–700（15 aa）
Not recorded 9CR (9cis)-retinoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；HEPES, sodium formate, sodium chloride, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.50 Å R-free 0.243
1ZAF Crystal structure of estrogen receptor beta complexed with 3-Bromo-6-hydroxy-2-(4-hydroxy-phenyl)-inden-1-one Deposited 2005-04-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 630–640（11 aa）
Chain D 630–640（11 aa）
Not recorded 789 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.5；291 K；15% PEG3350, 0.2M Mg Acetate, pH 7.5, VAPOR DIFFUSION, temperature 291K
Resolution 2.20 Å R-free 0.286
2A3I Structural and Biochemical Mechanisms for the Specificity of Hormone Binding and Coactivator Assembly by Mineralocorticoid Receptor Deposited 2005-06-24 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 1430–1441（12 aa）
Not recorded C0R CORTICOSTERONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.9；293 K；PEG mme5K, Sodium Acetate, 1-6 Hexanediol, pH 7.9, VAPOR DIFFUSION, temperature 293K
Resolution 1.95 Å R-free 0.253
2C52 Structural diversity in CBP p160 complexes Deposited 2005-10-25 Different construct Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 920–970（51 aa） Fragment：AD1, RESIDUES 920-970
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K；Ionic strength (raw mmCIF value) 100
NMR measurement conditions pH 7；298 K；Ionic strength (raw mmCIF value) 100
NMR measurement conditions pH 7；298 K；Ionic strength (raw mmCIF value) 100
NMR measurement conditions pH 7；298 K；Ionic strength (raw mmCIF value) 100
NMR sample composition 90% WATER/10% D2O
NMR sample composition 90% WATER/10% D2O
NMR sample composition 100% D2O
NMR sample composition 100% D2O
Resolution not provided
2FVJ A novel anti-adipogenic partial agonist of peroxisome proliferator-activated receptor-gamma (PPARG) recruits pparg-coactivator-1 alpha (PGC1A) but potentiates insulin signaling in vitro Deposited 2006-01-31 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 628–640（13 aa） Fragment：COACTIVATOR FRAGMENT SRC-1, 13-mer peptide from Nuclear receptor coactivator 1
Not recorded RO0 1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXY-4-{[4-(2-METHOXYPHENYL)PIPERIDIN-1-YL]METHYL}ISOQUINOLINE × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；20% PEG3350, 0.2M magnesium chloride, 0.1M Tris, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.99 Å R-free 0.246
2GTK Structure-based Design of Indole Propionic Acids as Novel PPARag CO-Agonists Deposited 2006-04-28 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 631–640（10 aa） Fragment：residues 631-640
Not recorded 208 (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.1M TRIS, PEG 3350, 0.2M MGSO4, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.10 Å R-free 0.261
2HBH Crystal structure of Vitamin D nuclear receptor ligand binding domain bound to a locked side-chain analog of calcitriol and SRC-1 peptide Deposited 2006-06-14 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa）
Not recorded XE4 1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z) × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；Li sulfate 1.6M, Mg sulfate 50mM, Bis Tris 0.1M, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.65 Å R-free 0.261
2HC4 Crystal structure of the LBD of VDR of Danio rerio in complex with calcitriol Deposited 2006-06-15 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa）
Not recorded VDX 5-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANE-1,3-DIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；Li sulfate 1.6M, Mg sulfate 50mM, Bis Tris 0.1M, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.20 Å R-free 0.250
2HCD Crystal structure of the ligand binding domain of the Vitamin D nuclear receptor in complex with Gemini and a coactivator peptide Deposited 2006-06-16 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa）
Not recorded BIV 21-NOR-9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-1,3,25-TRIOL, 20-(4-HYDROXY-4-METHYLPENTYL)-, (1A,3B,5Z,7E) × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；Li sulfate 1.6M, Mgsulfate 50mM, Bis tris 0.1M, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.60 Å R-free 0.260
2NV7 Crystal Structure of Estrogen Receptor Beta Complexed with WAY-555 Deposited 2006-11-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 631–640（10 aa）
Chain D 631–640（10 aa）
Not recorded 555 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；precipitant: PEG3350, Mg formate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.10 Å R-free 0.265
2P54 a crystal structure of PPAR alpha bound with SRC1 peptide and GW735 Deposited 2007-03-14 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 686–696（11 aa） Fragment：SRC1 peptide
Not recorded 735 2-METHYL-2-(4-{[({4-METHYL-2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL}CARBONYL)AMINO]METHYL}PHENOXY)PROPANOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；7% PEG 3350, 200 mM NaF, 12% 2,5-hexanediol, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 1.79 Å R-free 0.227
3BEJ Structure of human FXR in complex with MFA-1 and co-activator peptide Deposited 2007-11-19 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain E 676–700（25 aa） Fragment：residues 676-700
Not recorded YT3 YTTRIUM (III) ION × 1 MUF (8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；16-22% PEG3350, 0.1M Bis-Tris, 4 mM YCl(3), 0.2M Ammonium acetate, 1 mM DTT. Protein was carboxymethylated with iodoacetic acid, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.90 Å R-free 0.254
3BEJ Structure of human FXR in complex with MFA-1 and co-activator peptide Deposited 2007-11-19 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain F 676–700（25 aa） Fragment：residues 676-700
Not recorded YT3 YTTRIUM (III) ION × 1 MUF (8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；16-22% PEG3350, 0.1M Bis-Tris, 4 mM YCl(3), 0.2M Ammonium acetate, 1 mM DTT. Protein was carboxymethylated with iodoacetic acid, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.90 Å R-free 0.254
3BQD Doubling the Size of the Glucocorticoid Receptor Ligand Binding Pocket by Deacylcortivazol Deposited 2007-12-20 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 1429–1441（13 aa） Fragment：nuclear receptor coactivator 1 isoform 1 coactivator motif (residues 739-751)
Not recorded DAY 1-[(1R,2R,3aS,3bS,10aR,10bS,11S,12aS)-1,11-dihydroxy-2,5,10a,12a-tetramethyl-7-phenyl-1,2,3,3a,3b,7,10,10a,10b,11,12,12a-dodecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl]-2-hydroxyethanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；1.3 M ammonium sulfate, 100 mM Tris, 8% glycerol, 3 mM n-hexadecyl-beta-maltoside, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
Resolution 2.50 Å R-free 0.261
3CTB Tethered PXR-LBD/SRC-1p apoprotein Deposited 2008-04-11 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 678–700（23 aa） Fragment：PXR, residues 130-434, linker, SRC-1, residues 678-700
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7；277 K；10-30% MPD or isopropanol, 100 mM imidazole, pH 7, VAPOR DIFFUSION, temperature 277K
Resolution 2.00 Å R-free 0.244
3CTB Tethered PXR-LBD/SRC-1p apoprotein Deposited 2008-04-11 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain B 678–700（23 aa） Fragment：PXR, residues 130-434, linker, SRC-1, residues 678-700
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7；277 K；10-30% MPD or isopropanol, 100 mM imidazole, pH 7, VAPOR DIFFUSION, temperature 277K
Resolution 2.00 Å R-free 0.244
3CTB Tethered PXR-LBD/SRC-1p apoprotein Deposited 2008-04-11 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 3 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 678–700（23 aa） Fragment：PXR, residues 130-434, linker, SRC-1, residues 678-700
Chain B 678–700（23 aa） Fragment：PXR, residues 130-434, linker, SRC-1, residues 678-700
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7；277 K；10-30% MPD or isopropanol, 100 mM imidazole, pH 7, VAPOR DIFFUSION, temperature 277K
Resolution 2.00 Å R-free 0.244
3CWD Molecular recognition of nitro-fatty acids by PPAR gamma Deposited 2008-04-21 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 685–700（16 aa） Fragment：LXXLL motif of SRC1-2
Not recorded LNA (9E,12Z)-10-nitrooctadeca-9,12-dienoic acid × 1 LNB (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.40 Å R-free 0.290
3CWD Molecular recognition of nitro-fatty acids by PPAR gamma Deposited 2008-04-21 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 685–700（16 aa） Fragment：LXXLL motif of SRC1-2
Not recorded LNA (9E,12Z)-10-nitrooctadeca-9,12-dienoic acid × 1 LNB (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.40 Å R-free 0.290
3DCT FXR with SRC1 and GW4064 Deposited 2008-06-04 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 741–761（21 aa） Fragment：UNP residues 741-761
Not recorded 064 3-[(E)-2-(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-(1-methylethyl)isoxazol-4-yl]methoxy}phenyl)ethenyl]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions hanging drop；pH 6.5；298 K；0.2M Li2SO4, 0.1M Bis-Tris pH6.5, 25% PEG3350, hanging drop, temperature 298K
Resolution 2.50 Å R-free 0.240
3DCU FXR with SRC1 and GSK8062 Deposited 2008-06-04 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 741–761（21 aa） Fragment：UNP residues 741-761
Not recorded O62 6-(4-{[3-(2,6-dichlorophenyl)-5-(1-methylethyl)isoxazol-4-yl]methoxy}phenyl)naphthalene-1-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.2M Li2SO4, 0.1M Bis-Tris pH6.5, 25% PEG3350, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.95 Å R-free 0.228
3DR1 Side-chain fluorine atoms of non-steroidal vitamin D3 analogs stabilize helix 12 of vitamin D receptor Deposited 2008-07-10 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa）
Not recorded MG MAGNESIUM ION × 2 C5D (1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；Li sulfate 1.6M, Mg sulfate 50mM, Bis Tris 0.1M , pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.70 Å R-free 0.286
3ET1 Structure of PPARalpha with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid Deposited 2008-10-06 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain P 681–696（16 aa） Fragment：residues 681-696
Not recorded ET1 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；277 K；The purified PPARa LBD protein was diluted to 10 mg/ml and 1mM of indeglitazar and 2x molar excess of SRC-1 peptide were added prior to crystallization by mixing equal volumes of protein/compound sample with reservoir solution containing 16% PEG 8000, 0.1 M Tris buffer at pH 8.0, 0.02 M lithium sulfate, and 5% glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 2.50 Å R-free 0.258
3ET1 Structure of PPARalpha with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid Deposited 2008-10-06 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain Q 681–696（16 aa） Fragment：residues 681-696
Not recorded ET1 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；277 K；The purified PPARa LBD protein was diluted to 10 mg/ml and 1mM of indeglitazar and 2x molar excess of SRC-1 peptide were added prior to crystallization by mixing equal volumes of protein/compound sample with reservoir solution containing 16% PEG 8000, 0.1 M Tris buffer at pH 8.0, 0.02 M lithium sulfate, and 5% glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 2.50 Å R-free 0.258
3ET3 Structure of PPARgamma with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid Deposited 2008-10-06 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain P 680–695（16 aa） Fragment：residues 681-696
Not recorded ET1 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5；277 K；The purified PPARg LBD protein was diluted to 12 mg/ml and 1mM of indeglitazar and 2x molar excess of SRC-1 peptide were added prior to crystallization by mixing equal volumes of protein/compound sample with reservoir solution containing 27% polyethylene glycol (PEG) 4000, 0.1 M 2-(bis-(2-hydroxy-ethyl)-amino)-2-hydroxymethyl- propane-1,3-diol (BisTris) buffer at pH 6.5, 0.2 M ammonium acetate, and 5% glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.95 Å R-free 0.236
3FEI Design and biological evaluation of novel, balanced dual PPARa/g agonists Deposited 2008-11-30 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain Z 744–756（13 aa）
Not recorded CTM (2S)-3-(4-{[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methoxy}-2-methylphenyl)-2-ethoxypropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.1M Tris, 0.2M MgCl2, 25% PEG3350, 15% Glycerol, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.40 Å R-free 0.260
3FEJ Design and biological evaluation of novel, balanced dual PPARa/g agonists Deposited 2008-11-30 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 628–640（13 aa）
Not recorded CTM (2S)-3-(4-{[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methoxy}-2-methylphenyl)-2-ethoxypropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.1M Tris, 15-20% PEG3350, 10% Glycerol, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.01 Å R-free 0.250
3FUR Crystal Structure of PPARg in complex with INT131 Deposited 2009-01-14 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain H 629–640（12 aa） Fragment：FRAGMENT CONTAINING HD1, UNP residues 629-640
Not recorded Z12 2,4-dichloro-N-[3,5-dichloro-4-(quinolin-3-yloxy)phenyl]benzenesulfonamide × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；30% PEG 4000, 0.2M MgCl2, Tris-HCl 8.5, vapor diffusion, hanging drop, temperature 298K
Resolution 2.30 Å R-free 0.242
3FXV Identification of an N-oxide pyridine GW4064 analogue as a potent FXR agonist Deposited 2009-01-21 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 744–756（13 aa） Fragment：residues 744-756
Not recorded 643 6-(4-{[3-(3,5-dichloropyridin-4-yl)-5-(1-methylethyl)isoxazol-4-yl]methoxy}-2-methylphenyl)-1-methyl-1H-indole-3-carbox ylic acid × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.26 Å R-free 0.242
3G8I Aleglitazar, a new, potent, and balanced PPAR alpha/gamma agonist for the treatment of type II diabetes Deposited 2009-02-12 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain Z 744–756（13 aa） Fragment：motif 5
Not recorded RO7 (2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8.5；293 K；20-22% PEG 2000, 0.2M NACL, 5% GLYCEROL, 0.1M TRIS-CL, pH 8.5, VAPOR DIFFUSION, temperature 293K
Resolution 2.20 Å R-free 0.261
3G9E Aleglitaar. a new. potent, and balanced dual ppara/g agonist for the treatment of type II diabetes Deposited 2009-02-13 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 628–640（13 aa） Fragment：CO-ACTIVATOR MOTIF 3
Not recorded RO7 (2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.2M NaK TARTRATE, 25% PEG 3350, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.30 Å R-free 0.262
3H0A Crystal Structure of Peroxisome Proliferator-Activated Receptor Gamma (PPARg) and Retinoic Acid Receptor Alpha (RXRa) in Complex with 9-cis Retinoic Acid, Co-activator Peptide, and a Partial Agonist Deposited 2009-04-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 629–640（12 aa） Fragment：UNP RESIDUES 629-640
Chain E 629–640（12 aa） Fragment：UNP RESIDUES 629-640
Not recorded 9RA 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid × 1 D30 [(4-{[2-(pent-2-yn-1-yloxy)-4-{[4-(trifluoromethyl)phenoxy]methyl}phenyl]sulfanyl}-5,6,7,8-tetrahydronaphthalen-1-yl)oxy]acetic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.5；289 K；25% PEG 2000 monomethyl ether, 0.3 M sodium acetate, 0.1 M Hepes 7.5, vapor diffusion, temperature 289K
Resolution 2.10 Å R-free 0.342
3HC5 FXR with SRC1 and GSK826 Deposited 2009-05-05 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 741–761（21 aa） Fragment：SRC1
Not recorded 82X 3-(6-{[3-(2,6-dichlorophenyl)-5-(1-methylethyl)isoxazol-4-yl]methoxy}-1-benzothiophen-2-yl)benzoic acid × 1 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.2M Li2SO4, 0.1M Bis-Tris, 25% PEG3350, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.60 Å R-free 0.269
3HC6 FXR with SRC1 and GSK088 Deposited 2009-05-05 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 741–761（21 aa） Fragment：LXXLL Motif
Not recorded 088 3-[(5-{[3-(2,6-dichlorophenyl)-5-(1-methylethyl)isoxazol-4-yl]methoxy}-1H-indol-1-yl)methyl]benzoic acid × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.2M Li2SO4, 0.1M Bis-Tris, 25% PEG3350, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 3.20 Å R-free 0.287
3HVL Tethered PXR-LBD/SRC-1p complexed with SR-12813 Deposited 2009-06-16 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 678–700（23 aa） Fragment：PXR, residues 130-434, linker, SRC-1, residues 678-700
Not recorded SRL [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7；277 K；10-30% MPD OR ISOPROPANOL, 100 mM IMIDAZOLE, 1 mM SR12813, pH 7, VAPOR DIFFUSION, temperature 277K
Resolution 2.10 Å R-free 0.265
3HVL Tethered PXR-LBD/SRC-1p complexed with SR-12813 Deposited 2009-06-16 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain B 678–700（23 aa） Fragment：PXR, residues 130-434, linker, SRC-1, residues 678-700
Not recorded SRL [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7；277 K；10-30% MPD OR ISOPROPANOL, 100 mM IMIDAZOLE, 1 mM SR12813, pH 7, VAPOR DIFFUSION, temperature 277K
Resolution 2.10 Å R-free 0.265
3HVL Tethered PXR-LBD/SRC-1p complexed with SR-12813 Deposited 2009-06-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 678–700（23 aa） Fragment：PXR, residues 130-434, linker, SRC-1, residues 678-700
Chain B 678–700（23 aa） Fragment：PXR, residues 130-434, linker, SRC-1, residues 678-700
Not recorded SRL [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7；277 K；10-30% MPD OR ISOPROPANOL, 100 mM IMIDAZOLE, 1 mM SR12813, pH 7, VAPOR DIFFUSION, temperature 277K
Resolution 2.10 Å R-free 0.265
3IPQ X-ray structure of GW3965 synthetic agonist bound to the LXR-alpha Deposited 2009-08-18 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 676–700（25 aa） Fragment：Steroid receptor co-activator 1: UNP residues 676-700
Not recorded 965 [3-(3-{[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino}propoxy)phenyl]acetic acid × 2 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；100mM (NH4)2SO4, 40mM Tris-HCl pH 7.8, 60mM Imidazole pH 6.2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.00 Å R-free 0.234
3IPS X-ray structure of benzisoxazole synthetic agonist bound to the LXR-alpha Deposited 2009-08-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 676–700（25 aa） Fragment：Steroid receptor co-activator 1: UNP residues 676-700
Chain D 676–700（25 aa） Fragment：Steroid receptor co-activator 1: UNP residues 676-700
Not recorded SO4 SULFATE ION × 2 O90 {3-chloro-4-[(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)sulfanyl]phenyl}acetic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；18% PEG MME 2000, 100mM (NH4)2SO4, 35mM Tris-HCl pH 7.8, 65mM Imidazole, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.26 Å R-free 0.315
3IPU X-ray structure of benzisoxazole urea synthetic agonist bound to the LXR-alpha Deposited 2009-08-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 676–700（25 aa） Fragment：Steroid receptor co-activator 1: UNP residues 676-700
Chain D 676–700（25 aa） Fragment：Steroid receptor co-activator 1: UNP residues 676-700
Not recorded O40 4-{[methyl(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)carbamoyl]amino}benzoic acid × 2 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；10% PEG MME 2000, 100mM (NH4)2SO4, 40mM Tris-HCl pH 7.8, 60mM Imidazole pH 6.2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.40 Å R-free 0.291
3KMR Crystal structure of RARalpha ligand binding domain in complex with an agonist ligand (Am580) and a coactivator fragment Deposited 2009-11-11 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 686–698（13 aa） Fragment：NR interaction motif 2 (UNP RESIDUE 686-698)
Not recorded EQN 4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；15% (w/v) PEG 6000, 5% (w/v) glycerol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 1.80 Å R-free 0.237
3LMP Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Deposited 2010-01-31 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 686–700（15 aa） Fragment：UNP residues 686-700
Not recorded CEK (9aS)-8-acetyl-1,7-dihydroxy-3-methoxy-9a-methyl-N-(1-naphthylmethyl)-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, NaSCN, vapor diffusion, temperature 295K, VAPOR DIFFUSION, HANGING DROP, pH 8.5
Resolution 1.90 Å R-free 0.242
3OKH Crystal structure of human FXR in complex with 2-(4-chlorophenyl)-1-[(1S)-1-cyclohexyl-2-(cyclohexylamino)-2-oxoethyl]-1H-benzimidazole-6-carboxylic acid Deposited 2010-08-25 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 744–757（14 aa） Fragment：UNP RESIDUES 744-757
Not recorded OKH 2-(4-chlorophenyl)-1-[(1S)-1-cyclohexyl-2-(cyclohexylamino)-2-oxoethyl]-1H-benzimidazole-6-carboxylic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；0.1M NaCl, 0.1M BisTris pH6.5, 1.5M AmmSulfate, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 2.50 Å R-free 0.273
3OKI Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N,2-dicyclohexylethanamide Deposited 2010-08-25 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 744–757（14 aa） Fragment：UNP RESIDUES 744-757
Not recorded OKI (2S)-2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N,2-dicyclohexylethanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；0.1M Bis-Tris pH 6.5, 28% PEG 2000, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 2.00 Å R-free 0.280
3OKI Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N,2-dicyclohexylethanamide Deposited 2010-08-25 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 744–757（14 aa） Fragment：UNP RESIDUES 744-757
Not recorded OKI (2S)-2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N,2-dicyclohexylethanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；0.1M Bis-Tris pH 6.5, 28% PEG 2000, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 2.00 Å R-free 0.280
3OLF Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-methylbenzoic acid Deposited 2010-08-26 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 744–757（14 aa） Fragment：UNP RESIDUES 744-757
Not recorded OLF 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-methylbenzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；0.1M HEPES pH 7.5, 1.4M tri-sodium citrate dihydrate, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.90 Å R-free 0.238
3OLF Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-methylbenzoic acid Deposited 2010-08-26 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 744–757（14 aa） Fragment：UNP RESIDUES 744-757
Not recorded OLF 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-methylbenzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；0.1M HEPES pH 7.5, 1.4M tri-sodium citrate dihydrate, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.90 Å R-free 0.238
3OLL Crystal structure of phosphorylated estrogen receptor beta ligand binding domain Deposited 2010-08-26 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 683–701（19 aa） Fragment：UNP residues 683-701
Not recorded EST ESTRADIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277.15 K；0.2 M Ammonium Acetate, 0.1 M BIS-TRIS pH 5.5, 17% PEG10000 (v/v), VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 1.50 Å R-free 0.208
3OLL Crystal structure of phosphorylated estrogen receptor beta ligand binding domain Deposited 2010-08-26 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 683–701（19 aa） Fragment：UNP residues 683-701
Not recorded EST ESTRADIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277.15 K；0.2 M Ammonium Acetate, 0.1 M BIS-TRIS pH 5.5, 17% PEG10000 (v/v), VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 1.50 Å R-free 0.208
3OLL Crystal structure of phosphorylated estrogen receptor beta ligand binding domain Deposited 2010-08-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 683–701（19 aa） Fragment：UNP residues 683-701
Chain D 683–701（19 aa） Fragment：UNP residues 683-701
Not recorded EST ESTRADIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277.15 K；0.2 M Ammonium Acetate, 0.1 M BIS-TRIS pH 5.5, 17% PEG10000 (v/v), VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 1.50 Å R-free 0.208
3OLS Crystal structure of estrogen receptor beta ligand binding domain Deposited 2010-08-26 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Not recorded EST ESTRADIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277.15 K；0.2 M Ammonium Acetate, 0.1 M BIS-TRIS pH 5.5, 17% PEG10000 (v/v), VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 2.20 Å R-free 0.266
3OLS Crystal structure of estrogen receptor beta ligand binding domain Deposited 2010-08-26 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Not recorded EST ESTRADIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277.15 K；0.2 M Ammonium Acetate, 0.1 M BIS-TRIS pH 5.5, 17% PEG10000 (v/v), VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 2.20 Å R-free 0.266
3OLS Crystal structure of estrogen receptor beta ligand binding domain Deposited 2010-08-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Chain D 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Not recorded EST ESTRADIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277.15 K；0.2 M Ammonium Acetate, 0.1 M BIS-TRIS pH 5.5, 17% PEG10000 (v/v), VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 2.20 Å R-free 0.266
3OMK Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexyl-N-(2-methylphenyl)ethanamide Deposited 2010-08-27 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 744–757（14 aa） Fragment：UNP RESIDUES 744-757
Not recorded OMK (2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexyl-N-(2-methylphenyl)ethanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；0.1M Bis-Tris pH 6.5, 25% PEG 3350, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.90 Å R-free 0.245
3OMK Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexyl-N-(2-methylphenyl)ethanamide Deposited 2010-08-27 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 744–757（14 aa） Fragment：UNP RESIDUES 744-757
Not recorded OMK (2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexyl-N-(2-methylphenyl)ethanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；0.1M Bis-Tris pH 6.5, 25% PEG 3350, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.90 Å R-free 0.245
3OMM Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-fluorobenzoic acid Deposited 2010-08-27 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 744–757（14 aa） Fragment：UNP RESIDUES 744-757
Not recorded OMM 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-fluorobenzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；0.1M 2,2-Bis(hydroxymethyl)-2,2',2''-nitrilotriethanol pH 6.5, 20% PEG 5000 MME, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 2.10 Å R-free 0.256
3OMM Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-fluorobenzoic acid Deposited 2010-08-27 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 744–757（14 aa） Fragment：UNP RESIDUES 744-757
Not recorded OMM 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-fluorobenzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；0.1M 2,2-Bis(hydroxymethyl)-2,2',2''-nitrilotriethanol pH 6.5, 20% PEG 5000 MME, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 2.10 Å R-free 0.256
3OMO Fragment-Based Design of novel Estrogen Receptor Ligands Deposited 2010-08-27 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Not recorded WV7 2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-6-ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277.15 K；0.2 M Ammonium Acetate, 0.1 M BIS-TRIS pH 5.5, 17% PEG10000 (v/v), VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 2.21 Å R-free 0.264
3OMO Fragment-Based Design of novel Estrogen Receptor Ligands Deposited 2010-08-27 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Not recorded WV7 2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-6-ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277.15 K；0.2 M Ammonium Acetate, 0.1 M BIS-TRIS pH 5.5, 17% PEG10000 (v/v), VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 2.21 Å R-free 0.264
3OMO Fragment-Based Design of novel Estrogen Receptor Ligands Deposited 2010-08-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Chain D 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Not recorded WV7 2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-6-ol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277.15 K；0.2 M Ammonium Acetate, 0.1 M BIS-TRIS pH 5.5, 17% PEG10000 (v/v), VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 2.21 Å R-free 0.264
3OMP Fragment-Based Design of novel Estrogen Receptor Ligands Deposited 2010-08-27 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Not recorded W14 2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-7-ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277.15 K；0.2 M Ammonium Acetate, 0.1 M BIS-TRIS pH 5.5, 17% PEG10000 (v/v), VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 2.05 Å R-free 0.255
3OMP Fragment-Based Design of novel Estrogen Receptor Ligands Deposited 2010-08-27 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Not recorded W14 2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-7-ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277.15 K；0.2 M Ammonium Acetate, 0.1 M BIS-TRIS pH 5.5, 17% PEG10000 (v/v), VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 2.05 Å R-free 0.255
3OMP Fragment-Based Design of novel Estrogen Receptor Ligands Deposited 2010-08-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Chain D 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Not recorded W14 2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-7-ol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277.15 K；0.2 M Ammonium Acetate, 0.1 M BIS-TRIS pH 5.5, 17% PEG10000 (v/v), VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 2.05 Å R-free 0.255
3OMQ Fragment-Based Design of novel Estrogen Receptor Ligands Deposited 2010-08-27 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Not recorded W23 2-[(trifluoromethyl)sulfonyl]-1,2,3,4-tetrahydroisoquinolin-6-ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277.15 K；0.2 M Ammonium Acetate, 0.1 M BIS-TRIS pH 5.5, 17% PEG10000 (v/v), VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 1.97 Å R-free 0.260
3OMQ Fragment-Based Design of novel Estrogen Receptor Ligands Deposited 2010-08-27 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Not recorded W23 2-[(trifluoromethyl)sulfonyl]-1,2,3,4-tetrahydroisoquinolin-6-ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277.15 K；0.2 M Ammonium Acetate, 0.1 M BIS-TRIS pH 5.5, 17% PEG10000 (v/v), VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 1.97 Å R-free 0.260
3OMQ Fragment-Based Design of novel Estrogen Receptor Ligands Deposited 2010-08-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Chain D 683–701（19 aa） Fragment：Box 2 (UNP residues 683-701)
Not recorded W23 2-[(trifluoromethyl)sulfonyl]-1,2,3,4-tetrahydroisoquinolin-6-ol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277.15 K；0.2 M Ammonium Acetate, 0.1 M BIS-TRIS pH 5.5, 17% PEG10000 (v/v), VAPOR DIFFUSION, HANGING DROP, temperature 277.15K
Resolution 1.97 Å R-free 0.260
3OOF Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)benzoic acid Deposited 2010-08-31 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 744–757（14 aa） Fragment：UNP RESIDUES 744-757
Not recorded OOF 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；0.1M Bis-Tris pH 5.5, 25% PEG 3350, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 2.29 Å R-free 0.255
3OOF Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)benzoic acid Deposited 2010-08-31 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 744–757（14 aa） Fragment：UNP RESIDUES 744-757
Not recorded OOF 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；0.1M Bis-Tris pH 5.5, 25% PEG 3350, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 2.29 Å R-free 0.255
3OOK Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3,5-difluorobenzoic acid Deposited 2010-08-31 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 744–757（14 aa） Fragment：UNP RESIDUES 744-757
Not recorded OOK 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3,5-difluorobenzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；0.1M Bis-Tris pH 6.5, 20% PEG 5000, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 2.29 Å R-free 0.271
3OOK Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3,5-difluorobenzoic acid Deposited 2010-08-31 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 744–757（14 aa） Fragment：UNP RESIDUES 744-757
Not recorded OOK 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3,5-difluorobenzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；0.1M Bis-Tris pH 6.5, 20% PEG 5000, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 2.29 Å R-free 0.271
3QT0 Revealing a steroid receptor ligand as a unique PPARgamma agonist Deposited 2011-02-22 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 685–700（16 aa） Fragment：UNP residies 685-700
Not recorded 486 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；PEG, Tris-HCl, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.50 Å R-free 0.277
3RUT FXR with SRC1 and GSK359 Deposited 2011-05-05 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 745–755（11 aa） Fragment：UNP residues 745-755
Not recorded SO4 SULFATE ION × 2 59G 6-(4-{[3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methoxy}phenyl)-1-benzothiophene-3-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions HANGING DROP；pH 6.5；298 K；25% PEG3350, 0.2 M lithium sulfate, 0.1 M Bis-Tris, pH 6.5, HANGING DROP, temperature 298K
Resolution 3.00 Å R-free 0.266
3RUU FXR with SRC1 and GSK237 Deposited 2011-05-05 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 745–755（11 aa） Fragment：UNP residues 745-755
Not recorded SO4 SULFATE ION × 2 37G 6-(4-{[3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methoxy}phenyl)-1H-indole-3-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions HANGING DROP；pH 6.5；298 K；25% PEG3350, 0.2 M lithium sulfate, 0.1 M Bis-Tris, pH 6.5, HANGING DROP, temperature 298K
Resolution 2.50 Å R-free 0.253
3RVF FXR with SRC1 and GSK2034 Deposited 2011-05-06 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 741–761（21 aa） Fragment：UNP residues 741-761
Not recorded SO4 SULFATE ION × 1 034 5-(4-{[3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methoxy}phenyl)-1H-indole-2-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions HANGING DROP；pH 6.5；298 K；25% PEG3350, 0.2 M lithium sulfate, 0.1 M Bis-Tris, pH 6.5, HANGING DROP, temperature 298K
Resolution 3.10 Å R-free 0.290
3S9S Ligand binding domain of PPARgamma complexed with a benzimidazole partial agonist Deposited 2011-06-02 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–697（13 aa） Fragment：LXXLL MOTIF 4 (RESIDUES 685-697)
Not recorded M0T 1-(3,4-dichlorobenzyl)-2-methyl-N-[(1R)-1-phenylpropyl]-1H-benzimidazole-5-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100MM HEPES, 1.4M SODIUM CITRATE, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.55 Å R-free 0.284
3T03 Crystal structure of PPAR gamma ligand binding domain in complex with a novel partial agonist GQ-16 Deposited 2011-07-19 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: monomeric
Chain C 683–700（18 aa） Fragment：UNP residues 683-700
Not recorded 3T0 (5Z)-5-(5-bromo-2-methoxybenzylidene)-3-(4-methylbenzyl)-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.2 M Ammonium acetate, 0.1 M Sodium citrate, pH 5.6, 30%(w/v) PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.10 Å R-free 0.247
3T03 Crystal structure of PPAR gamma ligand binding domain in complex with a novel partial agonist GQ-16 Deposited 2011-07-19 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: monomeric
Chain D 683–700（18 aa） Fragment：UNP residues 683-700
Not recorded 3T0 (5Z)-5-(5-bromo-2-methoxybenzylidene)-3-(4-methylbenzyl)-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.2 M Ammonium acetate, 0.1 M Sodium citrate, pH 5.6, 30%(w/v) PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.10 Å R-free 0.247
3UU7 Crystal structure of hERa-LBD (Y537S) in complex with bisphenol-A Deposited 2011-11-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain F 686–698（13 aa） Fragment：Coactivator peptide SRC-1
Chain G 686–698（13 aa） Fragment：Coactivator peptide SRC-1
Not recorded 2OH 4,4'-PROPANE-2,2-DIYLDIPHENOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；300 mM NaCl, 100 mM NaHepes pH 7.75, 30% PEG 3350, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.20 Å R-free 0.246
3UU7 Crystal structure of hERa-LBD (Y537S) in complex with bisphenol-A Deposited 2011-11-28 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain F 686–698（13 aa） Fragment：Coactivator peptide SRC-1
Not recorded 2OH 4,4'-PROPANE-2,2-DIYLDIPHENOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；300 mM NaCl, 100 mM NaHepes pH 7.75, 30% PEG 3350, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.20 Å R-free 0.246
3UU7 Crystal structure of hERa-LBD (Y537S) in complex with bisphenol-A Deposited 2011-11-28 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain G 686–698（13 aa） Fragment：Coactivator peptide SRC-1
Not recorded 2OH 4,4'-PROPANE-2,2-DIYLDIPHENOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；300 mM NaCl, 100 mM NaHepes pH 7.75, 30% PEG 3350, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.20 Å R-free 0.246
3UUA Crystal structure of hERa-LBD (Y537S) in complex with bisphenol-AF Deposited 2011-11-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain F 686–698（13 aa） Fragment：Coactivator peptide SRC-1
Chain G 686–698（13 aa） Fragment：Coactivator peptide SRC-1
Not recorded 0CZ 4,4'-(1,1,1,3,3,3-hexafluoropropane-2,2-diyl)diphenol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；300 mM NaCl, 100 mM Hepes pH 7.75, 32% PEG 3350, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.05 Å R-free 0.231
3UUA Crystal structure of hERa-LBD (Y537S) in complex with bisphenol-AF Deposited 2011-11-28 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain F 686–698（13 aa） Fragment：Coactivator peptide SRC-1
Not recorded 0CZ 4,4'-(1,1,1,3,3,3-hexafluoropropane-2,2-diyl)diphenol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；300 mM NaCl, 100 mM Hepes pH 7.75, 32% PEG 3350, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.05 Å R-free 0.231
3UUA Crystal structure of hERa-LBD (Y537S) in complex with bisphenol-AF Deposited 2011-11-28 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain G 686–698（13 aa） Fragment：Coactivator peptide SRC-1
Not recorded 0CZ 4,4'-(1,1,1,3,3,3-hexafluoropropane-2,2-diyl)diphenol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；300 mM NaCl, 100 mM Hepes pH 7.75, 32% PEG 3350, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.05 Å R-free 0.231
3UUD Crystal structure of hERa-LBD (Y537S) in complex with estradiol Deposited 2011-11-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 686–698（13 aa） Fragment：Coactivator peptide SRC-1
Chain D 686–698（13 aa） Fragment：Coactivator peptide SRC-1
Not recorded EST ESTRADIOL × 2 GOL GLYCEROL × 3 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；200 mM Li2SO4, 100 mM Tris pH 8.5, 30% PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.60 Å R-free 0.195
3UUD Crystal structure of hERa-LBD (Y537S) in complex with estradiol Deposited 2011-11-28 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 686–698（13 aa） Fragment：Coactivator peptide SRC-1
Not recorded EST ESTRADIOL × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；200 mM Li2SO4, 100 mM Tris pH 8.5, 30% PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.60 Å R-free 0.195
3UUD Crystal structure of hERa-LBD (Y537S) in complex with estradiol Deposited 2011-11-28 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 686–698（13 aa） Fragment：Coactivator peptide SRC-1
Not recorded EST ESTRADIOL × 1 GOL GLYCEROL × 2 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；200 mM Li2SO4, 100 mM Tris pH 8.5, 30% PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.60 Å R-free 0.195
3V9Y Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Deposited 2011-12-28 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 686–700（15 aa）
Not recorded 24L 4-{4-[({[(9aS)-8-acetyl-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-yl]carbonyl}amino)methyl]naphthalen-2-yl}butanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, sodium thiocyanate, Tris-hydrochloride, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.10 Å R-free 0.252
3VN2 Crystal Structure of PPARgamma complexed with Telmisartan Deposited 2011-12-21 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 685–700（16 aa） Fragment：Coactivator fragment SRC-1, UNP residues 685-700
Not recorded TLS 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M TRIS-HCL, 0.8M SODIUM CITRATE TRIBASIC DIHYDRATE, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293.0K
Resolution 2.18 Å R-free 0.309
4DK7 Crystal structure of LXR ligand binding domain in complex with full agonist 1 Deposited 2012-02-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 745–756（12 aa） Fragment：UNp residues 745-756
Chain D 745–756（12 aa） Fragment：UNp residues 745-756
Not recorded 0KS N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-N-methylbenzenesulfonamide × 2 ACT ACETATE ION × 1 CA CALCIUM ION × 7 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；293 K；0.1 M Tris pH 8, 12% PEG 10000, 0.2 M calcium acetate, 0.005 M DTT, vapor diffusion, temperature 293K
Resolution 2.45 Å R-free 0.270
4DK8 Crystal structure of LXR ligand binding domain in complex with partial agonist 5 Deposited 2012-02-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 745–756（12 aa） Fragment：UNP residues 745-756
Chain D 745–756（12 aa） Fragment：UNP residues 745-756
Not recorded 0KT N-methyl-N-(4-{(1S)-2,2,2-trifluoro-1-hydroxy-1-[1-(2-methoxyethyl)-1H-pyrrol-2-yl]ethyl}phenyl)benzenesulfonamide × 2 ACT ACETATE ION × 1 CA CALCIUM ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；293 K；0.1 M Tris, 12% PEG 10000, 0.2 M calcium acetate, 0.005 M DTT, pH 8, vapor diffusion, temperature 293K
Resolution 2.75 Å R-free 0.278
4DM6 Crystal structure of RARb LBD homodimer in complex with TTNPB Deposited 2012-02-07 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain E 676–700（25 aa） Fragment：unp residues 676-700
Not recorded TTB 4-[(1E)-2-(5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)PROP-1-ENYL]BENZOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.6；290 K；5% polyethylene glycol 8000, 0.2 M KCl, 0.01 M MgCl2 and 0.05 M MES, VAPOR DIFFUSION, HANGING DROP, temperature 290K, pH 5.6
Resolution 1.90 Å R-free 0.239
4DM6 Crystal structure of RARb LBD homodimer in complex with TTNPB Deposited 2012-02-07 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain F 676–700（25 aa） Fragment：unp residues 676-700
Not recorded TTB 4-[(1E)-2-(5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)PROP-1-ENYL]BENZOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.6；290 K；5% polyethylene glycol 8000, 0.2 M KCl, 0.01 M MgCl2 and 0.05 M MES, VAPOR DIFFUSION, HANGING DROP, temperature 290K, pH 5.6
Resolution 1.90 Å R-free 0.239
4DM8 Crystal structure of RARb LBD in complex with 9cis retinoic acid Deposited 2012-02-07 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 676–700（25 aa） Fragment：unp residues 676-700
Not recorded REA RETINOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.6；290 K；5% polyethylene glycol 8000, 0.2 M KCl, 0.01 M MgCl2 and 0.05 M MES pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 290K
Resolution 2.30 Å R-free 0.277
4DM8 Crystal structure of RARb LBD in complex with 9cis retinoic acid Deposited 2012-02-07 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 676–700（25 aa） Fragment：unp residues 676-700
Not recorded REA RETINOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.6；290 K；5% polyethylene glycol 8000, 0.2 M KCl, 0.01 M MgCl2 and 0.05 M MES pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 290K
Resolution 2.30 Å R-free 0.277
4DQM Revealing a marine natural product as a novel agonist for retinoic acid receptors with a unique binding mode and antitumor activity Deposited 2012-02-16 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 1432–1441（10 aa） Fragment：LXXLL motif 7, UNP RESIDUES 1432-1441
Not recorded LUF (5S)-4-[(3E,7E)-4,8-dimethyl-10-(2,6,6-trimethylcyclohex-1-en-1-yl)deca-3,7-dien-1-yl]-5-hydroxyfuran-2(5H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；2% v/v Tacsimate pH7.0, 5% 2-propanol, 0.1M imadazole , 8% PEG 3350, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.75 Å R-free 0.259
4DQM Revealing a marine natural product as a novel agonist for retinoic acid receptors with a unique binding mode and antitumor activity Deposited 2012-02-16 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 1432–1441（10 aa） Fragment：LXXLL motif 7, UNP RESIDUES 1432-1441
Not recorded LUF (5S)-4-[(3E,7E)-4,8-dimethyl-10-(2,6,6-trimethylcyclohex-1-en-1-yl)deca-3,7-dien-1-yl]-5-hydroxyfuran-2(5H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；2% v/v Tacsimate pH7.0, 5% 2-propanol, 0.1M imadazole , 8% PEG 3350, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.75 Å R-free 0.259
4F9M Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Deposited 2012-05-19 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 686–700（15 aa） Fragment：LXXLL box, UNP residues 686-700
Not recorded FCM (9aS)-8-acetyl-N-[(2-ethyl-4-fluoronaphthalen-1-yl)methyl]-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, Sodium thiocyanate, Tris-HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 1.90 Å R-free 0.254
4FGY Identification of a unique PPAR ligand with an unexpected binding mode and antibetic activity Deposited 2012-06-05 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 686–696（11 aa） Fragment：UNP RESIDUES 686-696
Not recorded 0W3 (4R,6S,8S,12R,14R,16Z,18R,19R,20S,21S)-19,21-dihydroxy-22-{(2S,2'R,5S,5'S)-5'-[(1R)-1-hydroxyethyl]-2,5'-dimethyloctahydro-2,2'-bifuran-5-yl}-4,6,8,12,14,18,20-heptamethyl-9,11-dioxodocos-16-enoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；0.2 M sodium acetate, 5% ethylene glycol, 20% PEG 3350, pH 7.0, VAPOR DIFFUSION, HANGING DROP
Resolution 2.84 Å R-free 0.285
4G1D Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor Deposited 2012-07-10 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa） Fragment：unp residues 686-700
Not recorded 0VK 3-(5'-{[3,4-bis(hydroxymethyl)benzyl]oxy}-2'-methyl-2-propylbiphenyl-4-yl)pentan-3-ol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；Bis-Tris 0.1 M, lithium sulfate 1.6 M and magnesium sulfate 50 mM, VAPOR DIFFUSION, HANGING DROP, temperature 295K, pH 6.5
Resolution 2.90 Å R-free 0.291
4G1Y Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor Deposited 2012-07-11 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa） Fragment：unp residues 686-700
Not recorded 0VO (4E,6Z)-7-(3-{[3,4-bis(hydroxymethyl)benzyl]oxy}phenyl)-3-ethylnona-4,6-dien-3-ol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；Bis-Tris 0.1 M, lithium sulfate 1.6 M and magnesium sulfate 50 mM, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.85 Å R-free 0.270
4G1Z Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor Deposited 2012-07-11 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa） Fragment：unp residues 686-692
Not recorded 0VP 3-(5'-{[3,4-bis(hydroxymethyl)benzyl]oxy}-2'-ethyl-2-propylbiphenyl-4-yl)pentan-3-ol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；Bis-Tris 0.1 M, lithium sulfate 1.6 M and magnesium sulfate 50 mM, VAPOR DIFFUSION, HANGING DROP, temperature 295K, pH 6.5
Resolution 2.50 Å R-free 0.274
4G20 Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor Deposited 2012-07-11 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa） Fragment：unp residues 686-700
Not recorded 484 3-(5'-{2-[3,4-bis(hydroxymethyl)phenyl]ethyl}-2'-methyl-2-propylbiphenyl-4-yl)pentan-3-ol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；Bis-Tris 0.1 M, lithium sulfate 1.6 M and magnesium sulfate 50 mM, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.90 Å R-free 0.287
4G21 Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor Deposited 2012-07-11 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa） Fragment：unp residues 686-700
Not recorded 0VP 3-(5'-{[3,4-bis(hydroxymethyl)benzyl]oxy}-2'-ethyl-2-propylbiphenyl-4-yl)pentan-3-ol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；Bis-Tris 0.1 M, lithium sulfate 1.6 M and magnesium sulfate 50 mM , pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.90 Å R-free 0.291
4G2H Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor Deposited 2012-07-12 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa） Fragment：unp residues 686-692
Not recorded 0VQ (3E,5E)-6-(3-{2-[3,4-bis(hydroxymethyl)phenyl]ethyl}phenyl)-1,1,1-trifluoro-2-(trifluoromethyl)octa-3,5-dien-2-ol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；Bis-Tris 0.1 M, lithium sulfate 1.6 M and magnesium sulfate 50 mM, VAPOR DIFFUSION, HANGING DROP, temperature 293K, pH 6.5
Resolution 2.50 Å R-free 0.285
4HEE Crystal structure of PPARgamma in complex with compound 13 Deposited 2012-10-03 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain Y 676–700（25 aa） Fragment：UNP Residues 676-700
Not recorded 14R 5-benzyl-2-ethyl-3-{(1S)-5-[2-(1H-tetrazol-5-yl)phenyl]-2,3-dihydro-1H-inden-1-yl}-3,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；100mM PIPES, 200mM Sodium Thiocyanate, 16% PEG4000, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.50 Å R-free 0.258
4J5W Crystal Structure of the apo-PXR/RXRalpha LBD Heterotetramer Complex Deposited 2013-02-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 678–700（23 aa）
Chain B 678–700（23 aa）
Chain C 678–700（23 aa）
Chain D 678–700（23 aa）
Not recorded MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；277.15 K；16-20% PEG 8000, 0.1-0.2 M MgCl, 0.1 M bis-tris proprane, 0.02% sodium azide, pH 7.0, vapor diffusion, hanging drop, temperature 277.15K
Resolution 2.80 Å R-free 0.298
4J5X Crystal Structure of the SR12813-bound PXR/RXRalpha LBD Heterotetramer Complex Deposited 2013-02-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 678–700（23 aa）
Chain B 678–700（23 aa）
Chain C 678–700（23 aa）
Chain D 678–700（23 aa）
Not recorded SRL [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；277.15 K；16-20% PEG 8000, 0.1-0.2 M MgCl, 0.1 M bis-tris proprane, 0.02% sodium azide, pH 7.0, vapor diffusion, hanging drop, temperature 277.15K
Resolution 2.80 Å R-free 0.298
4JYG Crystal structure of RARbeta LBD in complex with agonist BMS411 [4-{[(5,5-dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl)carbonyl]amino}benzoic acid] Deposited 2013-03-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain F 686–698（13 aa） Fragment：UNP residues 686-698
Chain G 686–698（13 aa） Fragment：UNP residues 686-698
Not recorded 1NY 4-{[(5,5-dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl)carbonyl]amino}benzoic acid × 2 PE4 2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL × 1 FLC CITRATE ANION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 5.5；291 K；200 mM Tri Sodium Citrate pH 5.5, 25 % PEG 4000, VAPOR DIFFUSION, temperature 291K
Resolution 2.35 Å R-free 0.257
4JYH Crystal structure of RARbeta LBD in complex with selective agonist BMS948 [4-{[(8-phenylnaphthalen-2-yl)carbonyl]amino}benzoic acid] Deposited 2013-03-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 686–698（13 aa） Fragment：UNP residues 686-698
Chain G 686–698（13 aa） Fragment：UNP residues 686-698
Not recorded JYH 4-{[(8-phenylnaphthalen-2-yl)carbonyl]amino}benzoic acid × 2 FLC CITRATE ANION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 5.5；291 K；200 mM Tri Sodium Citrate pH 5.5, 25% PEG 4000, VAPOR DIFFUSION, temperature 291K
Resolution 2.60 Å R-free 0.267
4JYI Crystal structure of RARbeta LBD in complex with selective partial agonist BMS641 [3-chloro-4-[(E)-2-(5,5-dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl)ethenyl]benzoic acid] Deposited 2013-03-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain F 686–698（13 aa） Fragment：UNP residues 686-698
Chain G 686–698（13 aa） Fragment：UNP residues 686-698
Not recorded JYI 3-chloro-4-[(E)-2-(5,5-dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl)ethenyl]benzoic acid × 2 FLC CITRATE ANION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 5.5；291 K；200 mM Tri Sodium Citrate pH 5.5, 25% PEG 4000, VAPOR DIFFUSION, temperature 291K
Resolution 1.90 Å R-free 0.227
4MG5 Crystal structure of hERa-LBD (Y537S) in complex with chlordecone Deposited 2013-08-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Chain D 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Not recorded GOL GLYCEROL × 3 A1AQV chlordecone × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；340 mM sodium chloride, 100 mM HEPES, 32% PEG3350, pH 7.75, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.05 Å R-free 0.228
4MG6 Crystal structure of hERa-LBD (Y537S) in complex with benzylbutylphtalate Deposited 2013-08-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Chain D 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Not recorded 27G benzyl butyl benzene-1,2-dicarboxylate × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；320 mM sodium chloride, 100 mM HEPES, 26% PEG3350, pH 7.75, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.10 Å R-free 0.230
4MG7 Crystal structure of hERa-LBD (Y537S) in complex with ferutinine Deposited 2013-08-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Chain D 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Not recorded 27H ferutinine × 2 EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；320 mM sodium chloride, 100 mM HEPES, 24% PEG3350, pH 7.75, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.15 Å R-free 0.230
4MG8 Crystal structure of hERa-LBD (Y537S) in complex with alpha-zearalanol Deposited 2013-08-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Chain D 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Not recorded 27J alpha-zearalanol × 2 GOL GLYCEROL × 1 EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；300 mM sodium chloride, 100 mM HEPES, 24% PEG3350, pH 7.75, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.85 Å R-free 0.213
4MG9 Crystal structure of hERa-LBD (Y537S) in complex with butylparaben Deposited 2013-08-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain F 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Chain G 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Not recorded 27K butyl 4-hydroxybenzoate × 2 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；300 mM sodium chloride, 100 mM HEPES, 28% PEG3350, pH 7.75, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.00 Å R-free 0.237
4MGA Crystal structure of hERa-LBD (Y537S) in complex with 4-tert-octylphenol Deposited 2013-08-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Chain D 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Not recorded 27L 4-(2,4,4-trimethylpentan-2-yl)phenol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；320 mM sodium chloride, 100 mM HEPES, 28% PEG3350, pH 7.75, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.80 Å R-free 0.222
4MGB Crystal structure of hERa-LBD (Y537S) in complex with TCBPA Deposited 2013-08-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Chain D 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Not recorded XDH 4,4'-propane-2,2-diylbis(2,6-dichlorophenol) × 2 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；320 mM sodium chloride, 100 mM HEPES, 30% PEG3350, pH 7.75, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.85 Å R-free 0.250
4MGC Crystal structure of hERa-LBD (Y537S) in complex with benzophenone-2 Deposited 2013-08-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain F 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Chain G 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Not recorded 27M bis(2,4-dihydroxyphenyl)methanone × 2 GOL GLYCEROL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；300 mM sodium chloride, 100 mM HEPES, 28% PEG3350, pH 7.75, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.15 Å R-free 0.240
4MGD Crystal structure of hERa-LBD (Y537S) in complex with HPTE Deposited 2013-08-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain F 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Chain G 686–698（13 aa） Fragment：coactivator peptide SRC-1 (UNP residues 686-698)
Not recorded 27N 4,4'-(2,2,2-trichloroethane-1,1-diyl)diphenol × 2 GOL GLYCEROL × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；340 mM sodium chloride, 100 mM HEPES, 24% PEG3350, pH 7.75, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.90 Å R-free 0.234
4RUJ Crystal structure of zVDR L337H mutant-VD complex Deposited 2014-11-20 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa） Fragment：UNP residues 686-700
Not recorded VDX 5-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANE-1,3-DIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；297 K；50 mM BIS-TRIS pH6.5, 1.6 M lithium sulfate, 50 mM magnesium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 297K
Resolution 2.35 Å R-free 0.255
4RUP Crystal structure of zVDR L337H mutant-Gemini72 complex Deposited 2014-11-21 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa） Fragment：UNP residues 686-700
Not recorded H97 (1R,3R,7E,17beta)-17-[(1R)-6,6,6-trifluoro-5-hydroxy-1-(4-hydroxy-4-methylpentyl)-5-(trifluoromethyl)hex-3-yn-1-yl]-9,1 0-secoestra-5,7-diene-1,3-diol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；Bis-Tris 0.1 M, lithium sulfate 1.6 M and magnesium sulfate 50 mM, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.75 Å R-free 0.253
4UDA MR in complex with dexamethasone Deposited 2014-12-09 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 1427–1441（15 aa） Fragment：RESIDUES 1427-1441
Not recorded GOL GLYCEROL × 1 DEX DEXAMETHASONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；30% PEG4000, 0.1M NACL, 0.2M PIPES PH 7.5
Resolution 2.03 Å R-free 0.240
4UDB MR in complex with desisobutyrylciclesonide Deposited 2014-12-09 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 1427–1441（15 aa） Fragment：RESIDUES 1427-1441
Not recorded DMS DIMETHYL SULFOXIDE × 1 GOL GLYCEROL × 1 SO4 SULFATE ION × 1 CV7 DESISOBUYTYRYL CICLESONIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.5；18% PEG4K, 0.14M LISO4, 85MM TRIS PH 8.5, 15% GLYCEROL
Resolution 2.36 Å R-free 0.218
4Y29 Identification of a novel PPARg ligand that regulates metabolism Deposited 2015-02-09 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 1432–1441（10 aa）
Not recorded CTI 1,2-dimethoxy-12-methyl[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293.15 K；0.2 M Sodium thiocyanate, 20% w/v PEG 3350
Resolution 1.98 Å R-free 0.219
5A86 Structure of pregnane X receptor in complex with a Sphingosine 1- Phosphate Receptor 1 Antagonist Deposited 2015-07-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 682–698（17 aa）
Chain D 682–698（17 aa）
Not recorded D7E 4-chloro-N-[(1R)-1-[1-ethyl-6-(trifluoromethyl)benzimidazol-2-yl]ethyl]benzenesulfonamide × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.25 Å R-free 0.256
5AVI Crystal structure of LXRalpha in complex with tert-butyl benzoate analog, compound 4 Deposited 2015-06-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 676–700（25 aa） Fragment：UNP residues 676-700
Chain D 676–700（25 aa） Fragment：UNP residues 676-700
Not recorded 4KM tert-butyl 2-[[4-[ethanoyl(methyl)amino]phenoxy]methyl]-5-(trifluoromethyl)benzoate × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；PEG2000MME, ammonium sulfate, Tris-HCl
Resolution 2.70 Å R-free 0.274
5AVL Crystal structure of LXRalpha in complex with tert-butyl benzoate analog, compound 32b Deposited 2015-06-17 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 676–700（25 aa） Fragment：UNP residues 676-700
Not recorded 4KQ 2-[4-[4-[[2-[(2-methylpropan-2-yl)oxycarbonyl]-3-oxidanyl-4-(trifluoromethyl)phenyl]methoxy]phenyl]phenyl]ethanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；PEG2000MME, ammonium sulfate, Tris-HCl
Resolution 2.80 Å R-free 0.243
5AZT Ternary complex of hPPARalpha ligand binding domain, 17-oxoDHA and a SRC1 peptide Deposited 2015-10-23 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 683–697（15 aa）
Not recorded 4M5 (4~{Z},7~{Z},10~{Z},13~{Z},19~{Z})-17-oxidanylidenedocosa-4,7,10,13,19-pentaenoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.9；293 K；0.1M HEPES, 35% PEG3350
Resolution 3.45 Å R-free 0.308
5DV3 Human PPARgamma ligand binding dmain complexed with SB1405 in a covalent bonded form Deposited 2015-09-21 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa） Fragment：UNP RESIDUES 685-700
Not recorded B05 N-[2-(benzyloxy)phenyl]-3-nitrobenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；2.2M sodium malonate pH 7.0
Resolution 2.75 Å R-free 0.230
5DV6 Human PPARgamma ligand binding dmain complexed with SB1404 in a covalent bonded form Deposited 2015-09-21 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa） Fragment：UNP RESIDUES 685-700
Not recorded B4H N-methylidene-3-nitrobenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；2.2M sodium malonate pH 7.0
Resolution 2.80 Å R-free 0.244
5DV8 Human PPARgamma ligand binding dmain complexed with SB1451 in a covalent bonded form Deposited 2015-09-21 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa） Fragment：UNP RESIDUES 685-700
Not recorded T51 N-[2-({2-[({4-[(4-methylpiperazin-1-yl)methyl]benzoyl}amino)methyl]benzyl}oxy)phenyl]-3-nitrobenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；297 K；0.19M sodium acetate trihydrate, 0.1M sodium cacodylate pH 6.5, 26% PEG 8000
Resolution 2.75 Å R-free 0.243
5DVC Human PPARgamma ligand binding dmain complexed with SB1453 in a covalent bonded form Deposited 2015-09-21 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa） Fragment：UNP RESIDUES 685-700
Not recorded T53 N-[2-({3-[({4-[(4-methylpiperazin-1-yl)methyl]benzoyl}amino)methyl]benzyl}oxy)phenyl]-3-nitrobenzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；2.2 M sodium malonate pH 7.0
Resolution 2.30 Å R-free 0.241
5DWL Human PPARgamma ligand binding dmain in complex with SR1664 Deposited 2015-09-22 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa） Fragment：UNP RESIDUES 685-700
Not recorded 3JX 4'-[(2,3-dimethyl-5-{[(1S)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；2.2 M sodium malonate pH7.0
Resolution 2.20 Å R-free 0.238
5HJS Identification of LXRbeta selective agonists for the treatment of Alzheimer's Disease Deposited 2016-01-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 676–700（25 aa）
Chain D 676–700（25 aa）
Not recorded 668 2-chloro-4-{1'-[(2R)-2-hydroxy-3-methyl-2-(trifluoromethyl)butanoyl]-4,4'-bipiperidin-1-yl}-N,N-dimethylbenzamide × 2 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；12% PEG MME 2000, 0.1M Ammonium Sulfate, 0.1M Tris buffer pH 7.8
Resolution 1.72 Å R-free 0.238
5JI0 PPARgamma-RXRalpha(S427F) heterodimer in complex with SRC-1, rosiglitazone, and 9-cis-retanoic acid Deposited 2016-04-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain E 676–700（25 aa）
Chain F 676–700（25 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) 9CR (9cis)-retinoic acid × 1 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；296 K；Crystals grew in the dark at room temperature from 0.5 + 0.5 uL sitting drops equilibrated over a reservoir containing 20-24% PEG3350 and 0.02M Na Citrate
Resolution 1.98 Å R-free 0.246
5JI0 PPARgamma-RXRalpha(S427F) heterodimer in complex with SRC-1, rosiglitazone, and 9-cis-retanoic acid Deposited 2016-04-21 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain F 676–700（25 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) 9CR (9cis)-retinoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；296 K；Crystals grew in the dark at room temperature from 0.5 + 0.5 uL sitting drops equilibrated over a reservoir containing 20-24% PEG3350 and 0.02M Na Citrate
Resolution 1.98 Å R-free 0.246
5JI0 PPARgamma-RXRalpha(S427F) heterodimer in complex with SRC-1, rosiglitazone, and 9-cis-retanoic acid Deposited 2016-04-21 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain E 676–700（25 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；296 K；Crystals grew in the dark at room temperature from 0.5 + 0.5 uL sitting drops equilibrated over a reservoir containing 20-24% PEG3350 and 0.02M Na Citrate
Resolution 1.98 Å R-free 0.246
5JMM Crystal structure of hERa-LBD (Y537S) in complex with biochanin A Deposited 2016-04-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain F 686–698（13 aa） Fragment：UNP residues 686-698
Chain G 686–698（13 aa） Fragment：UNP residues 686-698
Not recorded QSO 5,7-dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one × 2 GOL GLYCEROL × 2 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.75；291 K；250 mM NaCl 100 mM Hepes 16% PEG3350 5% DMSO 10 mM b-mercaptoethanol
Resolution 2.10 Å R-free 0.216
5MX7 1a,20S-dihydroxyvitamin D3 VDR complex Deposited 2017-01-21 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B1 686–700（15 aa） Fragment：UNP residues 686-700
Not recorded D3V 1a,20S-dihydroxyvitamin D3 × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；295 K；BisTris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate
Resolution 1.98 Å R-free 0.225
5NMA Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain Deposited 2017-04-05 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa） Fragment：UNP residues 686-700
Not recorded 9CW (1~{R},3~{S},5~{Z})-5-[(2~{E})-2-[(1~{R},3~{a}~{S},7~{a}~{R})-7~{a}-methyl-1-[(1~{S})-1-[(2~{S},5~{S})-5-(2-oxidanylpropan-2-yl)oxolan-2-yl]ethyl]-2,3,3~{a},5,6,7-hexahydro-1~{H}-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexane-1,3-diol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；290 K；0.1 M BTP pH 7.0, 3 M NaOAc
Resolution 2.80 Å R-free 0.272
5NMB Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain Deposited 2017-04-05 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B2 686–700（15 aa） Fragment：UNP residues 686-700
Not recorded 9CZ (1~{R},3~{S},5~{Z})-5-[(2~{E})-2-[(1~{R},3~{a}~{S},7~{a}~{R})-7~{a}-methyl-1-[(1~{S})-1-[(2~{S},5~{R})-5-(2-oxidanylpropan-2-yl)oxolan-2-yl]ethyl]-2,3,3~{a},5,6,7-hexahydro-1~{H}-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexane-1,3-diol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；290 K；0.1 M BTP pH 7.0, 3 M NaOAc
Resolution 2.50 Å R-free 0.260
5NWM Insight into the molecular recognition mechanism of the coactivator NCoA1 by STAT6 Deposited 2017-05-06 Different construct Different mutation/modification Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 257–385（129 aa） Fragment：UNP residues 257-385
Mutation：K343R No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；309 K；Ionic strength (raw mmCIF value) 150；Pressure 1
NMR sample composition 50 mM HEPES, 150 mM sodium chloride, 10 % D2O, 1 mM [U-99% 13C; U-99% 15N] STAT6, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 1 mM [U-99% 13C; U-99% 15N] STAT6, 0.7 mM NCoA1, 50 mM HEPES, 150 mM sodium chloride, 10 % D2O, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 0.7 mM [U-99% 13C; U-99% 15N] NCoA1, 1 mM STAT6, 50 mM HEPES, 150 mM sodium chloride, 10 % D2O, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 1 mM [U-99% 15N] STAT6, 0.7 mM NCoA1, 50 mM HEPES, 150 mM sodium chloride, 10 % D2O, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 0.7 mM [U-99% 15N] NCoA1, 1 mM STAT6, 50 mM HEPES, 150 mM sodium chloride, 10 % D2O, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 1 mM [U-99% 15N] STAT6, 50 mM HEPES, 150 mM sodium chloride, 10 % D2O, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 1 mM [U-99% 13C; U-99% 15N] STAT6, 0.7 mM NCoA1, 50 mM HEPES, 150 mM sodium chloride, 100 % D2O, 100% D2O | 100% D2O
NMR sample composition 0.7 mM [U-99% 13C; U-99% 15N] NCoA1, 1 mM STAT6, 50 mM HEPES, 150 mM sodium chloride, 100 % D2O, 100% D2O | 100% D2O
Resolution not provided
5OW7 VDR complex Deposited 2017-08-31 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa） Fragment：UNP residues 686-700
Not recorded AYK (3~{S})-3-[(1~{S},3~{a}~{S},4~{E},7~{a}~{S})-7~{a}-methyl-4-[(2~{Z})-2-[(5~{S})-2-methylidene-5-oxidanyl-cyclohexylidene]ethylidene]-2,3,3~{a},5,6,7-hexahydro-1~{H}-inden-1-yl]-3-oxidanyl-~{N}-propan-2-yl-butanamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；50 mM Bis-Tris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate
Resolution 2.10 Å R-free 0.227
5OW9 Vitamin D receptor complex Deposited 2017-08-31 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa） Fragment：UNP residues 686-700
Not recorded AYT (1~{S},3~{Z})-3-[(2~{E})-2-[(1~{S},3~{a}~{S},7~{a}~{S})-7~{a}-methyl-1-[(2~{S})-6-methyl-2-oxidanyl-heptan-2-yl]-2,3,3~{a},5,6,7-hexahydro-1~{H}-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；50 mM Bis-Tris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate
Resolution 2.40 Å R-free 0.246
5OWD Vitamin D receptor complex Deposited 2017-08-31 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa） Fragment：UNP residues 686-700
Not recorded B0B (1~{S},3~{Z})-3-[(2~{E})-2-[(1~{S},3~{a}~{S},7~{a}~{S})-7~{a}-methyl-1-[(2~{S})-6-methyl-2-oxidanyl-hept-5-en-2-yl]-2,3,3~{a},5,6,7-hexahydro-1~{H}-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；50 mM Bis-Tris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate
Resolution 2.15 Å R-free 0.219
5X0R Crystal Structure of PXR LBD Complexed with SJB7 Deposited 2017-01-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 676–700（25 aa）
Chain D 676–700（25 aa）
Not recorded 4WH 4-[(4-tert-butylphenyl)sulfonyl]-1-(2,4-dimethoxy-5-methylphenyl)-5-methyl-1H-1,2,3-triazole × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.8；291 K；Tris-HCl, imidazole, isopropanol,sodium chloride, glycerol, EDTA, pH 7.2-7.8, VAPOR DIFFUSION, HANGING DROP, temperature 291.0K
Resolution 2.67 Å R-free 0.252
5X8U Crystal Structure of the wild Human ROR gamma Ligand Binding Domain. Deposited 2017-03-03 Different construct Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 686–700（15 aa） Fragment：UNP residues 686-700
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.1M Sodium acetate pH8.0, 4M ammonium acetate
Resolution 2.00 Å R-free 0.247
5X8W Crystal Structure of the mutant Human ROR gamma Ligand Binding Domain. Deposited 2017-03-03 Different construct Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 686–700（15 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.1M Sodium acetate pH8.0, 4M ammonium acetate
Resolution 2.30 Å R-free 0.230
5Y44 A novel moderator XD4 for bile acid receptor Deposited 2017-08-01 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 745–755（11 aa）
Not recorded XD4 [(1R,2R,4R)-1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl] 4-azanyl-3-methyl-benzoate × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293.15 K；0.1M Magnesium sulfate, 25% w/v polyethylene glycol 8000
Resolution 2.35 Å R-free 0.271
5YCN Human PPARgamma ligand binding domain complexed with Lobeglitazone Deposited 2017-09-07 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa） Fragment：UNP RESIDUES 685-700
Not recorded 8LX (5S)-5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methyl-amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；296 K；1.6 M sodium citrate tribasic dihydrate (pH 6.5)
Resolution 2.15 Å R-free 0.228
5YCP Human PPARgamma ligand binding domain complexed with Rosiglitazone Deposited 2017-09-07 Different construct Different ligand/ion Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa） Fragment：UNP RESIDUES 685-700
Not recorded BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.00 Å R-free 0.233
6BNS STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC co-activator peptide and Compound 25a AKA BICYCLIC HEXAFLUOROISOPROPYL 2 ALCOHOL SULFONAMIDES Deposited 2017-11-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 678–710（33 aa）
Chain B 678–710（33 aa）
Not recorded XGH 2-[(2S)-4-[(4-fluorophenyl)sulfonyl]-7-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-(2-hydroxy-2-methylpropyl)acetamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；296 K；0.1M Hepes pH 7.5, 150mM NaCl, 10-15%(V/V)PEG10K.Crystals were cryoprotected by supplementing the mother liquor with 15% (v/v) ethylene glycol and harvested by flash-cooling in liquid nitrogen
Resolution 2.56 Å R-free 0.246
6FO7 Vitamin D nuclear receptor complex 3 Deposited 2018-02-06 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa）
Not recorded LX3 (1~{R},3~{S},5~{Z})-4-methylidene-5-[(~{E})-3-[3-(6-methyl-6-oxidanyl-heptyl)phenyl]hept-2-enylidene]cyclohexane-1,3-diol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；BisTris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate
Resolution 2.59 Å R-free 0.230
6GEV Mineralocorticoid receptor in complex with (s)-13 Deposited 2018-04-27 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 1427–1441（15 aa）
Not recorded GOL GLYCEROL × 3 EWN 6-[[(3~{S})-7-fluoranyl-3-(2-methylpropyl)-2,3-dihydro-1,4-benzoxazin-4-yl]carbonyl]-4~{H}-1,4-benzoxazin-3-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.9 M (NH4)2SO4, 3.5% 1,4-butanediol, 0.1 M CHES pH 9.5
Resolution 1.54 Å R-free 0.190
6GG8 Mineralocorticoid receptor in complex with (s)-13 Deposited 2018-05-03 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 1427–1441（15 aa）
Not recorded MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1 EY8 [(3~{R})-7-fluoranyl-4-[(3-oxidanylidene-4~{H}-1,4-benzoxazin-6-yl)carbonyl]-2,3-dihydro-1,4-benzoxazin-3-yl]methanesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.9M (NH4)2SO4, 0.1 M CHES pH9.5, 10% (v/v) of condition C8 of the Morpheus Screen (Molecular Dimension)
Resolution 1.80 Å R-free 0.228
6HTY PXR in complex with P2X4 inhibitor compound 25 Deposited 2018-10-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 678–700（23 aa）
Mutation：K129G,K129G GOL GLYCEROL × 1 DMS DIMETHYL SULFOXIDE × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；1 microliter protein at 12.1 mg/ml (in 20 millimolar Tris pH 7.8, 250 millimolar NaCl, 2.5 millimolar EDTA, 5% (v/v) glycerol, 5 mM DTT), preincubated with 10 millimolar compound 15 (from 200 millimolar stock in DMSO), mixed with 1 microliter of reservoir (100 mM imidazole pH 8.0, 17 % (v/v) MPD). Crystals additionally soaked in 20 millimolar compound 15 prior to data collection. cryo buffer 34% (v/v) MPD supplemented with 20 millimolar compound 15
Resolution 2.22 Å R-free 0.226
6HTY PXR in complex with P2X4 inhibitor compound 25 Deposited 2018-10-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain B 678–700（23 aa）
Mutation：K129G,K129G DMS DIMETHYL SULFOXIDE × 2 GRH (2~{R})-~{N}-[4-(3-chloranylphenoxy)-3-sulfamoyl-phenyl]-2-phenyl-propanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；1 microliter protein at 12.1 mg/ml (in 20 millimolar Tris pH 7.8, 250 millimolar NaCl, 2.5 millimolar EDTA, 5% (v/v) glycerol, 5 mM DTT), preincubated with 10 millimolar compound 15 (from 200 millimolar stock in DMSO), mixed with 1 microliter of reservoir (100 mM imidazole pH 8.0, 17 % (v/v) MPD). Crystals additionally soaked in 20 millimolar compound 15 prior to data collection. cryo buffer 34% (v/v) MPD supplemented with 20 millimolar compound 15
Resolution 2.22 Å R-free 0.226
6ICJ Crystal structure of PPARgamma with compound BR102375K Deposited 2018-09-06 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 676–700（25 aa）
Not recorded GOL GLYCEROL × 2 A0L 2-butyl-5-[(3-tert-butyl-1,2,4-oxadiazol-5-yl)methyl]-6-methyl-3-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl}pyrimidin-4(3H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；0.2 M NH4 Acetate, 0.1 M HEPES 7.5 pH, 25 %w/v PEG 3350
Resolution 2.48 Å R-free 0.282
6IJR Human PPARgamma ligand binding domain complexed with SB1495 Deposited 2018-10-11 Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa）
Not recorded A9C N-{[3-({[(1S,2R)-2-{[(2E)-2-cyano-4,4-dimethylpent-2-enoyl]amino}cyclopentyl]oxy}methyl)phenyl]methyl}-4-[(4-methylpiperazin-1-yl)methyl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；60% (v/v) Tacsimate
Resolution 2.85 Å R-free 0.266
6IJR Human PPARgamma ligand binding domain complexed with SB1495 Deposited 2018-10-11 Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 685–700（16 aa）
Not recorded A9C N-{[3-({[(1S,2R)-2-{[(2E)-2-cyano-4,4-dimethylpent-2-enoyl]amino}cyclopentyl]oxy}methyl)phenyl]methyl}-4-[(4-methylpiperazin-1-yl)methyl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；60% (v/v) Tacsimate
Resolution 2.85 Å R-free 0.266
6IJS Human PPARgamma ligand binding domain complexed with SB1494 Deposited 2018-10-11 Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa）
Not recorded A9F N-{[3-({[(1R,2S)-2-{[(2E)-2-cyano-4,4-dimethylpent-2-enoyl]amino}cyclopentyl]oxy}methyl)phenyl]methyl}-4-[(4-methylpiperazin-1-yl)methyl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate
Resolution 2.15 Å R-free 0.241
6ILQ Crystal structure of PPARgamma with compound BR101549 Deposited 2018-10-19 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 676–700（25 aa）
Not recorded AE0 ethyl [2-butyl-6-oxo-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl}-4-(propan-2-yl)-1,6-dihydropyrimidin-5-yl]acetate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；0.2 M MgCl2, 0.1 M TRIS 8.5 pH, 27 %w/v PEG 3350
Resolution 2.41 Å R-free 0.303
6ITM Crystal structure of FXR in complex with agonist XJ034 Deposited 2018-11-23 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 744–757（14 aa）
Not recorded AWL 1-adamantyl-[4-(5-chloranyl-2-methyl-phenyl)piperazin-1-yl]methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；0.2M Ammonium acetate, 0.1M Bis-Tris pH 6.5, 25% w/v Polyethylene glycol 3350
Resolution 2.50 Å R-free 0.242
6ITM Crystal structure of FXR in complex with agonist XJ034 Deposited 2018-11-23 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 744–757（14 aa）
Not recorded AWL 1-adamantyl-[4-(5-chloranyl-2-methyl-phenyl)piperazin-1-yl]methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；0.2M Ammonium acetate, 0.1M Bis-Tris pH 6.5, 25% w/v Polyethylene glycol 3350
Resolution 2.50 Å R-free 0.242
6JQ7 The ligand-free structure of human PPARgamma LBD in the presence of the SRC-1 coactivator peptide Deposited 2019-03-29 Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；60% (v/v) Tacsimate (pH 7.0)
Resolution 2.55 Å R-free 0.257
6KTN Human PPARgamma ligand-binding domain R288A mutant in complex with imatinib Deposited 2019-08-28 Different ligand/ion Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa）
Not recorded STI 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.75 Å R-free 0.256
6NX1 STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC CO-ACTIVATOR PEPTIDE AND COMPOUND-3 AKA 1,1,1,3,3,3-HEXAFLUORO-2-{4-[1-(4- LUOROBENZENESULFONYL)CYCLOPENTYL]PHENYL}PROPAN-2-OL Deposited 2019-02-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 678–710（33 aa） Fragment：LIGAND BINDING DOMAIN
Chain B 678–710（33 aa） Fragment：LIGAND BINDING DOMAIN
Not recorded L7D 1,1,1,3,3,3-hexafluoro-2-(4-{1-[(4-fluorophenyl)sulfonyl]cyclopentyl}phenyl)propan-2-ol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；296 K；0.1M Hepes pH 7.5, 150mM NaCl, 10-15%(V/V)PEG10K, Crystals were cryoprotected by supplementing the mother liquor with 15% (v/v) ethylene glycol and harvested by flash-cooling in liquid nitrogen
Resolution 2.27 Å R-free 0.240
6NX1 STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC CO-ACTIVATOR PEPTIDE AND COMPOUND-3 AKA 1,1,1,3,3,3-HEXAFLUORO-2-{4-[1-(4- LUOROBENZENESULFONYL)CYCLOPENTYL]PHENYL}PROPAN-2-OL Deposited 2019-02-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 678–710（33 aa） Fragment：LIGAND BINDING DOMAIN
Chain B 678–710（33 aa） Fragment：LIGAND BINDING DOMAIN
Not recorded L7D 1,1,1,3,3,3-hexafluoro-2-(4-{1-[(4-fluorophenyl)sulfonyl]cyclopentyl}phenyl)propan-2-ol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；296 K；0.1M Hepes pH 7.5, 150mM NaCl, 10-15%(V/V)PEG10K, Crystals were cryoprotected by supplementing the mother liquor with 15% (v/v) ethylene glycol and harvested by flash-cooling in liquid nitrogen
Resolution 2.27 Å R-free 0.240
6P9F Crystal structure of RAR-related orphan receptor C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) in complex with a phenyl (3-phenylpyrrolidin-3-yl)sulfone inhibitor Deposited 2019-06-10 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 683–696（14 aa） Fragment：ligand-binding domain (UNP residues 265-508) fused to SRC peptide (UNP residues 683-696)
Not recorded O5A trans-4-{(3R)-3-[(4-fluorophenyl)sulfonyl]-3-[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)phenyl]pyrrolidine-1-carbonyl}cyclohexane-1-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；20-26% PEG3350, 0.2 M magnesium chloride, 0.1 M Bis-Tris pH 5.5-6.5
Resolution 2.80 Å R-free 0.223
6P9F Crystal structure of RAR-related orphan receptor C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) in complex with a phenyl (3-phenylpyrrolidin-3-yl)sulfone inhibitor Deposited 2019-06-10 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain B 683–696（14 aa） Fragment：ligand-binding domain (UNP residues 265-508) fused to SRC peptide (UNP residues 683-696)
Not recorded O5A trans-4-{(3R)-3-[(4-fluorophenyl)sulfonyl]-3-[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)phenyl]pyrrolidine-1-carbonyl}cyclohexane-1-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；20-26% PEG3350, 0.2 M magnesium chloride, 0.1 M Bis-Tris pH 5.5-6.5
Resolution 2.80 Å R-free 0.223
6SSQ Crystal structure of RARbeta LBD in complex with LG 100754 Deposited 2019-09-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain F 686–698（13 aa）
Chain G 686–698（13 aa）
Not recorded 754 (2E,4E,6Z)-3-methyl-7-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydronaphthalen-2-yl)octa-2,4,6-trienoic acid × 2 FLC CITRATE ANION × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；200 mM Tri Sodium Citrate pH 5.5, 25 % PEG 4000
Resolution 2.30 Å R-free 0.208
6T2M VDR-ZK168281 complex Deposited 2019-10-09 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa）
Not recorded M9Q ethyl (~{Z})-3-[1-[(~{E},1~{R},4~{R})-4-[(1~{R},3~{a}~{S},4~{E},7~{a}~{R})-7~{a}-methyl-4-[(2~{Z})-2-[(3~{S},5~{R})-2-methylidene-3,5-bis(oxidanyl)cyclohexylidene]ethylidene]-2,3,3~{a},5,6,7-hexahydro-1~{H}-inden-1-yl]-1-oxidanyl-pent-2-enyl]cyclopropyl]prop-2-enoate × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；50 mM Bis-Tris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate
Resolution 3.00 Å R-free 0.259
6TFI PXR IN COMPLEX WITH THROMBIN INHIBITOR COMPOUND 17 Deposited 2019-11-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 681–700（20 aa）
Mutation：K129G GOL GLYCEROL × 2 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；1 MICROLITER PROTEIN AT 12.1 MG/ML (IN 20 MILLIMOLAR TRIS PH 7.8, 250 MILLIMOLAR NACL, 2.5 MILLIMOLAR EDTA, 5% (V/V) GLYCEROL, 5 MM DTT), PREINCUBATED WITH 25 MILLIMOLAR COMPOUND 17 (FROM 500 MILLIMOLAR STOCK IN DMSO) for 24 hours at 277 K, MIXED WITH 1 MICROLITER OF RESERVOIR (100 MILLIMOLAR IMIDAZOLE PH 8.0, 20 % (V/V) MPD). CRYO BUFFER 100 MILLIMOLAR IMIDAZOLE PH 8.0, 30 % (V/V) MPD
Resolution 1.85 Å R-free 0.199
6TFI PXR IN COMPLEX WITH THROMBIN INHIBITOR COMPOUND 17 Deposited 2019-11-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain B 681–700（20 aa）
Mutation：K129G GOL GLYCEROL × 3 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1 DMS DIMETHYL SULFOXIDE × 2 N6H [2-[(3-chlorophenyl)methylamino]-7-methoxy-1,3-benzoxazol-5-yl]-(2,2-dimethylmorpholin-4-yl)methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；1 MICROLITER PROTEIN AT 12.1 MG/ML (IN 20 MILLIMOLAR TRIS PH 7.8, 250 MILLIMOLAR NACL, 2.5 MILLIMOLAR EDTA, 5% (V/V) GLYCEROL, 5 MM DTT), PREINCUBATED WITH 25 MILLIMOLAR COMPOUND 17 (FROM 500 MILLIMOLAR STOCK IN DMSO) for 24 hours at 277 K, MIXED WITH 1 MICROLITER OF RESERVOIR (100 MILLIMOLAR IMIDAZOLE PH 8.0, 20 % (V/V) MPD). CRYO BUFFER 100 MILLIMOLAR IMIDAZOLE PH 8.0, 30 % (V/V) MPD
Resolution 1.85 Å R-free 0.199
6U25 CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS- RORGT(244-487)-L6-SRC1(678-692)) IN COMPLEX WITH A TRICYCLIC INVERSE AGONIST Deposited 2019-08-19 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 683–696（14 aa） Fragment：LIGAND-BINDING DOMAIN (UNP RESIDUES 265-508) FUSED TO SRC PEPTIDE (UNP RESIDUES 683-696)
Not recorded O5B trans-4-[(3aR,9bR)-9b-[(4-fluorophenyl)sulfonyl]-7-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-1,2,3a,4,5,9b-hexahydro-3H-benzo[e]indole-3-carbonyl]cyclohexane-1-carboxylic acid × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；20-26% PEG3350, 0.2 M MAGNESIUM CHLORIDE, 0.1 M BIS-TRIS PH 5.5-6.5
Resolution 2.61 Å R-free 0.247
6W9H SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTS Deposited 2020-03-23 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 683–696（14 aa）
Not recorded TKJ 4-{(3R)-3-[4-(benzyloxy)phenyl]-3-[(4-fluorophenyl)sulfonyl]pyrrolidine-1-carbonyl}-1lambda~6~-thiane-1,1-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；295 K；protein at 8-10mg/ml, with 0.2M MgCl2, 22% PEG3350, 0.1M Bis-Tris pH 5.5
Resolution 2.00 Å R-free 0.258
6W9I SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTS Deposited 2020-03-23 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 683–696（14 aa）
Not recorded Z7D 1-(benzyloxy)-4-{1-[(4-fluorophenyl)sulfonyl]cyclopentyl}benzene × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；295 K；protein at 8-10mg/ml, with 0.2M MgCl2, 22% PEG3350, 0.1M Bis-Tris pH 5.5
Resolution 1.61 Å R-free 0.235
6XP9 STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC co-activator peptide IN COMPLEX WITH (S,S)-1 Deposited 2020-07-08 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 678–710（33 aa） Fragment：Ligand Binding Domain tethered with SRC co-activator peptide
Not recorded QCG (2S)-tert-butoxy[7-(8-fluoro-5-methyl-3,4-dihydro-2H-1-benzopyran-6-yl)-5-methyl-2-phenylpyrazolo[1,5-a]pyrimidin-6-yl]acetic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；296 K；0.1 M Ammonium acetate, 0.1 M Sodium HEPES pH 7.5, 18-20 % w/v PEG 4000.Crystals were cryoprotected by supplementing the mother liquor with 20% (v/v) Glycerol and harvested by flash-cooling in liquid nitrogen
Resolution 2.27 Å R-free 0.220
6XP9 STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC co-activator peptide IN COMPLEX WITH (S,S)-1 Deposited 2020-07-08 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain B 678–710（33 aa） Fragment：Ligand Binding Domain tethered with SRC co-activator peptide
Not recorded QCG (2S)-tert-butoxy[7-(8-fluoro-5-methyl-3,4-dihydro-2H-1-benzopyran-6-yl)-5-methyl-2-phenylpyrazolo[1,5-a]pyrimidin-6-yl]acetic acid × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；296 K；0.1 M Ammonium acetate, 0.1 M Sodium HEPES pH 7.5, 18-20 % w/v PEG 4000.Crystals were cryoprotected by supplementing the mother liquor with 20% (v/v) Glycerol and harvested by flash-cooling in liquid nitrogen
Resolution 2.27 Å R-free 0.220
7AOS crystal structure of the RARalpha/RXRalpha ligand binding domain heterodimer in complex with a fragment of SRC1 coactivator Deposited 2020-10-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 686–712（27 aa）
Chain D 686–712（27 aa）
Not recorded LG2 6-[1-(3,5,5,8,8-PENTAMETHYL-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)CYCLOPROPYL]PYRIDINE-3-CARBOXYLIC ACID × 1 GOL GLYCEROL × 1 EQN 4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；24% PEG 3350, 0.2M Na acetate, 0.1M Bis Tris Propane pH 7.0
Resolution 2.55 Å R-free 0.262
7B39 Allene-Based Design of a Noncalcemic Vitamin D Receptor Agonist Deposited 2020-11-29 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa）
Not recorded T0H (1R,3S,Z)-5-(2-((3aS,7aS,E)-1-(6-hydroxy-6-methylhept-1-en-1-ylidene)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol × 2 ACT ACETATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；50 mM BisTris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate
Resolution 2.13 Å R-free 0.247
7BNS VDR complex with BXL-62 Deposited 2021-01-22 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B2 686–700（15 aa）
Not recorded U5W 1,25-Dihydroxy-16-ene-20-cyclopropyl-vitamin D3 × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；273 K；50 mM Bis-Tris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate
Resolution 2.70 Å R-free 0.260
7BNU VDR complex with BXL-62 Deposited 2021-01-22 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B2 686–700（15 aa）
Not recorded U5W 1,25-Dihydroxy-16-ene-20-cyclopropyl-vitamin D3 × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；273 K；50 mM Bis-Tris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate
Resolution 2.40 Å R-free 0.261
7BO6 VDR complex with LCA derivative Deposited 2021-01-24 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa）
Not recorded FKC (4R)-4-[(3R,5R,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-3-(2-methyl-2-oxidanyl-propyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；50 mM Bis-Tris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate
Resolution 2.86 Å R-free 0.263
7BPY X-ray structure of human PPARalpha ligand binding domain-clofibric acid-SRC1 coactivator peptide co-crystals obtained by delipidation and co-crystallization Deposited 2020-03-23 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 683–697（15 aa）
Not recorded E0O 2-(4-chloranylphenoxy)-2-methyl-propanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；0.1 M Tris (pH 8.5), 30 %(w/v) PEG3350
Resolution 2.09 Å R-free 0.215
7BPY X-ray structure of human PPARalpha ligand binding domain-clofibric acid-SRC1 coactivator peptide co-crystals obtained by delipidation and co-crystallization Deposited 2020-03-23 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 683–697（15 aa）
Not recorded E0O 2-(4-chloranylphenoxy)-2-methyl-propanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；0.1 M Tris (pH 8.5), 30 %(w/v) PEG3350
Resolution 2.09 Å R-free 0.215
7BPZ X-ray structure of human PPARalpha ligand binding domain-bezafibrate-SRC1 coactivator peptide co-crystals obtained by soaking Deposited 2020-03-23 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 683–697（15 aa）
Not recorded PEM 2-[P-[2-P-CHLOROBENZAMIDO)ETHYL]PHENOXY]-2-METHYLPROPIONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；0.1 M Tris (pH 8.5), 25 %(w/v) PEG3350
Resolution 2.43 Å R-free 0.242
7BPZ X-ray structure of human PPARalpha ligand binding domain-bezafibrate-SRC1 coactivator peptide co-crystals obtained by soaking Deposited 2020-03-23 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 683–697（15 aa）
Not recorded PEM 2-[P-[2-P-CHLOROBENZAMIDO)ETHYL]PHENOXY]-2-METHYLPROPIONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；0.1 M Tris (pH 8.5), 25 %(w/v) PEG3350
Resolution 2.43 Å R-free 0.242
7BQ0 X-ray structure of human PPARalpha ligand binding domain-fenofibric acid-SRC1 coactivator peptide co-crystals obtained by delipidation and co-crystallization Deposited 2020-03-23 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 683–697（15 aa）
Not recorded F5A 2-[4-(4-chlorobenzene-1-carbonyl)phenoxy]-2-methylpropanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；0.1M Tris (pH 8.5), 25 %(w/v) PEG3350
Resolution 1.77 Å R-free 0.217
7BQ0 X-ray structure of human PPARalpha ligand binding domain-fenofibric acid-SRC1 coactivator peptide co-crystals obtained by delipidation and co-crystallization Deposited 2020-03-23 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 683–697（15 aa）
Not recorded F5A 2-[4-(4-chlorobenzene-1-carbonyl)phenoxy]-2-methylpropanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；0.1M Tris (pH 8.5), 25 %(w/v) PEG3350
Resolution 1.77 Å R-free 0.217
7BQ1 X-ray structure of human PPARalpha ligand binding domain-intrinsic fatty acid (E. coli origin)-SRC1 coactivator peptide co-crystals obtained by co-crystallization Deposited 2020-03-23 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 683–697（15 aa）
Not recorded PLM PALMITIC ACID × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；0.1 M Tris (pH 8.0), 25 %(w/v) PEG3350
Resolution 1.52 Å R-free 0.213
7BQ2 X-ray structure of human PPARalpha ligand binding domain-pemafibrate-SRC1 coactivator peptide co-crystals obtained by soaking Deposited 2020-03-23 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 683–697（15 aa）
Not recorded P7F (2~{R})-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；0.1M Tris (pH 8.0), 25%(w/v) PEG3350
Resolution 1.52 Å R-free 0.206
7BQ3 X-ray structure of human PPARalpha ligand binding domain-GW7647-SRC1 coactivator peptide co-crystals obtained by delipidation and co-crystallization Deposited 2020-03-23 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 683–697（15 aa）
Not recorded 2VN 2-[(4-{2-[(4-cyclohexylbutyl)(cyclohexylcarbamoyl)amino]ethyl}phenyl)sulfanyl]-2-methylpropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；0.1M Tris (pH 8.5), 25%(w/v) PEG3350
Resolution 1.98 Å R-free 0.237
7BQ4 X-ray structure of human PPARalpha ligand binding domain-eicosapentaenoic acid (EPA)-SRC1 coactivator peptide co-crystals obtained by delipidation and co-crystallization Deposited 2020-03-23 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 683–697（15 aa）
Not recorded EPA 5,8,11,14,17-EICOSAPENTAENOIC ACID × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；0.1 M Tris (pH 8.0), 30 %(w/v) PEG3350
Resolution 1.62 Å R-free 0.214
7CXF The ligand-free structure of human PPARgamma LBD C285Y mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa）
Not recorded MLA MALONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.35 Å R-free 0.269
7CXH The ligand-free structure of human PPARgamma LBD Q286E mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.30 Å R-free 0.257
7CXI The ligand-free structure of human PPARgamma LBD F287Y mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa）
Not recorded MLI MALONATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.30 Å R-free 0.276
7CXJ The ligand-free structure of human PPARgamma LBD R288C mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.65 Å R-free 0.275
7CXK The ligand-free structure of human PPARgamma LBD R288H mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa）
Not recorded MLI MALONATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.20 Å R-free 0.264
7CXL The ligand-free structure of human PPARgamma LBD S289C mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 685–700（16 aa）
Not recorded MLA MALONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
Resolution 2.70 Å R-free 0.255
7JYM CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLEX WITH A TRICYCLIC SULFONE INVERSE AGONIST Deposited 2020-08-31 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 683–696（14 aa） Fragment：;LIGAND-BINDING DOMAIN (UNP RESIDUES 265-508) FUSED TO SRC PEPTIDE (UNP RESIDUES 683-696),LIGAND-BINDING DOMAIN (UNP RESIDUES 265-508) FUSED TO SRC PEPTIDE (UNP RESIDUES 683-696) ;
Not recorded Z8I (3R,5S)-3-fluoro-5-[(3aR,9bR)-9b-[(4-fluorophenyl)sulfonyl]-7-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-1,2,3a,4,5,9b-hexahydro-3H-benzo[e]indole-3-carbonyl]-1-(2-hydroxy-2-methylpropyl)pyrrolidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；20-26% PEG3350, 0.2 M MAGNESIUM CHLORIDE, 0.1 M BIS-TRIS PH 5.5-6.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
Resolution 3.05 Å R-free 0.264
7KXD CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLEX WITH {3,5-DICHLORO-4-[4-METHOXY-3-(PROPAN-2-YL)PHENOXY]PHENYL}METHANOL Deposited 2020-12-03 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 683–696（14 aa）
Not recorded Z7G {3,5-dichloro-4-[4-methoxy-3-(propan-2-yl)phenoxy]phenyl}methanol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；22% PEG3350, 0.2 M MAGNESIUM CHLORIDE, 0.1 M BIS-TRIS PH 5.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
Resolution 1.62 Å R-free 0.239
7KXE CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLEX WITH {3,5-DICHLORO-4-[4-METHOXY-3-(PROPAN-2-YL)PHENOXY]PHENYL}METHANOL Deposited 2020-12-03 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 683–696（14 aa）
Not recorded Z7H N-{3,5-dichloro-4-[4-methoxy-3-(propan-2-yl)phenoxy]phenyl}-2-(pyridin-3-yl)acetamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；295 K；22% PEG3350, 0.2 M MAGNESIUM CHLORIDE, 0.1 M BIS-TRIS PH 5.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
Resolution 2.42 Å R-free 0.241
7KXF CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLEX WITH {3,5-DICHLORO-4-[4-METHOXY-3-(PROPAN-2-YL)PHENOXY]PHENYL}METHANOL Deposited 2020-12-03 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 683–696（14 aa）
Not recorded Z7I N-(3,5-dichloro-4-{[6-methoxy-5-(propan-2-yl)pyridin-3-yl]oxy}phenyl)-2-[1-(methylsulfonyl)piperidin-4-yl]acetamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；22% PEG3350, 0.2 M MAGNESIUM CHLORIDE, 0.1 M BIS-TRIS PH 5.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
Resolution 2.14 Å R-free 0.234
7OXZ VDR complex with a side-chain hydroxylated derivative of lithocholic acid Deposited 2021-06-23 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa）
Not recorded 2UI (3R,6R)-6-[(3R,5R,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-3-(2-methyl-2-oxidanyl-propyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]heptane-1,3-diol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；50 mM Bis-Tris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate
Resolution 2.20 Å R-free 0.254
7OY4 VDR complex of a side-chain hydroxylated derivatives of lithocholic acid Deposited 2021-06-23 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa）
Not recorded 2WV (3S,6R)-6-[(3R,5R,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-3-(2-methyl-2-oxidanyl-propyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]heptane-1,3-diol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；290 K；50 mM Bis-Tris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate
Resolution 2.00 Å R-free 0.238
7QPI Structure of lamprey VDR in complex with 1,25D3 Deposited 2022-01-04 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain U 686–698（13 aa）
Not recorded VDX 5-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANE-1,3-DIOL × 1 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；PEG 3350 25%, Tris 0.1M pH 8.5, magnesium chloride 0.2M
Resolution 2.50 Å R-free 0.256
7WGO X-ray structure of human PPAR gamma ligand binding domain-bezafibrate co-rystals obtained by co-crystallization Deposited 2021-12-28 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 683–697（15 aa）
Not recorded PEM 2-[P-[2-P-CHLOROBENZAMIDO)ETHYL]PHENOXY]-2-METHYLPROPIONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M Tris (pH 8.0), 1.1 M trisodium citrate
Resolution 2.36 Å R-free 0.225
7WGP X-ray structure of human PPAR gamma ligand binding domain-fenofibric acid co-crystals obtained by co-crystallization Deposited 2021-12-28 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 683–697（15 aa）
Not recorded F5A 2-[4-(4-chlorobenzene-1-carbonyl)phenoxy]-2-methylpropanoic acid × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M Tris (pH 8.0), 1.1 M trisodium citrate
Resolution 2.53 Å R-free 0.269
7WGQ X-ray structure of human PPAR gamma ligand binding domain-pemafibrate co-crystals obtained by co-crystallization Deposited 2021-12-28 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 683–697（15 aa）
Not recorded P7F (2~{R})-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M HEPES (pH 7.5), 1.1 M trisodium citrate
Resolution 2.43 Å R-free 0.252
7WQQ Retinoic acid receptor alpha mutant - N299H Deposited 2022-01-25 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 686–698（13 aa）
Not recorded 5Z6 4-[(E)-3-(3,5-ditert-butylphenyl)-3-oxidanylidene-prop-1-enyl]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；0.05M Bis-Tris Propane pH 5.0, 0.05M Citric acid, 18% PEG 3350
Resolution 1.90 Å R-free 0.206
7XVY Human Estrogen Receptor beta Ligand-binding Domain in Complex with S-DPN Deposited 2022-05-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 628–640（13 aa）
Chain D 628–640（13 aa）
Not recorded I0K (2~{S})-2,3-bis(4-hydroxyphenyl)propanenitrile × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；16-20% PEG3350, 100 mM BisTris pH6.5, 200 mM Magnesium Acetate
Resolution 1.54 Å R-free 0.237
7YFK The structure of human pregnane X receptor in complex with an SRC-1 coactivator peptide and a limonoid compound, nomilin Deposited 2022-07-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 676–700（25 aa）
Chain B 676–700（25 aa）
Not recorded G3L Nomilin × 2 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 8；277.15 K；10% (v/v) 2-propanol, 100 mM Imidazole/ Hydrochloric acid, pH 8.0
Resolution 2.10 Å
7ZFG VDR complex with aromatic D-ring analog Deposited 2022-04-01 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 686–700（15 aa）
Not recorded ACT ACETATE ION × 1 IV5 (1R,3S,5Z)-4-methylidene-5-[(E)-9-methyl-3-[3-(6-methyl-6-oxidanyl-heptyl)phenyl]-9-oxidanyl-dec-2-enylidene]cyclohexane-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；NaAcetate 2.5M, BisTris 0.1M
Resolution 2.62 Å R-free 0.261
7ZFX VDR complex with Aromatic-D-Ring Analog Deposited 2022-04-01 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 686–700（15 aa）
Not recorded ACT ACETATE ION × 1 IV1 (1R,3S,5Z)-5-[(E)-3-[3,5-bis(6-methyl-6-oxidanyl-heptyl)phenyl]prop-2-enylidene]-4-methylidene-cyclohexane-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；NaActetae 2.5M, Tris 0.1M
Resolution 2.60 Å R-free 0.254
8CK5 VDR LBD complex with 25-nitro derivative of 1,25D3 Deposited 2023-02-14 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 686–700（15 aa）
Not recorded ACT ACETATE ION × 1 UYO (1S,3R,5Z,7E,13xi)-25-nitro-9,10-secocholesta-5,7,10-triene-1,3-diol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；50 mM Bis-Tris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate
Resolution 2.10 Å R-free 0.243
8CKC Vitamin D receptor complex with 25-amine derivative of 1,25D3 Deposited 2023-02-15 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa）
Not recorded ACT ACETATE ION × 2 UYU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-azanyl-6-methyl-heptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexane-1,3-diol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；50 mM Bis-Tris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate
Resolution 2.10 Å R-free 0.232
8F5Y Crystal structure of pregnane X receptor ligand binding domain complexed with JQ1 Deposited 2022-11-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 676–700（25 aa）
Chain D 676–700（25 aa）
Not recorded JQ1 (6S)-6-(2-tert-butoxy-2-oxoethyl)-4-(4-chlorophenyl)-2,3,9-trimethyl-6,7-dihydrothieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-10-ium × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；50 mM imidazole pH 7.0, 8% isopropanol
Resolution 2.15 Å R-free 0.215
8HUK X-ray structure of human PPAR alpha ligand binding domain-lanifibranor-SRC1 coactivator peptide co-crystals obtained by soaking Deposited 2022-12-24 Different construct Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 683–697（15 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；0.1 M Tris (pH 8.5), 25%(w/v) PEG3350
Resolution 2.98 Å R-free 0.254
8HUM X-ray structure of human PPAR gamma ligand binding domain-lanifibranor-SRC1 coactivator peptide co-crystals obtained by co-crystallization Deposited 2022-12-24 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 683–697（15 aa）
Not recorded BJB 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl]butanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M HEPES (pH 7.5), 1.0 M trisodium citrate
Resolution 2.29 Å R-free 0.250
8HUP X-ray structure of human PPAR gamma ligand binding domain-seladelpar-SRC1 coactivator peptide co-crystals obtained by co-crystallization Deposited 2022-12-24 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 683–697（15 aa）
Not recorded KKB Seladelpar × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M Tris (pH 8.0), 1.1 M trisodium citrate
Resolution 2.36 Å R-free 0.234
8HUQ X-ray structure of human PPAR alpha ligand binding domain-elafibranor-SRC1 coactivator peptide co-crystals obtained by soaking Deposited 2022-12-24 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 683–697（15 aa）
Not recorded GOL GLYCEROL × 1 MUO 2-[2,6-dimethyl-4-[(~{E})-3-(4-methylsulfanylphenyl)-3-oxidanylidene-prop-1-enyl]phenoxy]-2-methyl-propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；0.1 M Tris (pH 8.5), 25%(w/v) PEG3350
Resolution 1.65 Å R-free 0.213
8P9W vitamin D receptor complex with Xe4MeCF3 analog Deposited 2023-06-06 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa）
Not recorded XDO (1~{R},3~{S},5~{Z})-5-[(2~{E})-2-[(1~{S},3~{a}~{S},7~{a}~{S})-1,7~{a}-dimethyl-1-[6,6,6-tris(fluoranyl)-5-oxidanyl-5-(trifluoromethyl)hexa-1,3-diynyl]-2,3,3~{a},5,6,7-hexahydroinden-4-ylidene]ethylidene]-4-methylidene-cyclohexane-1,3-diol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M BTP pH 7.0, 3 M NaOAc
Resolution 2.90 Å R-free 0.234
8SVN Crystal structure of the apo form of pregnane X receptor ligand binding domain Deposited 2023-05-17 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 678–710（33 aa）
Chain B 678–710（33 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；in 0.1 M HEPES pH 7.0, and 14% Isopropanol
Resolution 2.20 Å R-free 0.235
8SVO Crystal structure of pregnane X receptor ligand binding domain in complex with SJPYT-310 Deposited 2023-05-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 678–710（33 aa）
Chain B 678–710（33 aa）
Not recorded WSO (1P)-N-(5-tert-butyl-2-{[(2S)-pentan-2-yl]oxy}phenyl)-1-(2-methoxy-5-methylphenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamide × 2 DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；50 mM Bis-Tris pH 6.0-7.0, 9-16% (v/v) 2-Methyl-2,4-pentanediol
Resolution 2.35 Å R-free 0.238
8SVP Crystal structure of pregnane X receptor ligand binding domain in complex with SJPYT-278 Deposited 2023-05-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 678–710（33 aa）
Chain B 678–710（33 aa）
Not recorded WSX (1P)-N-(5-tert-butyl-2-{[(3S)-hexan-3-yl]oxy}phenyl)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamide × 2 YGO (1P)-N-(5-tert-butyl-2-{[(3R)-hexan-3-yl]oxy}phenyl)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；50 mM Bis-Tris pH 6.0-7.0, 9-16% (v/v) 2-Methyl-2,4-pentanediol
Resolution 3.32 Å R-free 0.252
8SVQ Crystal structure of pregnane X receptor ligand binding domain in complex with SJPYT-312 Deposited 2023-05-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 678–710（33 aa）
Chain B 678–710（33 aa）
Not recorded WSX (1P)-N-(5-tert-butyl-2-{[(3S)-hexan-3-yl]oxy}phenyl)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamide × 2 DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；50 mM Bis-Tris pH 6.0-7.0, 9-16% (v/v) 2-Methyl-2,4-pentanediol
Resolution 2.75 Å R-free 0.262
8SVR Crystal structure of pregnane X receptor ligand binding domain in complex with SJPYT-326 Deposited 2023-05-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 678–710（33 aa）
Chain B 678–710（33 aa）
Not recorded DMS DIMETHYL SULFOXIDE × 1 WT1 (1P)-N-(5-tert-butyl-2-{[(3S)-hexan-3-yl]oxy}phenyl)-5-methyl-1-(2,4,5-trimethoxyphenyl)-1H-1,2,3-triazole-4-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；50 mM Bis-Tris pH 6.0-7.0, 9-16% (v/v) 2-Methyl-2,4-pentanediol
Resolution 2.92 Å R-free 0.258
8SVS Crystal structure of pregnane X receptor ligand binding domain in complex with SJPYT-328 Deposited 2023-05-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 678–710（33 aa）
Chain B 678–710（33 aa）
Not recorded WU2 (1P)-N-(5-tert-butyl-2-{[(3S)-hexan-3-yl]oxy}phenyl)-1-(2,4-dimethoxy-5-methylphenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；50 mM Bis-Tris pH 6.0-7.0, 9-16% (v/v) 2-Methyl-2,4-pentanediol
Resolution 2.68 Å R-free 0.250
8SVT Crystal structure of pregnane X receptor ligand binding domain in complex with SJPYT-331 Deposited 2023-05-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 678–710（33 aa）
Chain B 678–710（33 aa）
Not recorded WU6 methyl 3-{[(1P)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole-4-carbonyl]amino}-4-{[(3S)-hexan-3-yl]oxy}benzoate × 2 DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；50 mM Bis-Tris pH 6.0-7.0, 9-16% (v/v) 2-Methyl-2,4-pentanediol
Resolution 2.39 Å R-free 0.237
8SVU Crystal structure of the L428V mutant of pregnane X receptor ligand binding domain in apo form Deposited 2023-05-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 678–710（33 aa）
Chain B 678–710（33 aa）
Mutation：L428V Mutation：L428V GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；50 mM Bis-Tris pH 6.0-7.0, 9-16% (v/v) 2-Methyl-2,4-pentanediol
Resolution 2.89 Å R-free 0.244
8SVX Crystal structure of the L428V mutant of pregnane X receptor ligand binding domain in complex with SJPYT-331 Deposited 2023-05-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 678–710（33 aa）
Chain B 678–710（33 aa）
Mutation：L428V Mutation：L428V WU6 methyl 3-{[(1P)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole-4-carbonyl]amino}-4-{[(3S)-hexan-3-yl]oxy}benzoate × 2 DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；50 mM Bis-Tris pH 6.0-7.0, 9-16% (v/v) 2-Methyl-2,4-pentanediol
Resolution 2.14 Å R-free 0.235
9EYR VDR complex with gemini analog UG-480 Deposited 2024-04-09 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa）
Not recorded A1H75 (1~{R},3~{S},5~{Z})-5-[(2~{E})-2-[(1~{R},3~{a}~{S},7~{a}~{R})-7~{a}-methyl-1-[(1~{R})-5-methyl-1-[(1~{S},2~{S})-2-(3-methyl-3-oxidanyl-butyl)cyclopropyl]-5-oxidanyl-hexyl]-2,3,3~{a},5,6,7-hexahydro-1~{H}-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexane-1,3-diol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Li2SO4 1.8M
Resolution 2.56 Å R-free 0.259
9FBF VDR complex with UG-481 Deposited 2024-05-13 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 686–700（15 aa）
Not recorded A1IBM (1~{R},3~{S},5~{Z})-5-[(2~{E})-2-[(1~{R},3~{a}~{S},7~{a}~{R})-7~{a}-methyl-1-[(1~{S})-5-methyl-1-[(1~{R},2~{R})-2-(3-methyl-3-oxidanyl-butyl)cyclopropyl]-5-oxidanyl-hexyl]-2,3,3~{a},5,6,7-hexahydro-1~{H}-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexane-1,3-diol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；Li2SO4 1.8M
Resolution 3.01 Å R-free 0.258
9FZI A new crystal structure of the hPXR-LBD in fusion with an SRC1 co-activator peptide and in complex with SR12813 (P212121 form) Deposited 2024-07-05 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 678–700（23 aa）
Not recorded SRL [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；100 mM Imidazole 25 - 30% MPD
Resolution 2.70 Å R-free 0.237
9FZI A new crystal structure of the hPXR-LBD in fusion with an SRC1 co-activator peptide and in complex with SR12813 (P212121 form) Deposited 2024-07-05 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain B 678–700（23 aa）
Not recorded SRL [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；100 mM Imidazole 25 - 30% MPD
Resolution 2.70 Å R-free 0.237
9GC7 Mineralocorticoid receptor in complex with acylurea antagonists. Deposited 2024-08-01 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1430–1441（12 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293.15 K；0.9 M AMS 0.1 M CHES pH 9.5 +10% Morpheus G8
Resolution 1.46 Å R-free 0.210
9O41 Crystal structure of the L411A mutant of pregnane X receptor ligand binding domain (apo form) Deposited 2025-04-08 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 682–710（29 aa）
Chain B 682–710（29 aa）
Mutation：L411A Mutation：L411A No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；50 mM Bis-Tris (pH 6-7), 9-16% (v/v) 2-methyl-2,4-pentanediol
Resolution 2.05 Å R-free 0.222
9O42 Crystal structure of the L411A mutant of pregnane X receptor ligand binding domain in complex with SJPYT-328 Deposited 2025-04-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 682–710（29 aa）
Chain B 682–710（29 aa）
Mutation：L411A Mutation：L411A WU2 (1P)-N-(5-tert-butyl-2-{[(3S)-hexan-3-yl]oxy}phenyl)-1-(2,4-dimethoxy-5-methylphenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；50 mM Bis-Tris (pH 6-7), 9-16% (v/v) 2-methyl-2,4-pentanediol
Resolution 2.51 Å R-free 0.219
9O43 Crystal structure of the L411A mutant of pregnane X receptor ligand binding domain in complex with SJPYT-331 Deposited 2025-04-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 682–710（29 aa）
Chain B 682–710（29 aa）
Mutation：L411A Mutation：L411A WU6 methyl 3-{[(1P)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole-4-carbonyl]amino}-4-{[(3S)-hexan-3-yl]oxy}benzoate × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；50 mM Bis-Tris (pH 6-7), 9-16% (v/v) 2-methyl-2,4-pentanediol
Resolution 2.76 Å R-free 0.239
9O44 Crystal structure of the L411W mutant of pregnane X receptor ligand binding domain (apo form) Deposited 2025-04-08 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 682–710（29 aa）
Chain B 682–710（29 aa）
Mutation：L411W Mutation：L411W No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；50 mM Bis-Tris (pH 6-7), 9-16% (v/v) 2-methyl-2,4-pentanediol
Resolution 2.30 Å R-free 0.228
9O45 Crystal structure of the L411W mutant of pregnane X receptor ligand binding domain in complex with SJPYT-328 Deposited 2025-04-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 682–710（29 aa）
Chain B 682–710（29 aa）
Mutation：L411W Mutation：L411W WU2 (1P)-N-(5-tert-butyl-2-{[(3S)-hexan-3-yl]oxy}phenyl)-1-(2,4-dimethoxy-5-methylphenyl)-5-methyl-1H-1,2,3-triazole-4-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；50 mM Bis-Tris (pH 6-7), 9-16% (v/v) 2-methyl-2,4-pentanediol
Resolution 2.56 Å R-free 0.241
9O46 Crystal structure of the L411W mutant of pregnane X receptor ligand binding domain in complex with SJPYT-331 Deposited 2025-04-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 682–710（29 aa）
Chain B 682–710（29 aa）
Mutation：L411W Mutation：L411W WU6 methyl 3-{[(1P)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole-4-carbonyl]amino}-4-{[(3S)-hexan-3-yl]oxy}benzoate × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；50 mM Bis-Tris (pH 6-7), 9-16% (v/v) 2-methyl-2,4-pentanediol
Resolution 3.02 Å R-free 0.232
9S70 Crystal structure of RXR alpha LBD bound to a partial agonist 21 and a coactivator fragment SRC1 Deposited 2025-08-01 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 680–700（21 aa）
Not recorded A1JL7 3-[[4-cyclobutyl-6-(3,4-dihydro-2~{H}-quinolin-1-yl)pyrimidin-2-yl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；20% PEG2000, 0.1M Mes pH 6.5
Resolution 1.95 Å R-free 0.221
9S71 Crystal structure of RXR alpha LBD bound to a partial agonist 35 and a coactivator fragment SRC1 Deposited 2025-08-01 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 680–700（21 aa）
Not recorded A1JL8 3-[[4-(4,4-dimethyl-2,3-dihydroquinolin-1-yl)-6-(trifluoromethyl)pyrimidin-2-yl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；18% PEG 4000 0.1 M MES pH 6.5
Resolution 2.00 Å R-free 0.222
9VBQ Crystal structure of FXR in complex with agonist XJ02862-S2 Deposited 2025-06-04 Different construct Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 744–757（14 aa） Fragment：HD3 Peptide
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.30 Å R-free 0.244
9VBR Farnesoid X Receptor Agonists_FXR fused with a HD3 peptide Deposited 2025-06-04 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 745–756（12 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.50 Å R-free 0.251
9VBR Farnesoid X Receptor Agonists_FXR fused with a HD3 peptide Deposited 2025-06-04 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain B 745–756（12 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.50 Å R-free 0.251
9VNX Crystal Structure of the mutant ROR gamma LBD With Compound 28 Deposited 2025-07-01 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 686–700（15 aa）
Not recorded A1MAM (2~{R})-~{N}-[5-(5-cyano-6-propan-2-yloxy-pyridin-3-yl)-1-(trifluoromethyl)pyrazol-3-yl]-1-ethanoyl-4-propan-2-ylsulfonyl-piperazine-2-carboxamide × 1 EDO 1,2-ETHANEDIOL × 3 ACT ACETATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；297 K；0.1M sodium acetate (pH 7.0), 3.5M ammonium acetate
Resolution 1.93 Å R-free 0.218
9VZQ Crystal structure of RORgamma in complex with novel inverse agonist Deposited 2025-07-23 Different construct Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 1429–1441（13 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.18 Å R-free 0.251

204 other PDB entries and 251 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name NCOA1_HUMAN
Isoform —
PDB entities 2
Chains and sequence ranges Author chain B； PDBConstruct 1–16； UniProt 685–700

The page prioritizes protein identity, the current assembly, associated components, oligomeric state and cross-PDB links. Chain mapping and sequence ranges are retained as data evidence. Internal IDs, import timestamps and assembly operation expressions are maintenance fields and are not shown here.

SAXS scattering curve SAXS Profile

SAXS profile for 6ktm

P(r) Distance Distribution P(r) Distribution

P(r) distribution for 6ktm
Download Download
▼

2. Structure Basics 2. Structure Basics

Entry ID entry_id6ktm
Deposition date deposition_date2019-08-28
Structure title titleThe ligand-free structure of human PPARgamma ligand-binding domain R288A mutant in the presence of the SRC-1 coactivator peptide
Keywords keywordsType 2 diabetes mellitus, TRANSCRIPTION; TRANSCRIPTION
Experimental Method methodX-RAY DIFFRACTION
▼

3. SAXS Parameters (CRYSOL theoretical calculation) 3. SAXS Parameters (CRYSOL)

Radius of gyration Rg (Guinier) rg_guinier20.30 Å
Radius of gyration Rg (electron density) rg_electron18.96 Å
Forward intensity I(0) i015252700.00
Molecular weight molecular_weight30894.0 kDa
Excluded volume excluded_volume39430 ų
Envelope volume envelope_volume46391 ų
Hydration-shell volume shell_volume20380 ų
Envelope diameter envelope_diameter66.9 Å
Shell Rg shell_rg25.42 Å
Envelope Rg envelope_rg19.18 Å
Shape Rg shape_rg18.93 Å
Total Rg total_rg20.07 Å
Total atoms total_atoms2174
Residues n_residues271
Spherical-harmonic order n_harmonics20
q range q_range— – 0.5000 Å−1
Data points n_points101
Shell type shell_typedirectional
Solvent electron density solvent_density0.3340 e/ų
Shell contrast contrast_shell0.0300 e/ų
CRYSOL version crysol_version4.1.3
▼

4. P(r) Distance Distribution (GNOM inversion) 4. P(r) Analysis (GNOM)

Maximum dimension Dmax dmax67.2 Å
Rg (real space) rg_real20.21 Å
Rg uncertainty (real space) rg_real_error0.40 Å
I(0) (real space) i0_real1.5250e+07
I(0) uncertainty (real space) i0_real_error2.0390e+05
Rg (reciprocal space) rg_reciprocal20.22 Å
I(0) (reciprocal space) i0_reciprocal15250000.0000
Solution quality estimate total_estimate0.8053
Solution quality rating solution_quality GOOD a GOOD solution
P(r) peaks n_peaks2
Primary peak position r_peak_primary25.9 Å
Skewness Skewness skewness0.214
Kurtosis Kurtosis kurtosis-0.342
Angular range angular_range— – 0.3900 Å−1
Current regularization parameter α current_alpha0.0000
Highest regularization parameter α highest_alpha3572000.0000
Real-space data points n_real_points71
GNOM version gnom_version4.1.3
Quality Criteria quality_criteria AN1: 0.000; Oscil: 0.823; Stabil: 1.000; Sysdev: 1.000; Positv: 1.000; Valcen: 0.998; Smooth: 0.000
▶

5. Crystallography and Experiment 5. Crystallography & Experiment

▶

6. Entities and Polymers Entities & Polymers (3)

▼

7. Fold Classification (SCOP + CATH) 1 domains

CATH v4.4 (1 domains)

Domain ID domain_id6ktmA00
Class class1 — Mainly Alpha
Architecture architecture10 — Orthogonal Bundle
Topology topology565 — Retinoid X Receptor
Homologous superfamily homologous superfamily10 — Retinoid X Receptor
▶

8. Citations (1)

▶

9. Files and Curves (10)